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ABSTRACT 
 Most existing studies of receptor signaling are qualitative, which can lead 
scientists to misinterpret or overlook key information about the extent and timing 
of key events. To overcome these shortcomings, we have applied quantitative 
approaches to characterize receptor activation and signaling events. Most 
signaling studies focus on events occurring at a particular level in the system 
(e.g., on the membrane, at the level of phosphorylation of intracellular signaling 
molecules, or at the level of transcription). Instead, we are interested in taking a 
longitudinal view of signaling by achieving a quantitative understanding of a 
single signaling pathway from initial stimulation of the receptor by its growth 
factor (GF) ligand, through to gene expression, and functional cellular responses. 
As a model system for our studies, we used the growth factor receptor tyrosine 
kinase, REarranged during Transfection (RET), which requires a ligand and a 
glycosylphosphatidylinositol-anchored co-receptor for activation. RET mediates 
the response of cells to members of the glial cell-line derived neurotrophic factor 
(GDNF) family of neurotrophins, which are important in the development and 
maintenance of a subset of neuronal cells as well as in other cell types and 
		 vii 
tissues. We have characterized the molecular mechanisms of RET activation and 
signaling by pursuing the following four aims: 1) We developed a sensitive and 
robust luciferase reporter gene assay for RET signaling. 2) We characterized the 
dynamic relationship between receptor activation and downstream signaling 
events, including gene transcription and translation of three target genes. 3) We 
used the reporter gene assay, and other detection approaches, to test and 
quantify crosstalk between RET and other GF receptors. 4) We developed a 
FRET reporter system to enable monitoring of the assembly of the activated RET 
receptor complex on cells, as a means to distinguish between ligand-induced 
oligomerization and pre-associated oligomer mechanisms. Through these four 
aims, we have established new methods to quantitatively elucidate mechanisms 
of GF receptor activation, new insights into how signals are propagated from the 
receptor to the nucleus and into a functional response, and have established 
crosstalk between RET and other GF receptor pathways. 
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CHAPTER ONE. DEVELOPMENT OF A LUCIFERASE REPORTER GENE 
ASSAY FOR RET ACTIVATION BY ARTEMIN  
1.1 Introduction 
1.1.1 Composition and activation of RET growth factor receptor 
REarranged during Transfection (RET) is the signaling component of a 
multicomponent growth factor receptor involved in kidney development, 
spermatogenesis, and neuronal cell development and regulation (Cabrera et al.; 
Jain; Jijiwa et al.; Simpson et al.). RET is also a proto-oncogene, and 
deregulation of RET signaling plays a causal role in multiple types of cancer, 
including multiple endocrine neoplasias -2A and -2B, medullary thyroid 
carcinoma, and para-thyroid hyperplasia (Carson et al.; Donis-Keller et al.; 
Hofstra et al.; Kjaer et al.). The structural composition of RET includes a 
cadherin-like extracellular domain, a transmembrane domain, and an intracellular 
moiety containing the pivotal tyrosine kinase domain (Eketjäll et al.; Ibáñez). RET 
is a receptor tyrosine kinase that is activated by any four growth factors in the 
glial cell-line derived neurotrophic factor (GDNF) family: GDNF, neurturin, 
artemin (ART), or persephin. Activation of RET additionally requires the 
participation of one of four glycosylphosphatidyl inositol (GPI)-linked co-
receptors, known as GDNF Family Receptor alpha chains (GFRα)1-4. The 
prototypical activated receptor complex is believed to be composed of two 
molecules of RET bound to one molecule of a GDNF family ligand plus two 
molecules of its cognate GFRα c- 
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 Figure 1.1. Composition of the activated RET receptor complexes, and selected 
downstream intracellular signaling pathways. Phosphorylated molecules are 
indicated with red circles. Brackets indicate the species we measured in this 
study by ELISA. 
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co-receptor (Figure 1.1.1) (Parkash et al.; Schlee et al.; X. Wang et al.). 
Autophosphorylation of RET, as a result of ligand stimulation, triggers activation 
of several canonical signaling pathways, most notably, NF-κB, JNK/c-Jun, 
PI3K/Akt, and MAPK/ERK (Figure 1.1.1). These pathways have been extensively 
studied for their roles in cell survival, differentiation and apoptosis, as well as in 
diseases related to autoimmune deficiency, and cancer (Eriksson et al.; 
Hotamisligil and Davis; Seger and Krebs; Sun et al.; L. Wang et al.).  
1.1.2 Quantification of receptor activation 
The quantitative study of receptor activation and signaling is an important 
aspect of cell signaling research. Quantitative approaches to studying signaling 
enable context driven analyses, and enable a more detailed understanding of 
how signaling directs biological function, or the phenotypic response to signaling. 
For example, Li et al. applied quantitative approaches to study RET-activated 
coupling to intracellular signaling and biological function. Their efforts allowed 
them to distinguish between physiologically-relevant levels of receptor activation 
that directly relate to biological function and “super” saturation levels that produce 
high induction levels but are superficial to biological function (S. Li et al.). Their 
conclusions would have been difficult to discern without the application of 
quantitative approaches, since quantification of receptor activation and its 
effectors captured nuances in signaling dynamics that would have been missed 
by qualitative methods.  
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There are plenty of opportunities to develop and improve some of the 
existing quantitative methods that measure receptor activation and its 
downstream effectors. The standard methods used to measure RET activation 
include immunoassays, such as enzyme-linked immunosorbent assay (ELISA), 
Western Blot, fluorescent-staining microscopy, and flow cytometry, biological 
neurite outgrowth assays; any of these are laborious, and all require multiple 
antibodies that can be difficult and expensive. Furthermore, some of these 
methods, such as in Western Blotting and fluorescence microscopy, give results 
that can be quantified only indirectly, thereby requiring an additional step of 
digitization before the data can be quantified. Here we describe the development 
a luciferase reporter gene assay, as a convenient and robust method for to 
quantifying the activation of RET in live cells. 
1.1.3 Luciferase reporter gene assays 
Luciferase is a 61 kDa enzyme derived from various species including 
firefly, click beetle, and sea pansy. Generation of a luciferase reporter gene 
requires insertion of the luciferase gene downstream of a specific regulatory 
elements, or promoter, in the DNA of a cell. Activation of upstream pathways, 
such as by stimulating receptors related to the luciferase gene-associated 
pathway, induces luciferase protein expression, such that addition of the 
substrate, luciferin or luciferin derivatives, results in a bioluminescent readout 
(Figure 1.2). Luciferase reporter assays are optimal for the detection of activated  
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Figure 1.2. Scheme of luciferase reporter assay. Generate luciferase cell line by 
inserting luciferase gene downstream of targeted promoter. Stimulation of cells 
leads to binding of transcription factors (TF) to promoter sites, resulting in 
luciferase protein expression. The lysis of cells and addition of substrate results 
in a bioluminescent readout. 
 
 
 
		
6 
signaling pathways. Since the luciferase signal is quick and simple to measure 
using luminometers available in different platforms, these types of assays 
conveniently permit utility in high-throughput assays. Additionally, the different 
variants of luciferase enzymes have been modified by insertion of destabilizing 
sequences to minimize the accumulation of the luciferase protein, so that the 
measured biochemical signal better represents the activation of the regulatory 
element dynamically (Leclerc et al.; X. Li et al.). Since bioluminescence occurs 
as a result of exothermic chemical reactions, and does not require excitation by 
photons, the luciferase signal has low background and high sensitivity, making it 
superior to fluorescent readouts for many applications (Allard).  
There are diverse applications for luciferase reporter gene assays 
including quantifying receptor activation (Cavanaugh and DiMario; H. Li et al.), 
screening for agonists and/or antagonists targeting a specific receptor or 
signaling pathway (Aykul et al.; Tian), measuring in vivo tumorigenesis (Arwert et 
al.; Kalet et al.), elucidating protein degradation mechanisms (Kesarwala et al.), 
and characterizing transcription regulation (Missan et al.). The main caveat to 
developing a luciferase reporter gene assay is identification of the appropriate 
regulatory element to insert upstream of the luciferase gene. 
1.1.4 Goal: Develop luciferase reporter gene cell line to detect RET activation 
The goal of the work described here was to develop a sensitive, robust 
and reproducible method for quantifying RET activation at the level of gene 
transcription and translation. The developed assay was designed to enable the 
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quantitative evaluation of the activity of RET agonists, and for characterizing 
activated-RET downstream signaling and function. We aimed to develop a 
luciferase reporter gene assay that can produce high signal to background 
(untreated cells) induction, and for the assay to be performed with minimal cell 
culture maintenance (i.e., media changes), while enabling ample time for cells to 
synthesize enough luciferase protein for detection of a robust signal. Since most 
growth factor receptor stimulation experiments are done in serum-free media in 
which cells are deprived of nutrients, we determined that a treatment window of 
≤24 h would meet this criterion. We implemented two strategies to achieve this 
goal: 1) We used transcription-based RTqPCR to screen for potential target 
genes that are up-regulated upon RET activation, with the intention of generating 
a construct that expresses luciferase governed by the target gene’s regulatory 
elements. 2) We utilized commercially available reporter gene plasmids or 
lentivirus constructs to express luciferase under the control of regulatory 
elements of activated signaling pathways known to be downstream of RET. The 
following sections describe the results of these two lines of investigation, leading 
to the identification and validation of a stable, luciferase reporter cell-line that 
meet the aforementioned criteria, and the development of an optimized assay 
protocol.  
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1.2 Results 
1.2.1 Screen for RET-activated target genes 
 Based on literature data, we compiled a list of potential gene targets that 
have been shown to be up regulated upon RET activation (Table 1.1).  
Table 1.1. Summary of ART-activated induction of tested genes measured by 
RTqPCR. 
Gene Number of 
Trials 
Averaged Highest 
Induction 
Bcl-2
1,
 
2
 3 unchanged 
CDKN1B
3, 4
 3 4-fold  
CCND1
3
 2 unchanged 
CCNE1
3
 2 down-regulated 
HIF1A
5
 3 <2-fold 
MAP3K14
6
 3 <2-fold 
NFKB1A
6
 3 unchanged 
CTNNB1
7
 3 2.5-fold 
FGF2
8
 2 2.5-fold 
1J Cell Biochem 2000. 79:355–369. 2J Neurosci Res. 
2002. 69(3):397-405. 3Cancer Res 2004;64:3823-3829. 
4Oncogene. 2002. 21, 1739-49. 5Oncogene. 2010. 29, 
2938–2949. 6Oncogene. 2011. 30, 87–96. 7Cancer Res. 
2009. 69(5):1867-76. 8Mol Cell Biol. 2006, 26(7):2746. 
 
To determine whether any of the gene targets listed in Table 1.1 were 
good candidates for the reporter gene construct, we treated murine NB41A3-
mGFRα3 neuroblastoma cells that endogenously express RET and had been 
engineered to stably express GFRα3 (Carmillo et al.) with various doses of ART 
at times ranging from 10 min to 24 h. We chose this cell line to screen for RET-
activated gene expressions since these cells have been well characterized as a 
cellular model system for studying RET activation mechanisms and receptor 
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coupling to downstream effectors (S. Li et al.; Schlee et al.). We monitored RET 
activation using a previously validated Kinase Receptor Activation (KIRA) ELISA 
(Sadick et al.; Schlee et al.) to confirm that ART treatment led to RET activation. 
In NB41A3-mGFRα3 cells, RET activation is maximal at approximately 10 min 
after stimulation using 1-10 nM ART concentrations, after which phosphoRET 
levels slowly decreases back to baseline over several hours (S. Li et al.). We 
treated cells with varying doses of ART for 10 min, 1 h, and 24 h, followed by 
extraction of RNA from cell lysates, and synthesized cDNA. We performed qPCR 
using the cDNA to quantify the fold change of mRNA expression of ART treated 
cells from untreated cells. However, due to high variability, we did not find robust 
expression for any of our target genes at any of the measured time-points (Table 
1, Appendix I). We therefore did not investigate these target genes further.  
1.2.2 Screen for RET-activated regulatory elements 
RET activation triggers the onset of multiple downstream signaling 
pathways, including NF-kB, JNK/c-Jun, PI3K/Akt, and MAPK/ERK. Commercial 
vendors offer luciferase expression plasmids and/or lentivirus constructs that 
enable induction of luciferase expression under the regulatory element control of 
many of the pathways mentioned. We therefore tested commercially available 
luciferase-encoding plasmid constructs that express luciferase upon activation of 
regulatory elements involved in the following signaling pathways (name of 
corresponding regulatory element, if different): NF-kB (HIF1), MAPK/JNK 
(activator protein-1; AP-1), PI3K/Akt (forkhead box; FOXO), STAT3, and 
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MAPK/ERK (serum response element; SRE). The commercial plasmids we used 
to transfect the NB41A3-mGFRα3 cells to express luciferase protein downstream 
of the regulatory elements did not have antibiotic selection. As such, the 
transfected cells were unsuitable for the generation of stable cell lines, but had 
the advantage that they allowed rapid screening for luciferase activity in multiple 
cell lines expressing different regulatory elements. Previous experiments 
quantifying pERK and pAkt levels using ELISA showed that 10 min treatment 
with ART generated a maximal signal (S. Li et al.). We therefore tested whether 
ART induced a luciferase signal after 10 min treatment.  
The FOXO regulatory element is downstream of the Akt/PI3K pathway, 
and regulates the transcription of many protein targets involved in cell cycle (i.e., 
cyclins, p19, p21, p27, etc.), DNA repair (catalase, GADD45, ATM), apoptosis 
(i.e., Fas, PTEN, TRAIL, etc), metabolism, and immune response (i.e., Bcl-6, 
KLF2, etc.) (Lam et al.; X. Zhang et al.). When the Akt/PI3K pathway is inactive, 
the FOXO transcription factor binds to target genes, thereby activating gene 
expression. Upon phosphorylation of FOXO by phosphorylated Akt (pAkt), FOXO 
interacts with 14-3-3 protein, which can shuttle FOXO out of the nucleus and thus 
prevent FOXO binding to DNA, which results in inactivation of expression of 
targeted genes (Brunet et al.; Cahill et al.; Tzivion et al.). Consequently, 
luciferase expression should decrease upon ART stimulation of the FOXO-
luciferase expressing NB41A3-mGFRα3 cells.  
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Such a result was observed in our initial screen, in which we saw a ~20% 
decrease in luciferase activity upon stimulation of the FOXO-luciferase cell line 
with ART (Figure 1.3 A). Since it is known that Akt signaling couples robustly with 
RET activation (S. Li et al.), and we also observed a modest decrease in the 
luciferase response in this experiment, we proceeded to test whether there would 
be a dose-dependent reduction of luciferase activity by ART stimulation with 
different treatment times. We treated the cells with various concentrations of ART 
for 10 min, 1 h, and 5 h, lysed them, and measured luciferase activity. We found 
that there was a weak dose-dependent reduction in luciferase levels, for 
treatment times of 10 min and 1 h (Figure 1.3B). However, we decided not to 
move forward in developing a FOXO-luciferase reporter cell line since an assay 
read-out involving an increase in luciferase signal was preferred.  
The serum response element (SRE) consists of interacting sites for the 
transcription factors Elk-1 and SRF, which are ternary complex factors that are 
nuclear targets for activated ERK (Buchwalter et al.; Vickers et al.) (Figure 1.4). 
Recruitment of Elk-1/SRF to the SRE promoter region results in expression 
changes of immediate early genes such as c-fos (H.-M. Zhang et al.) (Figure 
1.4). The c-fos protein is known to be involved in canonical neuronal biology, 
including neuronal elongation and differentiation (Eriksson et al.; Gil). We found 
that treatment with ART for 10 min to cells that express the  
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Figure 1.3. Preliminary screen for ART-induced luciferase signal in NB41A3-
mGFRα3 cells infected using commercial plasmids encoding luciferase reporter 
genes. Luciferase activity is expressed as percent change relative to untreated 
cells (dashed line). (A) Single trial of stimulation of transfected cells with 1 nM 
ART for 10 min. Vectors used the promotors for the NFkB pathway, AP-1 
(MAPK/JNK pathway), SRE (MAPK/ERK pathway), or FOXO (PI3K/AKT 
pathway). (B) Stimulation of FOXO-luciferase transfected cells with various ART 
concentrations for 10 min, 1 h, and 5 h. Error bars represent the range of two 
replicate measurements. 
 
Figure 1.4. Illustration of activation of the serum response element (SRE). 
Endogenously, activation of the MAPK/ERK pathway leads to binding of 
transcription factors Elk-1 and SRF to SRE, which then activates transcription of 
c-fos and other genes. 
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SRE promoter gave a modest increase of 25% compared to untreated SRE-
luciferase transfected cells (Figure 1.3A). We therefore proceeded to optimize 
the luciferase signal by varying treatment conditions for the SRE luciferase 
reporter gene, and to cease further characterization of other promoters. As we 
did for the FOXO-luciferase cell line, we tested for the optimal ART treatment 
times giving the highest luciferase signal in cells that were transiently transfected 
with the reporter SRE plasmid. Our results showed a 3.5-fold increase in 
luciferase expression after treatment with 2-4 nM ART for 5 h, while the 
luciferase signals measured at 10 min, 1 h, and 24 h were near background 
levels (Figure 1.5A). To confirm that the luciferase signal is under the control of 
the MAPK/ERK pathway, we pre-treated the cells with 10 µM of the MEK inhibitor 
CI1040 for 10 min, which was previously shown to fully inhibit pERK formation 
(S. Li), and then added 4 nM ART and incubated the cells for 5 h. In the 
presence of the inhibitor the luciferase signal was abolished, confirming that the 
SRE induction leading to luciferase expression in these cells is downstream of 
ERK (Fig. 1.5B).  
1.2.3 Generation of stable luciferase reporter gene cell line 
Having successfully identified a RET-activated genetic regulatory element, 
we proceeded to generate a stable cell line that expresses luciferase under SRE 
control. To do this, we switched to a lentival expression system. Specifically, we 
infected cells using Qiagen’s Cignal Lenti Reporter SRE-luciferase lentivirus that 
contains the puromycin antibiotic selection marker. Per the manufacturer’s proto- 
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Figure 1.5. Luciferase activity in NB41A3-mGFRα3 cells transiently expressing 
SRE-luciferase after treatment with ART. Luciferase activity expressed as fold 
change over untreated cells; error bars represent the range of results from two 
replicate measurements.  (A) ART dose-response for treatment times of 10 min, 
1 h, 5 h, and 24 h. (B) Luciferase activity observed after treatment with 4 nM ART 
without (gray bar) or with (white bar) pre-treatment with 10 µM of MEK inhibitor, 
CI1040. 
Figure 1.6. Effect of varying MOI on luciferase induction levels. Luciferase 
activity expressed in relative luminescent units (RLU) was measured 72 h post 
stimulation; error bars represent the spread of results from two replicate 
measurements.  
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col, we infected NB41A3-GFRα3 cells with varying multiplicities of infection 
(MOI), using the positive control plasmid to establish the optimal number of viral 
particles to infect our cells with in order to generate a robust luciferase signal. 
Since the signal increased with higher MOI (Figure 1.6), we decided that infecting 
our cells at MOI = 50 would be likely to generate a robust luciferase signal. After 
culturing the cells under puromycin selection for two weeks, we tested the activity 
of the resulting stable SRE-luciferase heterogeneous cell population, NB41A3-
GFRα3-SRELuci. Treatment with varying concentrations of ART for up to 5 h 
showed that luciferase expression was increased up to ~5-fold over background 
levels (Figure 1.7), comparable to the levels observed using the transiently 
expressing luciferase-SRE cells.  
1.2.4 Generation of a monoclonal luciferase reporter gene cell line 
In an attempt to increase the signal to background ratio for our reporter 
gene assay, we generated a stable monoclonal reporter gene cell line. To do 
this, we selected 71 single-cell colonies from the pooled stable cell population 
described above. We then expanded each of these clones, and characterized 
them to compare the amplitude of the induction in luciferase expression upon 
treatment with 1.6 nM ART for 5 h. Sixteen clones that showed an increased 
response, compared to the original, pooled cells, were further characterized in a 
full dose-response experiment. Clone number 11 was found to give the highest 
amplitude of luciferase protein induction, showing a 2-fold greater level of 
induction compared to the pooled cells, corresponding  to an  overall  increase  in 
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Figure 1.7. Luciferase induction activity of pooled puromycin-selected cells 
expressing the SRE luciferase reporter gene. Cells were treated with various 
ART doses for 10 min, 1 h, or 5 h. Activity is plotted as fold change compared to 
untreated cells; error bars represent the range of results from two independent 
trials. 
 
Figure 1.8. Induced luciferase activity of the monoclonal cell line “clone #11”. (A) 
Pooled (circles) and monoclonal (squares) cell populations stably expressing the 
SRE luciferase reporter gene, and cells that express luciferase constitutively 
(black squares) treated with various concentrations of ART for 4 h. (B) Clone #11 
cells treated with soluble GFRα1:GDNF (2:1 concentration ratio) for 4 h. Error 
bars represent the range of two replicate measurements.  
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luciferase expression of 12-fold compared to  untreated  cells  (Figure 1.8A).  We  
observed an increase in luciferase reporter activity in SRE-luciferase transfected 
cells treated either with ART or with another RET ligand/co-receptor pair, 
GDNF/soluble GFRα1 (Figure 1.8B). Luciferase activity for a cell line that 
constitutively expresses luciferase under the CMV promoter was unchanged by 
ART treatment. This result shows that the ART-induced luciferase activity 
observed in the NB41A3-GFRα3-SRELuci cell line is specific to the SRE 
regulatory element. Furthermore, this demonstrates that the ART-induced 
luciferase signal in the NB41A3-GFRα3-SRELuci cells is robust compared to 
constitutively luciferase expressing cells (Figure 1.8A). All subsequent 
experiments were conducted using clone number 11.  
1.2.5 Validation that the reporter gene assay reflects RET activation 
We measured luciferase activity and various RET signaling events in the 
presence of a blocking anti-GFRα3 antibody to examine whether our assay was 
capable of detecting signaling when the ART-GFRa3-RET complex was 
compromised. First, we determined that binding of the blocking anti-GFRα3 
antibody to clone 11-NB41A3-GFRα3-SRELuci cells approached saturation at 
100 nM, using flow cytometry (Figure 1.9A). As such, we pre-treated the cells 
with 100 nM of the blocking anti-GFRα3 antibody for 1 h, followed by stimulating 
the cells with 1.6 nM ART for appropriate times for each assay type – 10 min for 
the phosphoRET (pRET) and phosphoERK (pERK) ELISAs, and 4 h for the  
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Figure 1.9. Inhibition of activated RET complex by anti-GFRα3 antibody. (A) 
Binding affinity of anti-GFRα3 antibody on NB41A3-GFRα3-SRELuci cells 
measured by flow cytometry. The solid line shows the best fit of the data to one-
site specific binding equation, Kd = 2.50 nM. (B) Cells were pre-treated with the 
specified concentration of anti-GFRα3 antibody, then stimulated with 1.6 nM 
ART, and measured for pRET formation (red) or ERK activation (black) after 10 
min, or for luciferase expression after 4 h (blue). Signals are expressed as a 
percentage of the 1.6 nM ART only treatment (dashed line). Error bars represent 
the range of two independent trials. 
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luciferase assay. We found that all three signals were effectively inhibited (Figure 
1.9 B). This finding demonstrates that the reporter gene assay can distinguish 
between ART-induced activated RET complex assembly from GFRα3-blocked 
inactivated RET.  
1.2.6 Comparison of ART-induced pRET, pERK, and luciferase activity 
To establish how our ART-induced luciferase signal compared to other 
measures of RET activation and signaling, we treated clone 11-NB41A3-GFRα3-
SRELuci cells with various concentrations of ART for 10 min, 1 h, or 4 h, then 
assayed the cell lysates for luciferase activity, and for the levels of pRET and 
pERK using the appropriate ELISA assays (Figure 1.10). The results showed that 
both pRET and pERK levels were highest at the 10 min time point, consistent 
with our previous results for non-luciferase expressing NB41A3-GFRα3 cells (S. 
Li et al.). The maximum level of pRET decreased to 60% and then to 30% of the 
level seen at 10 min, when measured at 1 h and 4 h, respectively, while 
maximum pERK levels decreased more moderately to 80% of maximum at 1 h 
and then 60% by 4 h (Figure 10A,B). Using four-parameter fit (refer to methods) 
to determine the half-maximal response (EC50) values for each of the responses 
measured, at the time corresponding to the maximum signal for that response, 
showed that of the three responses pRET (at 10 min) was least sensitive (EC50 = 
0.92 ± 0.07 nM), followed by luciferase (at 4 h; EC50 = 0.60 ± 0.33 nM), while the 
pERK response (at 10 min) was the most sensitive to ART stimulation (EC50 =  
		
20 
Figure 1.10. ART dose responses for Clone 11 cells expressing SRE luciferase 
reporter gene. Signals are plotted as a percentage of the maximum signal 
observed for treatment times of 10 min (circles), 1 h (triangles), and 4 h 
(squares). Solid lines depict four-parameter fits using the indicated data points. 
EC50 values are summarized in Table 2. Error bars represent the standard 
deviation of 3 (for all measurements except for luciferase) or 6 (luciferase) 
independent experiments. (A) PhosphoRET. (B) PhosphoERK. (C) Luciferase 
activity. (D) Dose-response data expressed as a percentage of maximum signal 
at 4 h, for pRET (red), pERK (black), and luciferase (blue). 
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0.12 ± 0.02 nM) (Figure 1.8 B, Table 1.2). Interestingly, the sensitivity for pRET 
increased after 1 h ART (EC50 = 0.30 ± 0.05 nM), even though the actual signal 
amplitude at ~50% maximal pRET is substantially less at this time than at 10 min. 
The increased sensitivity of the pERK response compared to pRET is consistent 
with our previous results with non SRE-luciferase expression cells (S. Li et al.). 
The sensitivity of the luciferaseresponse measured at the same time of 4 h is 
closer to that of pRET than pERK (Figure 1.10D).  
 
Table 1.2. EC50 values from four-parameter curve fits of Figure 1.10 data. 
 10 min 1 h 4 h 
EC50 ± 
SD 
(nM) 
95% CI 
Max 
range 
(%) 
EC50 ± 
SD 
(nM) 
95% CI 
Max 
range 
(%) 
EC50 
± SD 
(nM) 
95% CI 
Max 
range 
(%) 
pRET 0.92 ± 
0.07 
96-110  0.30 ± 
0.05 
46 - 60 0.44 ± 
0.11 
28 - 45   
pERK 0.12 ± 
0.02 
95 - 110 0.11 ± 
0.03 
69 - 91 0.21 ± 
0.02 
58 - 64 
Luci ND ND 0.59 ± 
0.30 
12 - 71 0.59 ± 
0.06 
94-108 
EC50 = half-maximal concentration 
SD = standard deviation 
CI = confidence interval 
 
1.2.7 Optimizing treatment conditions to increase signal to background ratio 
To further optimize the performance of the reporter cell-line, we tested 
various treatment protocols including varying ART treatment time, culturing the 
cells with various amounts of low to no serum prior to ART treatment, and 
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altering carbon dioxide (CO2) levels before and during treatment. In particular, we 
had observed that treatment of Clone 11 with the MEK inhibitor CI1040 
significantly reduced the basal (untreated) level of luciferase expression, which 
suggested that reducing the basal activity of ERK/MAPK signaling might improve 
the signal-to-background ratio for ART-induced luciferase expression. To test the 
effect of CO2 on luciferase activity, cells were placed in a temperature controlled 
incubator without CO2 for 20 min before ART treatment. Cells were then briefly 
taken out of the incubator for ART stimulation, and moved back to CO2-
withdrawn incubator until the end of the treatment time. We found that treating 
the cells in the absence of CO2 caused a marked decrease in basal luciferase 
signal, to levels that were closer to those seen after CI1040 treatment (Figure 
1.11). The 4-fold averaged decrease in basal luciferase activity in CO2 withdrawn 
treatments is equivalent to an averaged ~30-fold change in maximal luciferase 
activity from untreated cell. Thus, in comparison to cells treated in the presence 
of CO2, which show higher basal luciferase activity, the CO2 withdrawn cells 
resulted in an averaged maximal induction of luciferase activity of ~10-fold 
compared to untreated cells (Figure 1.11).  Modification of CO2 in the protocol 
allowed us to reproducibly achieve a more robust ART-dependent luciferase 
induction. The sensitivity of the assay was unaltered as the half-maximal dose 
was unchanged between the two treatment conditions. 
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Figure 1.11. Effect on luciferase dose-response of withholding carbon dioxide 
during ART stimulation of clone 11 cells. Luciferase signal measured after 4 h 
ART treatment with CO2 (dashed line; EC50 = 0.57 ± 0.15 nM) versus without 
CO2 (solid line; EC50 = 0.52 ± 0.11 nM). A four-parameter fit was used to 
calculate EC50 values; error bars represent the standard deviation of four 
independent experiments. Treatment with 10 µM MEK inhibitor, CI1040, with 
ART for 4 h was also included (dotted line). 
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1.2.8 Characterization of ART-treated cells without CO2  for RET signaling 
molecules and luciferase 
We further characterized Clone 11 by measuring ART dose responses for 
luciferase, pRET, and pERK activities when stimulated without CO2 (Figure 1.12). 
The results show that our optimized conditions not only improved the signal to 
background ratio, but also appeared to increase the longevity of the pRET 
response, so that pRET amplitude maximized at 4 h when treated with ART 
without CO2. This result contrasts with what was observed for cells treated in the 
presence of CO2, where the level of pRET at 4 h is lowest, and peak level occurs 
at 10 min ART CO2 (Figures 1.12 A, 1.10 A.). Indeed, the amplitude of the pRET 
response appeared to actually increase over time, with saturating pRET levels at 
10 min and 1 h being ~50% and 70% of the maximum signal seen at 4 h. This 
observation is different from the pRET dynamics observed when the cells were 
stimulated with CO2, where levels peaked at around 10 min before decreasing to 
sustained levels by 1 h (Figure 1.10 A). Furthermore, the sensitivity for pRET 
was increased under non-CO2 conditions for all treatment times, compared to 
treatment with CO2, by a factor of 2 to 4-fold. The sensitivity to ART detected by 
the luciferase signal remained unchanged between the two conditions (Tables 
1,2 and 1.3). Thus, the increase in sensitivity for pRET does not cause any 
corresponding increase in the sensitivity of the luciferase signal, compared to 
treatments with CO2 (Figure 1.12 D). For ERK activation  and  luciferase  activity,  
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Figure 1.12. ART dose responses for Clone 11 cells treated without CO2. Signals 
are plotted as a percentage of the maximum signal observed for treatment times 
of 10 min (circles), 1 h (triangles), and 4 h (squares). Solid lines depict four-
parameter fits using the indicated data points. EC50 values summarized in Table 
1.3. Error bars represent the range of two independent trials. (A) PhosphoRET; 
(B) PhosphoERK (C) Luciferase activity; (D) Dose-response data expressed as a 
percentage of the maximum signal normalized to levels at 4 h for pRET (red), 
pERK (black), and luciferase (blue). 
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the times at which maximal signal amplitude were observed, at 10 min and 4 h, 
respectively, were the same regardless of the presence or absence of CO2. 
Moreover, the average pERK levels at 1 h and 4 h when cells were treated in the 
absence of added CO2 decreased to 20-25% of maximum, whereas ART 
treatment in the presence of CO2 resulted in sustained pERK levels at 60-75% of 
that seen at 10 min.  
 
Table 1.3. EC50 values from four-parameter curve fits of Clone 11 cells treated 
without CO2 data.  
 10 min 1 h 4 h 
EC50 ± 
SD 
(nM) 
95% CI 
Max 
range 
(%) 
EC50 ± 
SD 
(nM) 
95% CI 
Max 
range 
(%) 
EC50 
± SD 
(nM) 
95% CI 
Max 
range 
(%) 
pRET 0.21 ± 
0.08 
46 - 81  0.15 ± 
0.03 
68 - 83 0.17 ± 
0.03 
78 - 98   
pERK 0.05 ± 
0.01 
87 - 102 0.11 ± 
0.03 
22 - 29 0.12 ± 
0.03 
18 - 25 
Luci ND ND 0.65 ± 
0.14 
20 - 29 0.60 ± 
0.06 
86 - 102 
EC50 = half-maximal concentration 
SD = standard deviation 
CI = confidence interval 
 
1.2.9 Establishing the stability of the luciferase reporter gene cell line  
To ensure that the signaling capability of our stable reporter gene cell line 
was capable of enduring multiple passages, we compared the luciferase signal  
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Figure 1.13. Effects of thawing and passaging on the stability of the luciferase 
signal. Cells were either frozen at the indicated passages, thawed and 
immediately adhered to plate, then treated with varying ART doses; or did not 
undergo thawing (“non-thaw”) but instead were continually passaged and treated 
with varying ART doses. (A) Comparison of non-thaw high (p40) and low (p23) 
passage numbers with thawed passage 20 cells as reference. (B) Comparison of 
thawed cells that were frozen at indicated passage number, and after thawing 
and attachment to cell plates, were treated with ART, to non-thawed p23 cells as 
reference. Error bars represent range of two replicate experiments. 
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seen after treatment with ART for 4 h ART for cells between passages 20 and 
40. Additionally, we tested whether thawed cells that were given 48 h to adhere 
to tissue culture plates were able to produce a robust, and sensitive ART 
response. To this end, we compared luciferase signals for cells that were treated 
48 h immediately following thawing and plating (no subsequent passage), to cells 
that were continuously passaged at least 5 times (limited to 2 previous freeze-
thaw cycles overall) before treatment with ART (Figure 1.13). We found that 
there was a reduction in the signal to background ratio by half, from ~50 to ~25 
for non-thawed passage 23 compared to non-thawed passage 40 (Figure 1.13A). 
Despite this decrease in luciferase induction for cells that were passaged up to 
40 times, a large signal to background was still observed, demonstrating that this 
reporter gene cell line can endure multiple passages and still sustain the ability to 
robustly quantify RET activation. Comparison of the luciferase signal for non-
thawed, passage 23 cells versus thawed, passage 20 cells showed a decrease in 
maximal luciferase signal to background from ~50 to ~35 (Figure 1.13B). The 
maximal fold-change in luciferase signal was similar for all freshly thawed cells 
regardless of passage number. This result shows that the freeze-thaw process 
impacts luciferase signal comparably to repeated passaging of cells. 
Taken together, our results show that we have developed and validated a 
sensitive, robust, and reproducible stable luciferase reporter gene cell line 
capable of quantifying RET activation and signaling.  
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1.3 Discussion 
We have successfully developed a luciferase reporter assay for 
quantifying ART-induced RET activation. Our reporter gene cell line produces 
luciferase signal under the control of SRE regulatory elements directly activated 
by the MAPK/ERK pathway. We performed single-colony selection for NB41A3-
GFRα3 cells expressing luciferase under the SRE promoter, and systematically 
determined the optimal treatment conditions to produce a robust signal. By 
withdrawing CO2 during treatment with ART for 4 h, our assay is capable of 
producing a ~40-fold induction of luciferase signal compared to non-stimulated 
cells. This reporter cell line has multiple potential uses, including quantifying RET 
activation using other RET ligands paired with the appropriate co-receptor, and 
screening for RET-related agonists or antagonists in high-throughput platforms.  
It is worth noting that our assay exclusively tests for RET activation 
mediated by the MAPK/ERK pathway. Thus, although the luciferase reporter 
assay quantifies RET activation reliably and robustly, it provides a limited view on 
RET signaling effectors since the assay cannot distinguish differences in RET 
activators that impact other signaling pathways. 
We established that the reporter cell line is relatively robust, so that even 
though there is a drop in signal to background ratio for cells that have undergone 
multiple passages and/or freeze-thaw, the luciferase signal remains robust 
enough that the reporter gene cell line is still capable of accurately quantifying 
RET activation. The immediate assaying of freshly thawed cells decreased 
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luciferase induction to levels similar to those seen with highly passaged cells 
(P40). Cells not given enough time to recover from the freeze-thaw process 
resulted in a decrease in signal amplitude. This may be contributed by the 
inability of cells to produce luciferase in response to ligand stimulation. We 
observed many floating cells after the two-day attachment process, and we 
cannot distinguish between healthy, proliferating cells from cells that are 
undergoing cell death during the attachment process. It is highly possible that the 
cells plated for the assay are degenerate from producing luciferase activity if they 
are in process of cell death. Therefore, assaying freshly thawed cells would have 
resulted in lower luciferase activity, and the cells would be suboptimal for 
measuring RET activation. Prolonged passaging of cells increases the likelihood 
for genetic drift due to mutations in the genotype of passaged cells compared to 
parental cells (Marx; Masters and Stacey). Additionally, the longer the cells 
undergo sub-culturing, the higher the risk for cells to be subjected to suboptimal 
growth conditions, such as occurrences of overgrowth, which can affect pH 
and/or nutrient availability (Marx; Masters and Stacey). Our luciferase reporter 
gene cell line performs best at low passage numbers, and we recommend 
thawing a new aliquot of cells once they reach ~40 passages. Immediate use of 
the cells upon thawing is discouraged; we encourage allowing cells time to 
recover from the freeze-thaw process by passaging them a couple of times 
before running an assay.  
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Luciferase reporter gene assays are experimentally convenient in diverse 
quantitative applications. These types of biochemical assays are also 
advantageous for their ability to clearly define the transcription mechanism 
responsible for luciferase signal activation, because the regulatory element 
upstream of the luciferase gene is known. Our maximum luciferase signal 
induction of ~13-fold when treated with CO2, and ~40-fold without CO2, is 
comparable to the performance of published luciferase reporter assays 
developed to quantify other types of receptor activation (Z. Cheng et al.) or 
transcription regulation (Guan et al.; Usenko et al.), which range between 5- and 
100-fold induction. The aforementioned studies stimulated their cells for 2-24 h, 
and all studies included CO2.  
Our assay detects RET signaling via ERK/MAPK pathway-induced SRE 
activation, but we do not rule out the possibility of generating a RET reporter 
assay using other promoters. We did not thoroughly test other treatment times 
that may effectively produce luciferase activity. In fact, there is a high possibility 
of generating reporter assays under the control of other promoters related to 
other, non MAPK/ERK RET signaling pathways given the robustness of the 
phosphorylation events measured using other assays (S. Li et al.). In retrospect, 
the ART stimulation time of 10 min we used in our initial screen was too brief. We 
should have stimulated the cells for at least 60 min before detecting for luciferase 
signal. Synthesis of protein is a multi-step process, including and not limited to, 
transcription, translocation of the mRNA to the ribosome, and translation, which 
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typically takes ≥ 15 min for an average sized protein (~50 kDa) (Ardehali and Lis; 
Ingolia et al.; Singh and Padgett). Thus, we would likely have improved our 
chances of detecting a response had we allowed more than 10 min for upstream 
signaling events (i.e., pRET and pERK) to evolve and for the accumulation of 
newly synthesized luciferase to occur before measuring ART-induced luciferase 
activity.  
As an alternative approach, we measured the inhibition of luciferase signal 
by the FOXO regulatory element, which is inhibited upon activation of the 
Akt/PI3K pathway. But we decided not to proceed with designing a loss of 
function luciferase assay as a result of inactivation of FOXO-mediated gene 
expression. Though we did not proceed to fully develop a FOXO reporter gene 
assay, our initial results suggest that a RET-induced, ART-dependent luciferase 
assay based on FOXO could be feasible by optimizing treatment conditions to 
increase signal loss compared to background, similar to the optimization of 
conditions conducted for the SRE reporter gene assay.  
Under standard culture conditions including 5% CO2, the ART-
dependence of activation for both RET and luciferase show similar sensitivities, 
in terms of the EC50 values for pRET activation and luciferase activity at 4 h 
(Table 1.2). Thus, the luciferase response can be considered as an approximate 
surrogate for RET activation under standard culture conditions. On the other 
hand, the EC50 value for pERK at 4 h ART in standard cell culture conditions is 3-
fold lower than that for the luciferase signal; so that the ART-induced pERK 
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response occurs at lower ART doses than are required for a luciferase response. 
This finding is surprising, since the SRE regulatory element is downstream of the 
ERK in the MAPK/ERK pathway. The difference in sensitivity describes how the 
luciferase response requires more ART compared to pERK in order to achieve 
half-maximal activity. Even though the luciferase protein expression is a direct 
effect of MAPK/ERK signaling, the difference in sensitivities between ART-
induced luciferase protein and pERK responses may be explained by a number 
of speculative possibilities. For example, the luciferase response may require 
signaling of other parallel pathway downstream of RET, and the response of the 
other pathway(s) to ART is less sensitive compared to pERK, so that the other 
parallel event is limiting luciferase expression at ART levels when pERK is 
already close to maximal levels. Another possibility is that luciferase response, 
and perhaps others under the control of the SRE, is not as sensitive compared to 
pERK. Moreover, the pERK response may be more sensitive to ART compared 
to ART levels required for proper cellular function though ERK, though we did not 
measure other functional responses.  
We discovered that by treating the cells under carbon dioxide deprivation 
conditions, we effectively increased the assay’s signal to background ratio by 
lowering the background signal. We found that the averaged overall ART-
induced maximum signal without background normalization was similar 
regardless of the presence of CO2. This result indicates that the ability of the 
cells to express luciferase when ART was present was unaffected. Carbon 
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dioxide sustains the bicarbonate buffer system in the medium, so the purpose of 
culturing cells under carbon dioxide is to maintain optimal pH levels by 
preventing CO2 from evaporating from the medium. By not supplying CO2, we 
altered the pH of the cell medium to more alkaline levels. There are conflicting 
reports on the effect of low and high pH on MAPK/ERK activity. Stathopoulou. et 
al. found that high pH increases cell survival signaling by activating MAPK/ERK 
in cardiac myoblasts, while Punn, et al. found that simulated ischemia lowered 
pH, which resulted in sustained ERK activity for cytoprotection (Punn et al.; 
Stathopoulou et al.). Although we did not measure the pH of the culture medium 
during treatment conditions, the phenol red pH indicator present in the medium 
displayed a magenta color, indicating a basic pH. Our results suggest that high 
pH lowers basal luciferase activity by lowering MAPK/ERK signaling, though to 
prove this we would need to measure the pERK levels observed upon ART 
stimulation with and without CO2. Another possible explanation for this difference 
in basal luciferase activity may be that pH affects signaling components globally 
in the cell.  In other words, by lowering the synthesis of all proteins at basal 
conditions, this would decrease luciferase signal in untreated cells, and 
stimulation by growth factor would result in an induction of luciferase gene as a 
result of activation of the MAPK/ERK pathway, but more tests are required to 
confirm this hypothesis.  
Another interesting effect of withholding CO2 is the change in the 
sensitivity of the pRET response and the time at which maximum pRET levels 
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occur. ART has been shown to play a role in neuronal survival by the enhanced 
proliferation of cultured primary peripheral and central neurons in the presence of 
ART (Baloh et al.). Thus, if altering pH affects cells globally by stressing the cells 
to conserve energy by lowering protein production, extended ART-stimulated 
RET activation would turn on survival signals in response to the stressed 
condition. There are at least two possible mechanisms to explain the high levels 
of pRET seen at late treatment times in the absence of added CO2: 1) CO2 
withdrawal decreases the rate at which pRET is degraded, so that the lifetime of 
pRET molecules is extended; or 2) CO2 withdrawal stimulates an increase in the 
number of RET molecules on the cell surface, so that even though pRET 
degradation occurs at the normal rate, total RET levels – and levels of 
phosphoRET – are increased due to the accelerated expression of new RET 
molecules. These hypotheses could be tested in future experiments, by 
measuring ART-induced levels of protein translation factors such as eukaryotic 
inititation factor 4E-binding proteins or ribosomal activity.   
In conclusion, we have developed a stable, monoclonal luciferase reporter 
gene cell line that can be used to quantify RET-related or non-RET-related 
agonists or antagonists that affect MAPK/ERK signaling in NB41A3 cells. We 
have validated that the assay dose-dependently generates a robust and sensitive 
luciferase response upon treatment with ART. Furthermore the assay can be 
used with different ligand/co-receptor pairs to quantify RET activation as shown 
by the induction of luciferase activity when cells were stimulated by soluble 
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GFRα1/GDNF. Enhancement of the signal to background is achieved by altering 
the CO2 treatment condition, and the cell line is stable to produce robust signal 
through multiple passages and minimal freeze-thaw cycles. Thus, the luciferase 
reporter gene cell line provides a convenient way to quantify RET activation, and 
possibly to measure other stimuli that activates the MAPK/ERK. 
1.4 Materials and methods 
1.4.1 Materials. 
Sodium orthovanadate, sodium deoxycholate, Sodium fluoride, Sodium chloride, 
EDTA, EGTA, N-40, sodium pyrophosphate, phenylmethanesulfonyl fluoride 
(PMSF), Tween-20, beta-glycerophosphate (BPG), bovine serum albumin and 
trizma base were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine 
serum, puromycin, and Dulbecco’s phosphate buffered saline were purchased 
from Fisher Scientific (Waltham, MA). Human artemin and the NB41A3-mGFRα3 
cell line were generous gifts from Biogen Idec (Cambridge, MA). The PathScan 
phospho-p44/42 MAPK Thr202/Tyr204 Sandwich ELISA antibody pair (cat. no. 
7246S) was obtained from Cell Signaling Technology (Danvers, MA). The mAb2 
rabbit capture antibody for pRET KIRA ELISA and the anti-mGFRα3-blocking 
antibody were generous gifts from Biogen Idec (Cambridge, MA) and the generic 
mouse anti-phosphotyrosine antibody (cat. no. 037720) and human IgG isotype 
(cat. no. 12000C) were purchased from Invitrogen (Carlsbad, CA). The anti-
human goat antibody (cat. no. I5260) was purchased from Sigma Aldrich, and the 
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anti-goat-Alexa 647 (cat. no. A21244) was purchased from Invitrogen (Carlsbad, 
CA). The CI1040 MEK inhibitor (cat. no. S1020) was purchased from 
Selleckchem (Houston, TX). 
1.4.2 Cell culture 
 NB41A3-mGFRα3 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine 
and 500 ug/mL hygrogmycin B in an incubator with 5% CO2 at 37°C. Hygromycin 
B was purchased from EMD Millipore (Billerica, MA). All other reagents were 
obtained from Invitrogen (Carlsbad, CA).  
1.4.3 Generation of Transient Reporter Cells 
NB41A3-mGFRα3 were transfected at 1.5 x 106 cells onto 6-well 
polystyrene tissue culture dish one day before. A mixture of 1 µg SRE plasmid 
with 8 µl of Attractene transfection reagent in 400 µl serum-free DMEM was 
added to cells. Media was changed 24 h post transfection, and cells were ready 
for ART treatment 48 h after. Cignal Reporter SRE (cat. no. CCS-010L), NFκB 
(cat. no. CCS-013L), FOXO (cat. no. CCS-1022L) AP-1 (cat. no. CCS-011L) and 
Attractene (cat. no. 301005) were purchased from Qiagen (Valencia, CA) 
1.4.4 Generation of luciferase reporter gene cell line 
NB41A3-mGFRα3 were plated at 5 x 104 cells per well the day before, 
and infected with serum-response element (SRE) Cignal lentiviral luciferase 
reporter virus (cat. no. CLS-010L) at 50 MOI using 8 µg/ml polybrene. The SRE 
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luciferase reporter gene cell line was selected using 5µg/ml puromycin and 100 
µg/mL hygromycin B over a 14-day period. The SRE Cignal Lenti Reporter (cat. 
no. CLS-010L) was purchased from Qiagen (Valencia, CA).  
1.4.5 Single-cell selection 
Pooled cells were serially diluted out at 1:2 directly onto a 96-well 
polystyrene tissue culture plate. Single cell colonies were expanded onto 24-well 
polystyrene plates, and plated onto white opaque 96-well tissue culture plates. 
Preliminary tests were performed at 1.6 nM ART stimulation. Clones with ≥ 30-
fold change in luciferase readout compared to untreated cells were aliquoted out 
and frozen in 5% DMSO at 1x106 cells per tube. 
1.4.6 Luciferase assay 
NB41A3-mGFRα3-SRELuci cells were plated at 1x105 cells/well on an 
opaque 96-well tissue culture plate (Falcon, Miami, FL) and incubated overnight. 
The cells were starved with serum-free DMEM for 24 h prior to addition of human 
artemin (hART) for 10 min, 1h, 4h respectively. After incubation, cells were 
washed with PBS and lysed with 20 µl of cell culture lysis reagent (cat. no. 
E1531; Promega, Madison, WI) for 20 min with vigorous shaking. Luminescence 
was measured upon addition of 75 µl 5’-fluoroluciferin (Promega, Madison, WI) 
using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA).  
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1.4.7 KIRA (pRET) ELISA  
Kinase Receptor Activation (KIRA) ELISA was used to quantify receptor 
phosphorylation levels. SRE-NB41A3-mGFRα3 cells were seeded overnight on a 
clear-bottom 24-well plate (Falcon, Miami, FL) at 3x105 cells/well in 0.5 mL 
growth media. The receptor was activated by addition of hART for 10 min, 1h, 
and 4h respectively. After incubation with ART, the cells were lysed for 20 min 
with KIRA lysis buffer (10mM Tris, 0.5% NP-40, 0.2% sodium deoxycholate, 50 
MM NaF, 0.1 Na3VO4, 1mM PMSF) while shaking gently. The 96-well ELISA 
plate (Falcon, Miami, FL) was incubated overnight at 4°C with 100 µl of anti-rat 
RET MAB2 antibody in PBS and blocked for 1h with KIRA blocking buffer (PBS 
with 0.01% Tween-20 (PBST), 3% bovine serum albumin, 1% fetal serum 
albumin). For each treatment, a 100 µl aliquot of clarified cell lysate was added to 
a well and the plate was incubated for 2h at room temperature while shaking 
gently. The plate was then thoroughly washed with PBST and incubated at room 
temperature with 100 µl horseradish peroxidase (HRP)-conjugated mouse anti-
phosphotyrosine antibody (1:100 dilution) in blocking buffer. After 1h, the plate 
was washed with PBST and developed by incubation with 3,3’-5,5’-
tetramethylbenzidine dihydrochloride (TMB) (Pierce, Waltham, MA). The reaction 
was quenched with 1 M H2SO4 and the absorbance was obtained at 450 nm 
using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA). 
The plastic plate background was measured at 540 nm and subtracted from the 
sample absorbance.  
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1.4.8 pERK and pAkt ELISAs  
Downstream activation of ERK was measured by ELISA using PathScan 
phosphor-p44/42 Th. SRE-NB41A3-mGFRα3 cells were seeded overnight in a 
24-well plate at 3x105 cells/well in 0.5 mL growth media. The receptor was 
activated by addition of human artemin (0, 0.016, 0.041, 0.102, 0.256, 0.640, 1.6, 
4, 10 nM) for 10 min, 1h, and 4h respectively. After incubation with ART, the cells 
were lysed for 20 min with pERK/pAkt lysis buffer (20mM Tris, 150 mM NaCl, 
1mM EDTA, 1mM EGTA, 1%Trition-100, 2.5 mM sodium pyrophosphate, 1 mM 
beta-glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1 mM PMSF) while shaking 
gently. The 96-well ELISA plate was incubated overnight at 4°C with 100 µl of 
anti-phospho-p44/42 MAPK (T202/Y204) capture antibody, or anti-phospho-Akt1 
(Ser473) capture antibody in PBS and blocked for 1h with pERK/pAkt blocking 
buffer (1% bovine serum albumin in PBST). For each treatment, a 100 µl aliquot 
of clarified cell lysate was added to a well and the plate was incubated for 2h at 
room temperature while shaking gently. The plate was then thoroughly washed 
with PBST and incubated for 1 h at room temperature with 100 µl anti-pp44/42 
MAPK detection antibody or anti-Akt1 detection antibody (1:100 dilution) in 
blocking buffer. A wash step was followed by detection with HRP-conjugated 
anti-mouse IgG. After 1 h incubation, the plate was washed with PBST and 
developed by incubation with TMB. The reaction was quenched with 1 M H2SO4 
and the absorbance was obtained at 450 nm using a SpectraMax M5 microplate 
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reader (Molecular Devices, Sunnyvale, CA). The plastic plate background was 
measured at 540 nm and subtracted from the sample absorbance.  
1.4.9 Real-time reverse transcription polymerase chain reaction (RTqPCR) 
  To identify genes that are up-regulated upon RET activation, RTqPCR 
trials with different primers (refer to appendix for primer pairs) were conducted. 
SRE-NB41A3-mGFRα3 were plated on a 12-well plate at 6 x 105 cells/well in 0.5 
mL growth media. The cells were treated with specific doses of ART exactly as 
done previously for pERK/pAkt ELISA. RNA was extracted from cells using 
RNAeasy Mini Kit (cat. no. 74104, Qiagen, Valencia, CA). DNA was removed 
from RNA by treating with DNase Set (cat. no. 79254, Qiagen, Valencia, CA) and 
cDNA was synthesized using 1 µg RNA and the iScript cDNA synthesis kit (cat. 
no. 170-8891BUN, Bio-Rad, Waltham, MA). For each RTqPCR trial, 0.01 µg (1x) 
cDNA were combined with 5x SYBRGreen (cat. no. 4472918, Life Technologies, 
Carlsbad, CA), 0.75 nM final concentration of each forward/reverse primer, and 
water. All RTqPCR trials were conducted as 10 µl reaction on a 384-well plate 
using ABI 7900HT Fast Real-Time PCR System (Applied Biosystems, Grand 
Island, NY). Standard qPCR protocol: 1 cycle at 94°C for 15 sec, 40 cycles at 
94°C for 15 sec, 60°C for 30 sec, 72 °C for 30 sec.  
1.4.10 Blocking GFRα3 antibody 
NB41A3-mGFRα3 cells were lifted and 2 x 106 cells were stained with 
either anti-mGFRα3-blocking antibody or human IgG isotype for 1 h in 3% FBS. 
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Cells were then washed with PBS and stained with a pre-incubated anti-human 
goat and anti-goat-Alexa 647 detecting antibodies for 45 min. Cells were washed 
and analyzed for binding using FACSCalibur (BD Biosciences, San Jose, CA) 
using the FL-4 channel. To prevent activated RET-GFRα3-ART complex 
assembly, NB41A3-mGFRα3 cells were incubated with the anti-mGFRα3-
blocking antibody for 1 h before ART treatment, and followed by the procedures 
outlined in the KIRA, pERK, and luciferase sections above. 
1.4.11 Data analysis 
Dose-response data for ART-induced pRET, pERK, and luciferase were  
analyzed using a logistic four-parameter fit equation 1:  𝑋 = !!"#!! !"!"!"# !"#$%      (Eq. 1) 
where X = pRET, pERK, or luciferase, Xmax is the percent maximum upon 
stimulation by ART; the EC50 represents the ART concentration required to 
achieve half-maximal response; and slope corresponds to steepness of the 
curve. All curve fits were performed using Prism 7 software (GraphPad Software 
Inc., La Jolla, CA). 
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COUPLING OF TRANSCRIPTIONAL AND TRANSLATIONAL SIGNALING 
DYNAMICS TO ACTIVATION OF RET RECEPTOR TYROSINE KINASE 
2.1. Introduction 
Cells respond to environmental stimuli in a regulated way by transducing 
these stimuli into organized intracellular signals. One example of this type of 
activity is the activation and subsequent signaling of growth factor (GF) 
receptors, such as receptor tyrosine kinases. At the simplest level, such 
processes involve initial formation of an activated receptor complex through 
binding of a specific GF ligand, which then results in intracellular 
autophosphorylation of the receptor at tyrosine residues (Lemmon and 
Schlessinger; Ullrich and Schlessinger). Receptor activation initiates cascades of 
downstream signaling events that ultimately elicit a functional cellular response 
via changes in mRNA and protein levels. Thus, GF signaling plays an essential 
role in a myriad of cellular functions, including cell survival and proliferation, 
differentiation, and cell-cell communication (Bogenrieder and Herlyn; Böttcher 
and Niehrs; Dollé et al.; Mizui et al.; O’Kusky and Ye; Vlasova-St Louis and 
Bohjanen).  
2.1.1 Approaches to studying coupling of receptor activation and downstream 
effectors 
The quantitative relationships between receptor stimulation and the 
subsequent events that occur have been explored by determining the coupling of 
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upstream events to proximal and distal downstream processes (Costa et al.; 
Kaya et al.; S. Li et al.; Riese et al.; Salazar et al.). There are two main 
approaches to studying the relationships between receptor activation and 
downstream signaling events: 1) systems-based approaches that include “-
omics” methods that capture changes of global events in the cell, and 2) targeted 
approaches that measure the relationship between a specific pair of upstream 
and downstream events. Although there are trade-offs to both types of 
investigations, they are both valuable in providing a glimpse of the intricacies 
involved for cells to successfully transduce stimuli into cellular function. 
Proteomics and transcriptomics technologies have been instrumental in 
contributing to our understanding of the orchestration of cell signaling events in 
context specific conditions (Amit et al.; Lu et al.; Molina-Navarro et al.; Natarajan 
et al.; Olsen et al.; Reddy et al.). For example, Reddy et al. measured the early 
signaling dynamics of the epidermal growth factor receptor (EGFR) by 
stimulating human epithelial cells at different concentrations of epidermal growth 
factor (EGF) and used mass spectrometry to measure system-wide 
phosphorylation events for up to 80 s at 10 s after EGF stimulation (Reddy et al.). 
They uncovered EGFR activation mechanism dynamics relating to the proximal 
activation of src family kinases, a family of non-receptor tyrosine kinases, and the 
subsequent phosphorylation of PI3K, followed by recruitment of adaptor proteins 
to the receptor to fully activate MAPK/ERK pathway (Reddy et al.). As such, 
those types of studies generate an abundance of data, which can be further 
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broken down to profile signaling networks and help identify activation 
mechanisms of proximal and distal events. With improved availability and access 
to omics technologies, the dynamic quantitative relationships between signaling 
events and function are now more readily available, and can be put into 
biological contexts.  
Though lacking the breadth of omics methods, targeted approaches focus 
on specific events in signaling that can provide a deeper understanding of the 
quantitative, spatial and/or temporal factors that drive and regulate those events. 
For example, generating quantitative kinetic profiles for specific cell signaling 
events can provide insight on important dynamic features relating to the timing of 
when cells commit to certain events, such as protein expression of gene targets. 
Chen et al. used a targeted approach to uncovering key ERK/Akt signaling 
features that drive cellular function by treating PC12 cells with nerve growth 
factor (NGF) or EGF in addition treatments with inhibitors and measured 
activation of ERK and Akt activities by single-cell image analysis (Chen et al.). 
They generated a 2-dimensional pERK/pAkt response map to elucidate a 
signature response from the two molecules that form a “boundary” that 
distinguish cells that proliferate from cells that differentiate (Chen et al.). Their 
data shows a defined pERK/pAkt signaling boundary, where proliferating cells 
resulted in a distinct profile of pERK and pAkt responses from the pERK and 
pAkt responses of differentiating cells, and that the interplay of the pERK/Akt 
signals are different from the consequence of signaling of either pathways 
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independently (Chen et al.). Thus, there are diverse methods to studying signal 
transduction, and both are important in furthering the understanding of key 
signaling characteristics and relationships between them. Moreover, the 
quantitative approaches to studying signaling enable us to discuss those 
relationships in relative terms. 
2.1.2 Coupling of RET receptor activation and downstream effectors 
The activated RET receptor complex is believed to be a pentameric 
complex with the composition of [RET]2/[GFRα]2/[ligand], once activated, 
downstream events include activation of the Raf/MEK/ERK MAPkinse and 
PI3K/Akt pathways (Figure 2.1) (Schlee et al.; Takahashi). We have previously 
quantified the molecular and kinetic mechanisms of RET activation, along with 
the coupling of RET to downstream signaling pathways (S. Li et al.; Schlee et 
al.).  Schlee, et al., previously quantified the number of activated RET complexes 
induced by stimulation of NB41A3-mGFRα3 cells with ART, at various levels of 
available GFRα3 (Schlee et al.). Fitting the observed relationships to candidate 
mechanistic models led them to propose that RET activation occurs as a result of 
ART first binding to one molecule of GFRα3, followed by subsequent binding of 
one RET molecule, and then additional molecules of GFRα3 and RET. Li et al. 
addressed the coupling of RET activation to the divergent signaling pathways, 
MAPK/ERK and PI3K/Akt downstream, and to neurite outgrowth (S. Li et al.). 
Their work revealed that the coupling efficiency between RET and downstream 
signaling is dependent on the concentration of ligand, where the receptor-effector 
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coupling efficiency is high at physiologically low stimulus levels that correspond 
to stimulus levels that induce cells to differentiate. Furthermore, the receptor-
effector relationships that drive RET-activated cell signaling into biological 
function is obscured at high, super-physiological levels of stimulation since the 
high overall signaling resulted in lower receptor-effector coupling, which is not 
relevant to function. Although the work by Li et al. interrogated the early events in 
RET activation ≤ 90 min, they did not address further downstream events 
between activated intracellular signaling molecules and biological function. 
Activation of canonical signaling pathways such as the those mentioned above 
play important and diverse roles in gene expression that eventually drive 
biological function (El-Daly et al.; M.-S. Lee et al.; Shankar et al.; Zhao et al.).  
2.1.3 Transcriptional and translational responses to extracellular stimuli 
Changes in gene expression are driven by the cell’s response to 
environmental change, which then affect protein levels and direct the cell’s 
functional response by driving processes such as cell cycle, differentiation, 
apoptosis, and survival (Brivanlou; Karin). Regulation during gene expression 
occurs at the transcription level, mainly through transcription factors binding to 
promoter sites to induce or repress gene expression, thereby regulating mRNA 
synthesis (Bentley; Karin). Ultimately, the goal in tuning gene expression is to 
regulate the level of protein for which the gene codes. However, there are other 
many other processes, such as post-transcriptional regulation through mRNA 
maturation, degradation or inhibition (e.g. by siRNAs, miRNAs, etc.), and post-
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translational modifications and trafficking of the initial products of translation, that 
play pivotal roles in regulating protein expression, with each step having 
regulatory mechanisms of its own. Briefly, post-transcriptional regulation occurs 
when factors influence mRNA stability so that translation of the transcript will 
affect protein levels. mRNA decay is strongly influenced by the poly (A) tail, AU-
rich elements, and the 5’ and 3’ untranslated regions of the transcript, which 
dictate the exonucleases and other RNA binding factors that regulate mRNA 
stability. Thus, any components that affect mRNA lifetime describe post-
transcriptional regulation (Gilbert et al.; Radhakrishnan and Green; Thapar and 
Denmon; Vlasova-St Louis and Bohjanen). Likewise, post-translational 
modifications such as phosphorylation and ubiquitination affects protein stability, 
and thus are tools that cells use to affect overall protein abundance (Holt; Liu et 
al.). There is consensus that <0.50 correlation exist between mRNA and protein 
abundance, which led researchers to further investigate the contribution of 
transcription and translation machineries to protein expression (Lu et al.; 
Schwanhäusser et al.; Vogel et al.). Their findings, which are mostly based on 
systems-based proteomics experiments, are heavily context dependent. For 
example, Schwanhausser, et al. measured mRNA and protein levels in dividing 
murine fibroblasts, and ranked the factors contributing to protein abundance 
using combined predictive modeling and correlation scores as: translation rate > 
transcription rate > protein degradation = mRNA degradation (Schwanhäusser et 
al.). The fundamental relationship between mRNA and protein is that mRNA gets 
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translated into protein, although more complex relationships between RNA and 
protein exist. Nonetheless, the level of mRNA present should be considered 
when determining protein abundance. As such, in another study combining 
proteomics and computational modeling, Rabani et al. measured global RNA 
levels during cell-growth and differentiating human cells with the goal of 
addressing whether transcription rate or mRNA stability contributes most to 
mRNA abundance. They found that changes in transcription rates play a bigger 
role in RNA abundance compared to the impact of RNA degradation rates 
(Rabani et al.). Although they did not measure protein abundance, their findings 
are important to relate mRNA lifetime with protein production, and the potential 
impact transcription rate has on protein production. Besides measuring 
transcriptional changes, protein synthesis, and mRNA stability as determining 
factors to protein abundance, another approach to determining protein 
abundance is to measure the translation efficiency of a specific gene. Translation 
efficiency (TE) is commonly defined by two distinct definitions: 1) defined as the 
rate of translation per mRNA molecule encoding for the gene product in question, 
and 2) the ribosome density per mRNA (G.-W. Li; Plotkin and Kudla). The 
definitions are distinct because the first directly refers to total protein synthesis, 
while the second refers to the efficiency of ribosomal usage. There is little 
correlation between ribosomal density per mRNA and total protein production at 
basal conditions because ribosomal activity is not strained, translation initiation is 
the rate-determining step for protein production (Ghaemmaghami et al.) 
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However, there may be a correlation between the two TE definitions when genes 
are overexpressed since ribosomal activity is stressed, translation initiation would 
be reduced globally, and the density of ribosomes on mRNA during gene 
induction affects protein translation rate per mRNA (G.-W. Li; Plotkin and Kudla). 
Here, we refer to translation efficiency as rate of translation per mRNA, which 
may be a better indicator for protein abundance compared to level of mRNA 
abundance, mRNA stability, and even translation rate since it factors in 
translation rate and any dynamic changes in the number of available mRNA (G.-
W. Li; Vogel and Marcotte). To the best of our knowledge, how translation 
efficiency varies over time has yet to be addressed in the literature. Here, we 
show that measuring the kinetics of transcription and translation can be used to 
evaluate translation efficiency quantitatively, which can be useful to reveal if and 
how cells adjust TE over time to regulate gene expression. 
2.1.4 Quantitative measurements in activated receptor signaling 
 The number of studies that quantify the absolute number of molecules 
involved in receptor stimulated signal transduction is growing with increased 
interest in elucidating signaling networks by data-driven analyses (Barta et al.; 
Chatelier et al.; Novy et al.; Panke et al.; Shi et al.). Quantiative measurements of 
receptor stimulated signaling molecules are often difficult to generalize, due to 
the specific biological context of those measured values. For example, in a study 
that developed antibodies to quantify different growth factor receptors, including 
tyrosine-protein kinase Met (cMET), human epithelial growth factor receptor- 1 
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(EGFR1/HER1), -2 (ErbB2/ HER2), and -3 (ErbB3/HER3), the authors found that 
the number of growth factor receptors expressed on the cell surface is cell-type 
specific, ranging from 5 x 103 - 106 molecules per cell (Panke et al.). This broad 
range of values is also seen in the half-lives of mRNA. In one study in non-
synchronized dividing murine fibroblasts, the median mRNA half-life was 9 h, but 
in other studies using a different cell-type of murine dendritic cells, the median 
RNA half-life was 80 min (Rabani et al.; Schwanhäusser et al.). Though both 
studies acknowledge the large differences in half-lives in the respective papers, 
they did not explicitly explain why there was such a large difference. In addition 
to the apparent difference that one paper measured mRNA, while the other 
measured the half-life of total RNA, we can also speculate that the difference in 
median mRNA/RNA half-lives can be attributed by the differences in cell-types, 
as well as differences in the cell cycle states, which has been shown to influence 
RNA half-life in similar cell-types (Narsai et al.; Yang et al.).  
On the other hand, median protein half-lives measured by two different 
studies are in agreement, giving values between ~43-46 h, and with a broad half-
life range of 0.5 – 5,700 h, depending on the protein (Cambridge et al.; 
Schwanhäusser et al.). This large range in protein half-life has been associated 
with biological function, where proteins that have roles in cell proliferation, 
differentiation, metabolism, and respiration have longer half-lives, while proteins 
that have transcriptional regulatory functional and signal transduction roles have 
shorter half-lives (Kristensen et al.; Yang et al.). Furthermore, the number of 
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mRNA and proteins expressed in the cell are also gene specific, though there is 
a consensus that cells express a high number of proteins per mRNA regardless 
of gene type (Schwanhäusser et al.; Velculescu et al.). 
Collectively, the diversity in numbers of signaling effectors expressed or 
activated is highly dependent on the biological context of the cells and on the 
cell-type. This highly context-dependent interpretation of quantitative 
measurements highlights the fundamental difficulties of generalizing the 
measurements, and further extends the demand for quantitative measurements 
of the relationship between different input and output conditions at different time 
points. Cell signaling is a dynamic process in which key information on the extent 
and timing of key events can be misinterpreted or overlooked if studies include 
only measurements made at steady state. To expand the quantitative 
understanding of receptor stimulated cell signaling events, we measured the 
coupling of RET activation to proximal and distal responses including 
transcription and translation of different ART-induced genes, with the goal of 
developing a quantitative understanding of input-output relationships that 
captures key features that relate to the dynamics, amplification, and sensitization 
of those events. We further apply the understanding of key features to determine 
whether there are times at which cells commit to important events, such as 
protein expression. 
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2.1.5 Goals 
Most signaling studies focus on events occurring at a particular level in the 
process (e.g., on the membrane, at the level of phosphorylation of intracellular 
signaling molecules, at the level of transcription factor activity and their 
interactions with DNA, or at the levels of transcription or translation). Instead, we 
are interested in taking a longitudinal view of signaling by achieving a quantitative 
understanding of a single signaling pathway from initial stimulation of the 
receptor by its growth factor (GF) ligand, through to gene transcription and 
translation. Our work here describes the coupling of ART-induced RET activation 
to ERK phosphorylation, and to transcription and translation of endogenously up-
regulated genes, c-fos and IL-6, and to the exogenous luciferase gene using the 
luciferase reporter gene cell line developed in Chapter 1. The luciferase reporter 
gene is under the control of the serum response element (SRE), which is 
activated upon MAPK/ERK activation. The inducible transcription factor SRE 
response element is joined by the basal promoter element, TATA box, followed 
by the luciferase gene, and no other enhancers are present. Thus, we used the 
NB41A3-GFRα3-SRELuc cell-line that expresses luciferase under the control of 
the SRE element to isolate the downstream effects of the MAPK/ERK pathway 
downstream of RET signaling. We extended ART treatments for up to 8 h to 
quantify the dynamics, the amplitude, and the sensitivity of targeted signaling 
effectors to transcription and translation of the luciferase, c-fos, and IL-6 genes. 
We used the kinetic profiles to identify key features on how cells respond to 
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external stimuli, how upstream signaling events are coupled to transcription and 
translation, and at what point in the process do cells become committed to 
protein expression (Figure 2.1).  
2.2 Results 
2.2.1 Dynamics of ART-induced RET activation and pERK 
Previously, we characterized the dynamics of RET activation and of pERK 
levels in NB41A3-GFRα3 cells, occurring up to 90 min after stimulation of the 
cells with ART (S. Li et al.). Here, our aim was to characterize the coupling of 
phosphorylated RET (pRET) to the immediate intracellular signaling effector 
pERK, and to transcription and translation of targeted genes. To that end, we 
treated NB41A3-GFRα3-SRELuc cells with 1.6 nM ART for 8 h, and measured 
the pRET and pERK concentrations present in the cell lysates using ELISA 
methods (Figure 2.2). We have previously calibrated the ELISA assays used to 
measure pRET and pERK, which allowed us to express these results in terms of 
the absolute average number of activated RET and ERK molecules per cell (S. Li 
et al.). We found that after 30 min stimulation of the NB41A3-GFRα3-SRELuc 
cells with ART resulted in peak accumulation of phosphorylated RET (pRET) at 
~5,400 molec./cell, then a slight  decrease  to  ~4,000  molec./cell 
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Figure 2.1. Scheme of RET signaling pathway and nuclear responses. Signaling 
molecules that were measured in this study are indicated in red; small ovals 
indicate phosphorylation sites. 
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after 120 min, and remained at that level for at least up to 8 h after initial ART 
stimulation (Figure 2.2). Thus, the dynamics of the pRET and pERK responses 
were broadly similar, both peaking after a few minutes, diminishing out to ~ 120 
min, and then stabilizing at a sustained level out to 8h. The relative amplitudes of 
the sustained responses were somewhat different, however, with pRET dropping 
by 25% from its maximum, while pERK decreased by 50% from its maximum 
level. Our transient pRET peak is more pronounced, and involves activation of 
slightly more molecules per cell, compared to previously published time course 
for 1 nM ART stimulation for up to 90 min, (S. Li et al.). Although our pERK 
transient peak agrees well with the same previous report, occurring at 10 min 
ART, the number of molecules activated is also slightly higher. The previous 
measurements of ART-induced pRET response showed a steady increase of up 
to 3,500 molec/cell, from initial to 90 min ART, and that pERK levels maximized 
at 80,000 molec./cell (S. Li et al.). This minor variation in kinetics and amplitude 
could be due to the small difference in the ART concentrations used in the two 
studies (1.6 nM here versus 1.0 nM previously) or could reflect the use of 
NB41A3-GFRα3-SRELuc cells here versus the NB41A3-GFRα3 cells from which 
this clone was derived (see Chapter 1) in the previous work.  
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Figure 2.2. Dynamics of RET and ERK activation. NB41A3-GFRα3-SRELuc cells 
were treated with 1.6 nM ART and pRET (filled circles) and pERK (open circles) 
were measured using ELISA. The results were converted to absolute numbers of 
molecules per cell by reference to previously established standard curves 
(Appendix III). Error bars represent standard deviations of results from 3 
independent experiments. 
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2.2.2 Dynamics of RET-activated luciferase transcription  
To provide a convenient, robust and quantitative read-out for 
transcriptional and translational events controlled by RET, we developed a 
reporter gene assay in which stimulation of RET signaling resulted in the 
expression of luciferase (see Chapter 1). Having generated a stable luciferase 
reporter gene cell-line, NB41A3-GFRα3-SRELuc, that robustly expresses 
luciferase signal upon ART stimulation, we utilized this luciferase assay to study 
coupling of RET activation to transcriptional and translational gene expression. 
First, to construct a kinetic profile for luciferase transcription and 
translation, we treated cells with 1.6 nM ART for up to 8 h, and measured the cell 
lysates for luciferase mRNA and protein. After lysing cells with buffer that 
disrupts the cell and nuclear membranes, we extracted mRNA from cell lysates 
using column purification that isolated mRNA > 200 bp, so that other forms of 
RNA with size < 200 bp (e.g., ribosomal RNA, transfer RNA, micro RNA, small 
interfering RNA, etc.) are removed. To quantify the amount of luciferase mRNA 
expressed at various times after ART stimulation, we used reverse-transcription 
quantitative PCR (RT-qPCR). We included purified luciferase PCR product, 
synthesized by annealing to the same qPCR primers, to generate a standard 
curve for the RT-qPCR assay, to allow us to determine the absolute number of 
mRNA molecules in our samples (Appendix IV). The resulting luciferase mRNA 
time course shows that there is a lag of ~30 min before luciferase transcription 
begins, after which levels peak at an average of ~1,700 luciferase mRNA 
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molecules per cell after 120 min ART, and then decrease to low levels of 370 
molec./cell after stimulation with ART for 240 min (Figure 2.3A).  
2.2.3 Kinetics of ART-induced luciferase gene transcription  
The goal of this study is to achieve a quantitative understanding of how 
signals are transduced from the cell surface by RET receptors on the plasma 
membrane, through to the nuclear effects of transcription and translation of target 
genes. To fully understand how RET-activated transcription evolves over time, 
we were interested not only in how mRNA and expressed protein levels vary over 
time, but also in how the actual rates of transcription and translation evolve over  
time after stimulation of the cells by ART. To do this, we had to take into account 
the effect of mRNA and protein degradation on the time-course for the 
abundance of these molecules. 
 For the simple case in which (1) the lifetime of the mRNA in question can 
be described as a first-order reaction with rate constant, kdeg, and (2) where kdeg 
does not change over the duration of the experiment, the relationship between 
transcription rate and mRNA concentration is given by the following equation: 
 ![!"#$]!" =  𝑘!"#$%& − 𝑘!"#[𝑚𝑅𝑁𝐴]                           (Eq. 1) 
where ktscrip has units of molecules mRNA/min per cell, kdeg has units of min-1, 
and [mRNA] is expressed as molecules per cell. Thus, we can calculate the rate 
at which a gene  is being  transcribed at  any given time (i.e. ktscrip) if we know the  
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Figure 2.3. Dynamics of RET-activated transcription of the luciferase gene. (A) 
Cells were treated with 1.6 nM ART, and luciferase mRNA levels were measured 
at various times by lysing the cells and performing RT-qPCR on the cell lysate 
(open squares). The solid line represents the fit to Eq. 3. Error bars represent 
standard deviations for data from three independent experiments. Inset: the 
lifetime of luciferase mRNA in the cells was determined by adding actinomycin-D 
after treatment with ART for 2 h, and then lysing cells at subsequent times and 
measuring the mRNA levels by RT-qPCR (filled squares). The dashed line shows 
the best fit to first-order exponential equation, giving a lifetime of t1/2 = ~35 ± 17 ( 
n = 2) min. Error bars represent the spread of data from two independent 
experiments. (B) Luciferase mRNA synthesis rates back-calculated from the 
averaged time-course measurements shown in (A), either by calculating slopes 
of segments from consecutive data points (blue), or by generating a cubic spline 
curve through time-point measurements at 1 min resolution, and calculating the 
first-derivative of the cubic spline to give the synthesis rate (black). Refer to 
Appendix VI for a detailed description of these calculations.  
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amount of the corresponding mRNA that is present ([mRNA]), the net rate at 
which the mRNA level is increasing or decreasing (d[mRNA]/dt), and the lifetime 
of the mRNA (kdeg). 
 We directly measured the lifetime of luciferase mRNA in our cells, by 
stimulating the cells with 1.6 nM ART for 120 min, to allow peak levels of mRNA 
to accumulate, and then adding the transcription inhibitor, actinomycin D (4 uM) 
to block further mRNA synthesis, and monitoring the subsequent decay of 
luciferase mRNA by RT-qPCR at various times. Figure 2.3A (inset) shows that 
the decay of luciferase mRNA approximates to a single exponential, allowing us 
to estimate an average lifetime for the mRNA of t1/2 = ~35 ± 17 min (n=2), 
corresponding to a rate constant of 0.020 ± 0.007 min-1 (n=2).  
The rate of change of mRNA concentration with time, d[RNA]/dt, 
corresponds to the first derivative of the mRNA time-course shown in Figure 
2.4A. The simplest and most direct way to estimate d[mRNA]/dt is simply to 
connect each consecutive pair of experimental data points in Figure 2.3A using 
straight lines, and take the slope of each segment as a measure of the average 
transcription rate for the period between the two measurements. Each of the 
resulting values for d[mRNA]/dt can be assigned to a time mid-way between the 
two experimental time-points used in the calculation (Appendix VI). From 
Equation 1, it can be seen that ktrsc = d[mRNA]/dt + kdeg[mRNA]. The average 
value for ktscrip for each segment of experimental time-course can therefore be 
estimated by multiplying the average of each consecutive pair of experimental 
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[mRNA] values by the experimentally determined value of kdeg = 0.020 ± 0.007 
min-1, and adding the result to the d[mRNA]/dt values calculated above. The 
resulting estimates for luciferase transcription rates at various times after ART 
stimulation are shown by the blue square symbols in Figure 2.3B. The results 
show that, after a brief lag, there is a spike in transcription rate that peaks at 
~100 min and lasts until ~180 min, followed by a slow tail-off of transcription 
activity. 
 In reality, mRNA levels likely do not evolve in a series of linear segments. 
A somewhat more nuanced estimate of transcription rates can potentially be 
obtained if the experimental data points for [mRNA] versus time are connected in 
a smoother fashion, for example by means of a spline fit. Application of a spline 
fit to the data from Figure 2.3A allows numerical computation of a continuous 
curve approximating how d[mRNA]/dt varies with time (Appendix VI). A 
corresponding estimate of how ktrsc varies with time can be obtained from 
Equation 1 by numerically computing the first derivative of the spline fit, and 
using the resulting values for d[mRNA]/dt at each experimental time-point, 
together with the corresponding experimental [mRNA] measurement from Figure 
2.3 A. Figure 2.3B (black circles) shows that this alternative method for 
estimating ktrsc gives results that are in good agreement with those obtained from 
the more direct but less nuanced method involving linear interpolations of the 
experimental mRNA time-course data. 
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The precise shape of the spike in transcription rate cannot be determined 
with precision from our data. For example, a simple triangular spike or a 
smoother Gaussian pulse are equally consistent with the experimental mRNA 
time-course (Figure 2.3B, Appendix VI), and also with the experimental time-
course for luciferase protein expression (vide infra). However, the following 
characteristics are robust features of the pulse: a brief lag (~10 min), a peak 
height of ~50 molec./min per cell, a peak time of ~100 min, a duration of ~200 
min, and a requirement for some low level of residual transcriptional activity after 
the main spike (Appendix VI). 
2.2.4 Kinetics of ART-induced luciferase gene translation 
The experimental time-course for luciferase protein shows that there is a 
lag of ~30 min after ART stimulation before luciferase expression begins, and 
that the signal increases to a maximum after ~120 min ART, after which protein 
levels slowly decrease over the subsequent 6 h (Figure 2.4A). This time-course 
confirms that the optimal times for ART-stimulated luciferase activity falls within 
2-4 h ART treatment window. To quantify the absolute number of luciferase 
protein molecules expressed during different times of ART stimulation, we 
created a standard curve using purified recombinant firefly luciferase protein 
(Appendix V), which allowed us to determine that the peak luciferase protein 
expression observed after 120 min ART corresponds to ~400,000 molecules per 
cell (Figure 2.4 A). We measured the lifetime of the luciferase protein by 
stimulating  cells  with 1.6 nM  ART for 4 h,  then added  the  translation  inhibitor, 
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Figure 2.4. Dynamics of RET-activated translation of the luciferase gene. (A) 
Cells were treated with 1.6 nM ART, lysed at various times, and measured for 
absolute protein levels for luciferase (open squares), solid line generated using 
Eq. 3; (inset) half-life of luciferase protein was determined by adding 
cycloheximide after 4 h ART (filled circles), and fitted to first-order exponential 
equation (dashed line); luciferase protein t1/2 = 104 ± 3 min (n = 3). (B) Luciferase 
protein synthesis rates derived from averaged time-course measurements from 
(A) either by calculating slopes of segments from consecutive data points (blue), 
or by generating a cubic spline curve through time-point measurements at 1 min 
resolution, and calculating the first-derivative of the cubic spline to give the 
synthesis rate (black); refer to Appendix VI for more info. Error bars represent 
standard deviation of 3 independent experiments for time course and range of 2 
independent experiments for decay. 
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cycloheximide (100 uM), to block further protein synthesis, and lysed the cells at 
various times thereafter to measure the level of luciferase activity remaining. 
Figure 2.4 A (inset) shows that, like the decay of luciferase mRNA, the decay of 
luciferase protein, too, could be approximated by a single exponential curve fit, 
giving a half-life for the protein of t1/2 = 104 ± 3 min (n = 3), corresponding to a 
rate constant of 0.0066 ± 0.0001 min-1.  
A similar approach that was used to calculate the rate of synthesis for 
luciferase mRNA was used to estimate the rate of luciferase protein synthesis, 
ktslat, at various times after ART stimulation. We used the experimental time-
course for luciferase protein levels shown in Figure 2.4A, plus the experimentally 
measured value for the degradation rate of luciferase protein in our cells (Figure 
2.4A, inset), to estimate ktslat, using d[protein]/dt values obtained from the linear 
interpolation method (plotted in Figure 2.4B as blue squares). Corresponding ktslat 
values derived from a smoother, spline interpolation are plotted as black circles. 
The results indicate that the rate of luciferase protein synthesis peaks around 
~100 min after stimulation at ~6,000 molec/cell, and then falls to a low, residual 
level of ~1,500 molec/cell after ~350 min ART that appears to be sustained up 
480 min. 
2.2.5 RET-activated translation efficiency of luciferase protein 
The rate of protein synthesis at a given time will depend on the 
concentration of the corresponding mRNA multiplied by the efficiency with which 
the mRNA is translated into protein: 
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 𝑘!"#$! = 𝑇𝐸 𝑥 [𝑚𝑅𝑁𝐴]    (Eq. 2) 
 
where ktslat is the rate of protein synthesis, with units of molec./min per 
cell, and TE represents the Translation Efficiency, defined for our purposes here 
as the number of protein molecules generated per min per mRNA molecule 
(units, molec./min per mRNA). In the event that the protein synthesis rate were 
regulated solely by how much of the relevant mRNA is present (i.e. if TE is 
constant), then plotting d[protein]/dt against [mRNA] will result in a straight line 
that passes through the origin, with slope = TE. Plotting the luciferase translation 
rates from Figure 2.4B against the experimentally measured mRNA levels from 
Figure 2.3A shows that for luciferase a linear relationship is not observed (Figure 
2.5A). Instead, the TE plot shows three clear phases of behavior: At early times, 
relatively high translation rates are seen even though mRNA levels have not yet 
approached peak levels. The TE during this early phase of the response 
corresponds to the slope of the line passing through these early data points, 
which is ~30 protein molec.min-1 per mRNA. The system then enters a second 
phase, in which translation rates remain roughly constant while mRNA levels 
quadruple from 400/cell to over 1,700/cell, corresponding to a large reduction in 
TE (Figure 2.5A). Finally, mRNA levels begin to fall from ~1200 mRNA 
molec./cell to ~350 mRNA molec/cell,  and  the  translation  rate  falls  with  them, 
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Figure 2.5. Translation Efficiency of luciferase protein. (A) Synthesis of luciferase 
protein (molec./cell per min) from Figure 2.4B plotted as a function of total mRNA 
(from Figure 2.3A). The solid line represents the best fit to Eq. 4. (B) Translation 
efficiency as a function of time. The solid line indicates the best fit to equation 4. 
Error bars represent standard deviation of three independent trials. 
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with the TE during this phase having the low value of ~3 protein molec./min per 
mRNA. This result indicates that the efficiency with which luciferase mRNA is 
translated into protein is not constant, but decreases over time. These dynamic 
changes in TE can be seen more clearly by plotting TE itself (that is, ktrsc from 
Figure 2.4B divided by the experimental [mRNA] values from Figure 2.3A) as a 
function of time.  Figure 2.5B shows that at 30 min, which due to the lag in 
transcription is the earliest time-point at which both ktrsc and [mRNA] are 
measurable, TE has a high value of ~ 27 protein molecules/min per mRNA, but 
rapidly falls by ~90% such that, by 120 min after ART stimulation, luciferase 
protein is being synthesized at only ~3 molec./min per mRNA. The solid line in 
Figure 2.5B shows that this decline in TE can empirically be described by an 
exponential with time-constant τ = 0.03 min-1 and a residual TE at long times of 
TEf = 2.3 molec./min per mRNA. Thus, for times ≥ 30 min, 
 
 𝑇𝐸 =  (𝑇𝐸! − 𝑇𝐸!)𝑒!!" + 𝑇𝐸!   (Eq. 3) 
 
The solid lines in panels B of Figures 2.3 and 2.4 are plotted using this equation. 
To illustrate that the experimental time-course for expression of luciferase protein 
can be accounted for solely from the experimentally determined mRNA levels, 
the measured lifetime of the luciferase protein, and the exponentially decreasing 
Translation Efficiency described in Equation 2, we substituted Equation (3) into 
Equation (2) as follows: 
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 𝑇𝐸 = [𝑚𝑅𝑁𝐴] (𝑇𝐸! − 𝑇𝐸!)𝑒!!" + 𝑇𝐸!   (Eq. 4) 
 
and used the experimental mRNA concentrations from Figure 2.3A, and the fitted 
values of TEi (i.e. TE at 30 min), TEf and τ from Figure 2.5B, to plot the solid line 
in Figure 2.5A. 
The variation in Translation Efficiency as the RET signaling response 
evolves over time is shown directly in Figure 2.5B, in which TE is plotted against 
time after ART stimulation.  
Overall, therefore, the experimental time-courses for luciferase 
transcription and translation, and the measured lifetimes of the mRNA and 
protein products, are consistent with the following relatively simple sequence of 
events: After a brief lag, transcription of the luciferase gene can be described by 
a roughly symmetrical spike in activity that peaks at ~100 min at a transcription 
rate of ~50 molec./min per cell, with a low residual level of transcription out to 
long times. The mRNA molecules are initially translated with the relatively high 
efficiency of ~30 molec./min per mRNA, but TE immediately begins to drop with a 
half-time of ~23 min to a level of ~10% of the initial value. Importantly, the key 
features of this description can be demonstrated from the experimental data 
using only minimal assumptions. For example, from the mRNA time-course in 
Figure 2.3A it is clear that the transcription rate is substantially higher between 
60 and 120 min than at 240 min and later. Similarly, the slope of the experimental 
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time-course for luciferase protein is comparably high from 30-60 min and from 
60-120 min, even though the level of mRNA is much higher during the second 
period, indicating that the rate of protein synthesis per mRNA is falling. 
The total number of luciferase mRNA and protein molecules synthesized 
during the 8 h after ART stimulation of the cells is given by the areas under the 
curve (AUC) of the plots shown in Figure 2.3 A, and 2.4 A, respectively 
(Appendix VI). The AUC for total luciferase mRNA = 6,000 ± 200 molecules, 
while AUC for luciferase protein molecules produced = 1.5 ± 0.1 x 106. Thus, 
each mRNA is, on average, translated 1,500,000 / 6,000 = 250 times during its 
lifetime. Given that the average lifetime of luciferase mRNA is ~35 min (Figure 
2.3A, inset), each mRNA is translated an average of 7 times per minute. 
However, Figure 2.5B shows that the maximum rate at which an individual 
mRNA molecule can be translated into protein is substantially higher than this 
average number. 
The overall picture of signaling dynamics emerges as one in which 
phosphorylation of RET and ERK occur rapidly, and are sustained at high levels 
with pRET and pERK falling only 25% and 50% from maximum, respectively, 
throughout the 8 h experimental period. Luciferase gene transcription shows an 
initial lag of ~30 min, then rises to a maximum rate of ~50 molec.cell-1min-1 at 
~90 min after ART stimulation, and then decreases to a residual rate of ~5 
molec.cell-1min-1 by 180 min ART stimulation. The degradation of luciferase 
mRNA is relatively slow, such that maximum mRNA abundance of 1,500 
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molec./cell occurs after stimulation with 1.6 nM ART for 120 min, and the 
subsequent decline to 300 molec./cell after 240 min lags slightly behind the 
corresponding rise and fall of the transcription rate. The rate of luciferase protein 
synthesis also shows an initial 30 min lag, then peaks at ~90 min at a rate of 
~6,000 molec.cell-1min-1. The efficiency with which the luciferase mRNA is 
translated into protein falls sharply from its initial level of ~30 protein molec.min-1 
per mRNA, until by 120 min, the TE decreases to 10% of its maximum level. The 
luciferase protein is fairly stable in cells, with an average half-life of ~70 min so 
that luciferase expression levels continue to increase for some time after the 
translation rate has started to diminish, and protein levels fall only slowly 
thereafter, persisting out to t > 8 h.  
2.2.6 Signal sensitivities and amplitudes at the levels of RET, ERK, and 
transcription and translation  
Having established the treatment times required to achieve a robust 
signaling response at the level of luciferase transcription and translation, we were 
in a position to compare the amplitudes and sensitivities of pRET, pERK, 
transcription rate and translation rate, each at its time of maximum response. We 
define response amplitude as the peak number of pRET, pERK, mRNA or protein 
molecules, and the response sensitivity (EC50) as the stimulus level (i.e. ART 
concentration) required to achieve a half-maximal level of response. We have 
previously reported that ART stimulation of NB41A3-GFRα3 cells (from which the 
NB41A3-GFRα3-SRELuc cell line used in the current study was derived) for 10 
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min resulted in the production of up to ~6,500 pRET molecules and ~140,000 
pERK molecules per cell (S. Li et al.). In this work we quantified that receptor 
phosphorylation occurred with EC50 = 2.3 ± 0.8 nM, while the pERK response 
was ~8 times more sensitive, with EC50 = 0.28 ± 0.09 nM, and the functional 
response of neurite outgrowth was ~10-fold more sensitive still, with EC50 = 
~0.05 nM (S. Li et al.). An aim of the current study was to determine how the 
amplitude and sensitivity of gene transcription and of translation compares to 
these upstream signaling responses as cells progressively transduce signals 
from receptor stimulation through to functional cellular response. 
To measure the sensitivities and maximal amplitudes of luciferase 
transcription and translation, we treated NB41A3-GFRα3-SRELuc cells with 
various concentrations of ART, then measured the responses at the times when 
pRET or pERK (10 min), luciferase mRNA (2 h), or luciferase protein (4 h) peak. 
Each dose-response data set can be expressed either as a percent of maximum 
response, or as the absolute numbers of molecules at peak response minus the 
background response seen in untreated cells. EC50 values were determined by 
fitting the data to a four-parameter curve fit. Figure 2.6A shows that pRET and 
pERK gave half-maximal responses of EC50 = 0.96 ± 0.06 nM (n = 3) and 0.11 ± 
0.01 nM (n = 3), respectively, in good agreement with our previously established 
measurements on NB41A3-GFRα3 cells. The half-maximal responses for 
luciferase mRNA is EC50 = 0.40 ± 0.04 nM (n = 3), and luciferase protein with 
EC50 = 0.57 ± 0.03 (n = 3). Thus, both the transcriptional and translational respo- 
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Figure 2.6. Coupling of RET-activation to pERK, transcription, and translation. 
(A) ART dose-responses, plotted as percent of maximum, background 
subtracted, after stimulation times of 10 min for pRET and pERK, 2 h for 
luciferase mRNA, and 4 h for luciferase protein. EC50 values were calculated by 
fitting to a four-parameter equation. (B) Percent maximum signal plotted as a 
function of percent maximum pRET. The solid lines are linear fits of the 
relationships over the range 0.10- 0.64 nM ART. (C) ART dose-dependent 
response expressed in absolute molecules per cell after 10 min for pRET and 
pERK, 2 h for luciferase mRNA, and 4 h for luciferase protein. (D) Peak signal 
amplitudes as ART-activated signal progresses from receptor to ERK to 
transcription and translation. Error bars represent standard deviations from three 
independent experiments. 
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nses for luciferase showed sensitivities to ART stimulation that were in between 
the sensitivities of the pRET and pERK responses, rather than resembling the 
very high sensitivity of the functional response of neurite outgrowth which occurs 
between 0.01 and 0.1 nM ART as reported previously (S. Li et al.). 
We can further explore the coupling of RET activation to downstream 
signaling events by plotting the responses for pERK, luciferase mRNA, and 
luciferase protein measured at each ART concentration, expressed as a 
percentage of the respective maximum response, against the percent maximum 
pRET for that same ART concentration (Figure 2.6B). The plot shows that 
coupling of pRET to pERK is characterized by a high initial slope (slope ~10), 
with the coupling of pRET to transcription and translation giving lower slopes of 
3-fold and 2-fold, respectively. Expressed in words, at low ART every 1% of RET 
that becomes activated, on average leads to 10% of maximum pERK, 3% of 
maximum luciferase mRNA, and 2% of maximum luciferase protein levels. Figure 
2.6C shows the signal amplitudes plotted in absolute units of molecules per cell. 
The maximal pRET and pERK responses are ~6,500 and ~140,000 molecules 
per cell, respectively, as described in our previous study (S. Li et al.; Schlee et 
al.). Luciferase mRNA reached a maximum level of ~1,700 molecules per cell, 
whereas luciferase protein accumulated at up to ~400,000 molecules per cell. 
Thus, at maximal ART stimulation there is substantial signal amplification 
between activation of the receptor and activation of ERK, a ~150-fold attenuation 
of signal amplitude between ERK and transcription, and then a ~440-fold 
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amplification between mRNA and protein (Figure 2.6D). The results in Figure 2.6 
shows that the coupling efficiency of pRET to pERK signaling is high, as is the 
amplification in the number of activated molecules, which contrasts what was 
observed for the coupling of pRET to mRNA and protein expression. The 
coupling of pRET to mRNA slightly higher than the coupling of pRET to protein, 
though both are lower than what was measured for the coupling to pERK as 
shown in Figure 2.6B. At maximal response levels, the number of mRNA 
expressed is less than the number of pERK and protein molecules. Thus, there is 
a reduction in the amplitude of the transcriptional response compared to the 
amplitude of pERK, even though the small number of mRNA expressed resulted 
in a large amplification in amplitude of protein expression. Therefore, there does 
not appear to be any clear relationship between signal sensitivity and signal 
amplification as RET activation progresses from cell surface receptors to nuclear 
gene expression. Our quantification of signaling molecules shows that there is 
high variability in effector sensitivity and amplitude in response to receptor 
activation. 
2.2.7 Transcription and translation of endogenous c-fos gene 
The gene for luciferase was introduced into the NB41A3 cells by lentiviral 
infection. The exogenous introduction of this gene raises questions about the 
extent to which its transcriptional and translational responses to ART stimulation 
accurately reflect the behavior of endogenous RET-induced genes. To address 
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this question, we examined the transcriptional and translational dynamics of two 
endogenous genes, interleukin-6 (IL-6) and c-fos. 
  Similar to the characterization of the luciferase response, described 
above, cells were stimulated with 1.6 nM ART, and c-fos mRNA and protein 
expression quantified at various subsequent times up to 8 h. The maximal 
response of c-fos mRNA occurred at 60 min, and quickly decayed to basal levels 
by 120 min after ART stimulation (Figure 2.7A). We measured the c-fos mRNA 
decay rate by administering 4 µM actinomycin D at 60 min after initial ART 
stimulation. Fitting the results to an exponential equation gave a value for t1/2 = 
~40 ± 3 min (Figure 2.7A, inset), a value that is ~2-fold longer than the 20 min 
half-life reported by others (Shyu et al.). Thus, c-fos mRNA has already peaked 
and fully decayed by the time luciferase mRNA approaches maximal expression 
(Fig 2.3A and 2.7A). The cells maximally expressed ~300 molecules per cell of c-
fos mRNA, compared to ~1,700 molecules per cell of luciferase mRNA seen at 
the peak time for this response. This ~5-fold difference in peak mRNA expression 
may be due to a difference in copy number per cell between the endogenous and 
exogenous genes. We used Western blot to measure c-fos protein expression, 
quantifying the results by densitometry and calibrating them against a standard 
curve, as described in Appendix V. The results showed that cells express ~6 x 
105 molec./cell c-fos protein under basal conditions, and there is a 60 min lag 
between initial ART stimulation until the induction of additional c- 
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Figure 2.7. Dynamics of RET-activated transcription and translation of the c-fos 
gene. Cells were treated with 1.6 nM ART, and levels of c-fos mRNA and protein 
measured at various subsequent times. (A) Absolute mRNA levels for c-fos 
(open squares), measured by RT-qPCR. Inset: half-life of c-fos mRNA was 
determined by adding actinomycin D after 1 h ART treatment and measuring 
residual c-fos mRNA at subsequent times (filled squares), and fitted to first-order 
exponential equation (dashed line). This fit shows that c-fos mRNA t1/2 = ~40 ± 3 
min (n = 2). (B) Absolute protein expression levels for c-fos (open circles). Error 
bars represent standard deviations of data from 3 independent experiments for 
the stimulation time-courses, and from 2 independent experiments for the mRNA 
lifetime measurements. 
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fos protein, similar to the lag observed for luciferase  protein  response.  
Expression  of  c-fos protein peaked at 120 min after initial ART stimulation, at 
2.5 x 106 molecules per cell, and then decreased to a residual level of 106 
molecules per cell by 240 min (Figure 2.7B). Comparison of the time-courses for 
c-fos mRNA and protein expression shows that the level of c-fos mRNA has 
already peaked and decayed almost back to baseline by the time c-fos protein 
expression reaches its maximal level (Figure 2.7).  
 We attempted to measure the lifetime of c-fos protein by treating cells with 
protein synthesis inhibitors such as cycloheximide and homoharringtonine, after 
stimulating cells with 1.6 nM ART for 2 h, but instead of decay we observed a 
further induction of c-fos protein expression (Appendix VII). The c-fos gene is 
known as an immediate-early gene (IEG), characterized by a quick response 
leading to a transient peak of mRNA within 15 minutes of stimulation, without 
requiring synthesis of new protein (Bahrami and Drabløs). Protein synthesis 
inhibitors are known to up-regulate IEG at the mRNA level, called superinduction, 
through a mechanism in which the inhibitors promote phosphorylation of nuclear, 
chromatin-associated proteins pp33/pp15 which induces IEG expression 
(Edwards and Mahadevan; Greenberg et al.; Sariban et al.). Murphy, et al. have 
identified that c-fos acts as a sensor for pERK activity, and that the stability of c-
fos protein is regulated by the phosphorylation of c-fos by activated ERK (Murphy 
et al.). They, too, reported that they did not observe c-fos protein decay upon 
addition of cycloheximide, though they did not mention an increase in c-fos 
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expression (Murphy et al.). Furthermore addition of cycloheximide has been 
shown to prolong the lifetime of pERK in EGF-stimulated HeLa cells (Amit et al.). 
Thus, aside from induction of c-fos transcription via the receptor-dependent 
activity of appropriate transcription factors, there are at least two other 
mechanisms for regulation of c-fos gene expression; one at the protein level, due 
to the direct effect on c-fos protein stability of sustained pERK activity, and 
another at the mRNA level through superinduction of c-fos mRNA in the 
presence of protein synthesis inhibitors. This interplay of MAPK/ERK signaling 
and c-fos protein, and the complexities associated with downstream feedback 
regulation, indicates that using general protein translation inhibitors are 
ineffective at measuring c-fos protein lifetimes. Others who have measured the 
lifetime c-fos protein have implemented radiolabeling methods. Due to these 
complexities, we decided not to proceed with establishing translation efficiency 
for c-fos (Curran et al.; Ferrara et al.; Ito et al.).  
The sensitivities of the responses for c-fos mRNA and protein were also 
quantified by measuring ART dose-responses, using incubation times of 1 h and 
2 h, respectively. The results can be expressed in terms of the absolute number 
of molecules per cell (Figure 2.8A), or as percent of maximum response 
(Figure2.8B). The expression of c-fos mRNA maximized at an amplitude of ~300 
molecules per cell with EC50 = 0.41 ± 0.10 nM (n = 3), while protein levels 
peaked at ~2.7 x 106 molec./cell with EC50 = 0.96 ± 0.11 nM (n = 3). Interestingly,  
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Figure 2.8. Dose-response 
comparison between pRET, 
pERK, c-fos mRNA, and c-fos 
protein. (A) ART dose-
dependent responses 
expressed in molecules per 
cell after 10 min ART 
treatment, for pRET and 
pERK, after 1 h for c-fos 
mRNA, and after 2 h for c-fos 
protein. (B) ART dose-
response curves plotted as 
percent maximum response. 
EC50 values were calculated 
by fitting to a four-parameter 
equation. (C) Percent of 
maximum signal plotted 
against % max pRET. Solid 
lines show a linear fit of data 
for at 0.10-0.64 nM ART. 
Error bars represent standard 
deviation of data from three 
independent experiments. 
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both the absolute response amplitudes and the response sensitivities are very 
similar to the values we measured for the luciferase gene (Figure 2,6), both for 
mRNA and for protein. The coupling of RET activation to c-fos mRNA and protein 
levels, expressed as a percent of maximum signals, are also similar to values 
measured for the luciferase gene, with each 1% increase in pRET (at low ART) 
resulting in a ~2% increase toward maximal c-fos mRNA expression and a ~1%, 
increase towards maximal protein expression (Figure 2.8C). Taken together, the 
luciferase reporter gene displays similar signaling characteristics in coupling 
efficiency and sensitivity as its endogenous c-fos counterpart. As such these 
results correspond well that both genes are controlled under the same regulatory 
element.  
2.2.8 Transcription and translation of endogenous IL-6 gene 
It was previously observed that a positive feed-forward loop between RET 
and IL-6 exist so that stimulation with IL-6 activates its receptor, gp130, which 
then increases RET expression, and RET activation by GDNF also increases IL-
6 production, and that the feed-forward relationship plays a role in breast cancer 
migration (Gattelli et al.). Quantification of the IL-6 gene expression provides 
insight into the dynamic relationship between RET activation and the 
transcription and translation of an endogenous gene not directly controlled by the 
same transcription factors as the exogenous luciferase gene we characterized in 
Sections 2.2.2-2.2.6. Stimulation of the cells with 1.6 nM ART led to no change in 
IL-6 mRNA levels for the first 30 min, followed by a slow increase at a rate of ~4 
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molec./cell per minute until at least 360 min, after which the mRNA concentration 
appeared to stabilize at a level of ~1,500 molec./cell (Figure 2.9A). The increase 
in overall IL-6 mRNA levels between 30 and 300 min is approximately linear, 
implying a roughly constant value for d[mRNA]/dt over this period. In an attempt 
to measure IL-6 mRNA decay, we treated cells with 1.6 nM ART for 120 min, 
then added actinomycin D, and measured IL-6 mRNA levels for another 360 min 
by RT-qPCR. Figure 2.9A, inset, shows that IL-6 mRNA is highly stable, with no 
degradation at all detected over a period of 480 min. Thus, the accumulation of 
IL-6 mRNA over time reflects the aggregate number of transcriptional events that 
have taken place, so that the IL-6 transcription rate is simply the slope of the 
function of IL-6 mRNA concentration over time, without the need to adjust for 
mRNA decay because in this case kdeg is negligible. Interpolation of the mRNA 
synthesis rate was set to a constant rate of ~4 molec./cell, which was determined 
by a simple linear fit of IL-6 mRNA levels measured at 60 - 360 min ART 
stimulation, and plotted as black circles and line in Figure 2.9B, per minute from 
~30-400 min (Figure 2.9B, black; Appendix VI). This time frame is when IL-6 
levels steadily increased before protein levels stabilized. Similar to the luciferase 
gene, IL-6 mRNA synthesis rate was also interpolated using the cubic spline 
method and is plotted in purple squares as shown in Figure 2.9B and D.  These 
results suggest that IL-6 transcription occurs at a roughly constant rate between 
30 and 300 min, approximating a  square  pulse  of  transcription  between  these  
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Figure 2.9. Dynamics of RET-activated transcription and translation of the IL-6 
gene. Cells were treated with 1.6 nM ART, and levels of IL-6 mRNA and protein 
measured at subsequent times. (A) Absolute mRNA levels for IL-6 (open 
squares), measured by RT-qPCR. Solid line represents linear fit of data points 
between 60 - 360 min ART treatment times. Inset: no decay was detected for IL-
6 mRNA determined by adding actinomycin-D after 2 h ART and measuring for 
IL-6 mRNA at subsequent times (filled squares) (B) IL-6 mRNA synthesis rates 
by generating a cubic spline curve through time-point measurements at 1 min 
resolution, and calculating the first-derivative of the cubic spline to give the 
synthesis rate (black) or simply as a constant rate (purple and solid black line) as 
calculated by the linear fit from 60 – 360 min shown in (A). Refer to Appendix VI 
for more detail. (C) Absolute protein levels for IL-6 (open circles), solid line 
generated with a constant mRNA synthesis rate multiplied by a constant TE rate, 
refer to Appendix VI for more detail. Inset: half-life of IL-6 protein was determined 
by adding cycloheximide after 6 h ART (filled circles), and fitted to first-order 
exponential equation (dashed line); IL-6 protein t1/2 = ~800 ± 44 min (n = 2). (D) 
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IL-6 protein synthesis rates derived from averaged time-course measurements 
from (C) either by calculating slopes of segments from consecutive data points 
(purple), or by generating a cubic spline curve through time-point measurements 
at 1 min resolution, and calculating the first-derivative of the cubic spline to give 
the synthesis rate (black); refer to Appendix VI for more info. The solid line 
represents the behavior expected from constant TE until ~270 min ART, when 
TE exhibits exponential decay. Error bars represent standard deviation of 3 
independent experiments for non-inhibited treatments, and represent range of 2 
independent trials for decay treatment. 
 
time-points with amplitude ~4 molec./min per cell (Figure 2.9B). The IL-6 mRNA 
synthesis rates derived from the cubic spline analysis interpolates the rate 
between 1 min time points, which explains the difference in how the synthesis 
rates were plotted by interpolation by a linear fit. 
IL-6 is a secreted protein that acts as a pro-inflammatory cytokine. To 
measure total IL-6 production at each time-point, it was therefore necessary to 
separately measure both the secreted IL-6 present in the culture medium and 
intracellular IL-6 in cell lysates, which we did by ELISA. The protein was 
quantified using standard curves generated using purified IL-6 (Appendix V). The 
secreted and intracellular IL-6 values were summed, taking into account the 
different volumes of cell lysate and culture medium, to calculate the total number 
of IL-6 molecules present per cell. The resulting time-course shows that 
accumulation of IL-6 protein starts slowly at 60-120 min, but then accelerates 
between 120-240 min, after which the protein levels peak by 300 min at a level of 
~225,000 molec./cell (Figure 2.9C). Experiments in which IL-6 was allowed to 
accumulate for 360 min before adding cycloheximide to block further protein 
synthesis showed that IL-6 protein was stable over the duration of our time 
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course experiments. The half-life was determined to be t1/2 = ~800 ± 44 min (kdeg 
≤ 0.0009 ± 0.0001 min-1; n = 2) when we measured IL-6 protein up to 39 h after 
addition of cycloheximide. Thus, similar to the IL-6 mRNA transcription rate, the 
IL-6 translation rate simply corresponds to the first derivative of the function 
describing the accumulation of IL-6 protein over time. This function was plotted 
using the method described above for estimating luciferase mRNA and protein 
synthesis rates (Figure 2.9D). The line fitted to the estimated IL-6 protein 
synthesis rates was calculated similar to equation 2, where the TE is a constant 
value of 1.25 protein molec./cell/mRNA, which is the calculated by a constant 
rate of ~4 mRNA molec./min as shown in Figure 2.9A, so the protein synthesis 
rate is product of the TE and mRNA concentration accumulated at any given 
time. 
The translation efficiency for IL-6 at various times after initial stimulation 
with ART was determined by plotting the IL-6 translation rates from Figure 2.9D 
against the experimental mRNA levels from Figure 2.9A. The resulting 
relationship, shown in Figure 2.10A, indicates that IL-6 translation rates increase 
roughly in proportion to mRNA levels until that latter has accumulated to a level 
of ~1000 mRNA molec./cell. However, by the time IL-6 mRNA has accumulated 
to a level of ~1500 mRNA molec./cell, at 360 min after initial stimulation by ART, 
the translation rate has dropped to 400 molec./cell/min, and by 480 min 
translation has effectively ceased even though the concentration of mRNA 
remains at its highest level. These results show that, after an initial lag of ~30 min 
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Figure 2.10. Translation Efficiency of IL-6 protein after stimulation of cells with 
1.6 nM ART for various times. A) Synthesis of IL-6 protein (molec./cell per min) 
from Figure 2.9D plotted as a function of total mRNA (from Figure 2.9A). The 
solid line represents protein synthesis rate as a function of mRNA concentration 
accumulated over time; the protein synthesis rate is a product of mRNA 
concentration accumulated at over time and constant TE rate of 1.25 protein 
molec/cell/mRNA until 300 min, after which the TE is represented by exponential 
decay. (B) Translation efficiency as a function of time. The solid line indicates 
constant TE of 1.25 protein molec/cell/mRNA until 300 min when the solid line 
represents exponential decay with time constant τ = 0.03 min-1. Error bars 
represent standard deviation of three independent trials.  
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TE for IL-6 remains roughly constant over the next 5-6 hours, at a level of ~1.25 
molec./min per mRNA, but then decreases to zero over the subsequent 2-4 h 
(Figure 2.10B). This late shut-down in IL-6 translation can be seen directly from 
the primary data in which there is no increase in IL-6 protein levels after 300 min 
even though mRNA levels are at their highest at this period. The available data 
are not sufficient to inform the deduction of a precise mathematical equation to fit 
the experimental decline in IL-6 TE at t > 240 min. To plot the solid line in Figure 
2.10B we arbitrarily assumed that TE decreases exponentially with the same 
time constant seen for the exponential decrease in TE seen with luciferase, by 
using Equation 4 to describe the decrease in TE at later times, but setting TEi = 
1.25 molec./min per mRNA and TEf = 0. However, equally good fits could likely 
be obtained using some other manner of curved or linear relationship to describe 
the decrease in TE at long times. 
The above results show that the transcriptional and translational behavior 
of the IL-6 gene in response to ART stimulation differs from that seen for 
luciferase both qualitatively and quantitatively. First, IL-6 transcription occurs as a 
prolonged square pulse rather than a transient spike. Second, the maximal 
transcription rate was much lower for IL-6 than for luciferase, at ~4 molec./cell 
per min versus ~50 molec./cell per min. The maximum TE was also lower for IL-6 
than for luciferase, at ~1.25 molec./min per mRNA for IL-6 versus ~27 molec./min 
per mRNA for luciferase. Additionally, TE for IL-6 remained roughly constant for 
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at least 240 min after stimulation, whereas TE for luciferase began to drop 
sharply after ≤ 30 min ART stimulation. 
The sensitivities of the IL-6 mRNA and protein responses were measured 
by treating cells with various ART doses for 8 h. The results, expressed in 
molecules per cell and as a percent of the maximum signal, are shown in Figure 
2.11A. IL-6 mRNA expression maximized at ~2,200 molecules per cell, with EC50 
= 0.69 ± 0.07 nM (n = 3), while protein levels peaked at ~3.2 x 105 molec./cell 
with EC50 = 1.04 ± 0.04 nM (n = 3), similar to the values for these quantities 
observed for the luciferase and c-fos genes. The coupling of IL-6 mRNA 
expression and protein expression to pRET levels are also similar to the values 
measured for the luciferase and c-fos genes, with 2% of maximal mRNA 
expression and 1% of maximal protein expression seen for every 1% of maximal 
pRET (Figure 2.11 B).  
2.2.9 Commitment to luciferase protein expression 
 Quantification of the relationship between receptor-activated gene 
transcription and translation enabled us to examine the time dependence of 
protein synthesis in terms of how mRNA levels and TE evolve over time, using 
the luciferase gene as a model. We went on to hypothesize that the time after 
initial receptor stimulation at which the cells become committed to maximum 
protein output is determined by the earlier of (1) the time at which transcription 
has effectively ceased, or (2) the time at which TE decays to a negligible level. 
We hypothesize that  inhibition of upstream signaling before this critical  time  will 
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Figure 2.11. Dose-response relationships for pRET, pERK, IL-6 mRNA, and IL-6 
protein. (A) Dose-response curves, expressed in molecules per cell or as percent 
of maximum response (inset plot), after treatment with the indivated 
concentrations of ART for 10 min (pRET and pERK) or 8 h (IL-6 mRNA and 
protein). EC50 values were calculated by fitting to four-parameter equation (B) 
Percent of maximum signal for IL-6 mRNA and protein expression plotted as a 
function of pRET level. The solid lines show linear fits of the signals for 0.10-0.25 
nM ART for IL-6 mRNA and 0.10-0.64 nM IL-6 ART for protein. Error bars 
represent standard deviation of data from three independent experiments. 
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lead to a significant decrease in overall expression of the protein gene product, 
while inhibition of upstream signaling after this time will have a negligible effect 
on protein production. This hypothesis is non-trivial in that, to be true, it requires 
that no signaling mediator downstream of the inhibited step and upstream of 
transcription can be long-lived. If, for example, relevant transcription factors were 
to have a very long life-time in their activated states then, once these 
transcription factors have become fully activated, transcription and translation 
might persist for a considerable time after upstream steps in signaling are 
blocked. Similarly, for our hypothesis to be correct requires that there are no 
significant feed-forward effects of upstream steps in signaling on mRNA 
maturation or stability or on the process of translation itself. If this were not the 
case then protein output could be affected if upstream steps in signaling were 
inhibited, for example, even after transcription was fully complete and had 
ceased, by affecting the translation of the mRNAs into protein. Thus, testing the 
time at which the cells become committed to full expression of a protein gene 
product, and comparing this commitment time to the expression time-course for 
the relevant mRNA and the dynamic evolution of its TE, provides a method to 
probe the lifetimes of signaling mediators downstream of the inhibited step, and 
the existence of feed-forward connections between upstream and downstream 
signaling processes. 
Our analysis of the time-course for luciferase mRNA expression (Figure 
2.3A) and the evolution of luciferase TE (Figure 2.5B) indicates that transcription 
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takes place between ~30 and ~200 minutes after initiation of ART stimulation, but 
by 120 min TE has dropped to a low level (Figure 2.5B). Based on our 
hypothesis, we would therefore predict that, in the simplest case, inhibition of a 
signaling step upstream of luciferase gene expression – for example, ERK 
phosphorylation in the case of our reporter gene cell line (Figure 2.2) – in the first 
~120 min after ART stimulation should result in a substantial decrease in 
luciferase protein expression measured at a later time, whereas inhibition of ERK 
phosphorylation at times after ~120 min should have a negligible effect. 
 To test our hypothesis, we treated NB41A3-GFRα3-SRELuc with 1.6 nM 
ART at t = 0, then proceeded to inhibit MAPK/ERK signaling by adding 1 uM of 
the MEK inhibitor CI1040 at times ranging from 5 – 180 min after ART addition. 
All cells, regardless of the time at which inhibitor was added, were incubated for 
a full 240 min, to give time for the luciferase response to evolve, at which time 
they were lysed cells and the luciferase activity measured (Figure 2.12A, top). 
This experimental design enabled inhibition of MAPK/ERK signaling at different 
times, while giving cells equal time to synthesize luciferase protein by ART 
stimulation. The results show that addition of CI1040 at times up to 30 min 
resulted in almost complete suppression of luciferase expression. Addition of  
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Figure 2.12. Time-dependence of MEK inhibition on luciferase protein 
expression. (A) Cells were treated with 1.6 nM ART followed by addition of 1 µM 
CI1040 at various times up to 4 h (top panel). The resulting luciferase signal is 
plotted as a percentage of that seen for cells treated with 1.6 nM ART only 
(bottom). (B) Cells were treated with 1.6 nM ART for 60 min followed by addition 
of 1 µM CI1040, and luciferase activity was measured at the indicated times 
(top). The luciferase signal is plotted as a percentage of that seen for cells 
treated with 1.6 nM ART only at 180 min (bottom). Error bars represent range of 
two independent experiments. 
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CI1040 at 60 and 90 min resulted in partial suppression of luciferase expression, 
while inhibition of MAPK/ERK signaling at or after 120 min resulted in no loss in 
luciferase protein production compared to cells treated with 1.6 nM ART only 
(Figure 2.12A, bottom). These results demonstrate that the shorter the duration 
of upstream signaling through the MAPK/ERK pathway, the less luciferase 
expression is seen, but that by 120 min after initial stimulation the cells are 
committed to full luciferase expression such that continued ERK signaling 
beyond this time is not required for this particular downstream response to RET 
activation. To test possible mechanisms responsible for commitment to protein 
production, we measured how long it takes for CI1040 to affect luciferase protein 
expression. We did this by stimulating cells with 1.6 nM ART for 60 min, then 
adding 1 µM CI1040 and measuring luciferase protein expression levels at 
various subsequent times (Figure 2.12B, top). According to the previous 
experiment (Figure 2.12A), addition of inhibitor at this time eventually leads to a 
~40% reduction in the luciferase protein levels present at 240 min. We found that 
CI1040 had relatively little effect on luciferase expression over the first 60 min 
after the inhibitor was added, with significant effects on luciferase levels 
becoming apparent only at later times (Figure 2.12B, bottom). The attenuation of 
MEK-inhibited luciferase activity at t ≥ 180 min ART resulted in 50-70% of ART-
only levels. Based on the assumption that there is no long period of lag before 
CI1040 inhibits luciferase mRNA production, the result suggests that the mRNA 
accumulated after early ART stimulation is highly competent to be translated into 
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protein since luciferase protein levels were not affected up to 2 h after MEK 
inhibition, and protein levels are only minimally affected thereafter, though further 
analysis of mRNA levels is needed to support this claim. Overall, these results 
demonstrate a lag of ~60 min before MAPK/ERK signaling inhibition affects 
luciferase protein expression, but the reason for this lag remains unclear. 
Collectively, we have shown that elucidating TE by measuring 
transcription and translation rates is valuable in defining times at which pathway 
signaling is critical for protein expression.  
Table 2.1. Summary of maximal amplitudes, half-lives, and  maximal rates for 
Luc, c-fos, and IL-6 genes 
 Max. Amplitude ± SD (molec./cell) 
Half-life 
± SD (min) 
Max. Rate 
(molec./cell/min) 
mRNA Protein mRNA Protein mRNA Protein 
Luc 1731 ± 707 3.7 x 105  
± 4 x 10
3
  
35 ± 17  104 ± 3  47 6.2 x 103 
c-fos 300 ± 106 2.5 x 106 
± 600 
40 ± 3  NA 9 NA 
IL-6 1519 ± 510 2.3 x 105  
± 4.3 x 10
4 
ND 800 ± 44  7 900 
SD = standard deviation 
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Table 2.2. Summary of half-maximal concentrations and maximal amplitudes 
from ART dose-responses for Luc, c-fos, and IL-6 genes 
 EC50 ± SD (nM) Max. Amplitude ± SD (molec./cell) 
pRET 
(10 min) 
0.96 ± 0.06  4200 ± 61 
pERK 
(10 min) 
0.11 ± 0.01  1.4 x 105 ± 2156 
mRNA, 
protein 
treatment 
times (h) 
mRNA Protein mRNA Protein 
Luc 
(2, 4 h) 
0.40 ± 0.04  0.57 ± 0.03  929 ± 279 4 x 105  
± 1.4 x 10
4 
c-fos 
(1, 2 h) 
0.41 ± 0.10  0.96 ± 0.11  278 ± 30  2.7 x 106  
± 10
6
  
IL-6 
(8, 8 h) 
0.69 ± 0.07  1.04 ± 0.04  1497 ± 40 3.2 x 105  
± 6.6 x 10
4
  
EC50 = half-maximal concentration 
SD = standard deviation 
2.3 Discussion 
Our work quantifies the evolution of signaling over time as a result of RET 
stimulation by ART. We measured the coupling of signaling from ART-induced 
initial receptor stimulation to activation of one intracellular signaling pathway, and 
to transcription and translation of specific genes. Our extended time-courses 
provide kinetic profiles of the longitudinal responses from RET activation to 
transcriptional and translational activities. The results show that the dynamic 
responses are difficult to generalize across different genes. Our results indicate 
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that transcription occurs either as a transient spike or a sustained square pulse, 
depending on the gene being measured, and that the time at which mRNA levels 
peak also varies depending on the gene. Aside from the exogenously expressed 
luciferase gene, the difference in transcriptional kinetics between the two 
endogenous genes, c-fos and IL-6, can be explained by their functional roles as 
an IE gene or late-expressed gene, respectively. Immediately early genes 
typically having transcriptional regulation roles, and late-expressed genes usually 
play a role in cellular phenotypic outcomes, such as differentiation (Iyer et al.; 
Nagashima et al.; Segal et al.).  
Signal amplification from external stimuli to intracellular signaling 
activation, and also from mRNA to protein expression, has been extensively 
characterized (Bhalla; Chandrasekera et al.; Gygi et al.; Harding et al.; 
Kholodenko; Reddy et al.; Schwanhäusser et al.). Amplified effectors are 
molecules that have downstream regulatory roles that may or may not require 
translocation from where they are activated to their targets. With over 160 
targets, pERK mediates the activation of many different transcription factors in 
the nucleus and cytosol, its function rationalizes the high amplification of the 
molecule as a result of initial receptor stimulation (McCubrey et al.; Steelman et 
al.). The functional roles of synthesized proteins also justify their high 
amplification from initial stimulus. For example, c-fos protein acts as a biological 
sensor for MAPK/ERK activity and as a transcription factor for other genes, while 
IL-6 protein is an inflammatory cytokine that can provide a further stimulatory 
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response to other cells (Erta et al.; Karin et al.; Murphy et al.). Thus, the 
functional role of the proteins justifies their high amplification, where high levels 
of protein are necessary to elicit further downstream responses from external 
stimuli. We measured transcriptional responses of RET activation, and we found 
that the amplitudes of mRNA levels of three different genes were much lower 
than other downstream signaling responses such as pERK and protein 
expression. Modest levels of mRNA can result in high protein levels rapidly as 
mRNA can be translated simultaneously by clusters of ribosomes, termed 
polysomes (Warner et al.). Thus, this reduction in the amplitude of signaling 
effectors from pRET to mRNA expression is supported by recognizing that 
mRNA production is an energy cost, and high mRNA production would be 
wasteful in energy and is unnecessary to attain high protein expression.  
Low pRET levels corresponds to receptor activation by more 
physiologically relevant ART levels, and it can be seen that at low pRET levels 
there is a higher percent of mRNA expressed per percent of pRET compared to 
the percent of protein expressed per pRET (Figure 2.6B). High coupling 
efficiencies – defined as a high ratio in the amount of activated effectors to 
receptor activation – at low ART levels were also found previously when 
signaling from pRET to pERK and to pAKT were quantified (S. Li et al.). This 
result demonstrates how cells are engineered to optimize downstream signaling 
responses to efficiently relay signals for proper cellular function at very low, 
physiologically activated-receptor levels. As signals transduce from receptors to 
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intracellular signaling molecules and onto nuclear transcription and translation, it 
would be wasteful in energy for cells to continuously amplify the signals since not 
all downstream effectors need amplification to serve functional roles. Our 
longitudinal quantification of ART-induced signaling suggests that cells 
strategically expend more energy at steps with high amplitude, such as activating 
intracellular signaling molecules or synthesizing new proteins, and conserve 
energy at levels that do not require high levels of activation or expression by 
reducing signal amplitude, such as during receptor activation and mRNA 
synthesis. We rationalize that the higher percent of maximal mRNA expressed in 
response to pRET compared to the percent of maximal protein expressed in 
response to pRET is optimal and efficient since mRNA is the precursor for 
protein production that can eventually result in amplified protein expression by 
polysomes. 
We determined that receptor activation is the least sensitive compared to 
any of the other measured signaling responses, which means that a lower 
concentration of ART is required to produce half-maximal responses for 
intracellular signaling (pERK), transcription (mRNA), and translation (protein) 
levels compared to ART concentrations needed for half-maximal receptor 
activation (Figure 2.6A). Phosphorylation of RET has an energy cost, and the 
high sensitization to downstream effectors means that cells do not require 
maximum RET activation for effective downstream signaling, thereby conserving 
energy for other distal and proximal responses. Though not exhaustive and 
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highly speculative, our longitudinal quantification at various levels of cell signaling 
suggests that cells strategically respond to external environmental changes by 
transducing signals by maximizing efficiency.    
The luciferase and c-fos mRNA half-lives, t1/2 = 35 and 40 min, 
respectively, were shorter than the median 9 h mRNA decay rate measured by 
Schwannhausser et al., but still fall within the range of mRNA lifetimes that they 
measured across all genes. On the other hand, the luciferase and c-fos mRNA 
half-lives agree well with the median RNA half-life of 80 min that Rabani et al. 
measured for all genes. Since the IL-6 mRNA did not exhibit decay at up to 6 h in 
the presence of transcription inhibitor, the IL-6 mRNA lifetime would most likely 
be ≥ 9 h median mRNA half-life that was measured by Schwannhausser et al. 
The IL-6 protein was also stable with a t½  = ~13 h, whereas the half-life of 
luciferase protein was much shorter with a t½  = ~70 min. Together, both protein 
lifetimes measured were shorter than the median half-lives that were measured 
by both Schwannhauser et al. and Cambridge et al. of ~45 h. The very short 
luciferase protein half-life measured is not surprising since the reporter gene cell 
line expresses the luciferase gene with destabilizing hPEST sequence for rapid 
degradation (Leclerc et al.). 
Previous findings show that there is little correlation between protein and 
mRNA abundance, and that protein abundance is dependent on a combination of 
factors including mRNA expression, protein and mRNA stability via co-
transcriptional modifications, and translation efficiency (Kristensen et al.; Pérez-
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Ortín et al.; Schwanhäusser et al.; Vogel et al.). Although there is debate on 
whether transcription or translation contributes most to driving protein 
abundance, there is consensus that altering the decay rate of either protein or 
mRNA plays only a minor role (Lu et al.; Pérez-Ortín et al.). Though playing only 
a minor role in protein abundance relative to transcription and translation, 
modifying protein stability is still an important strategy cells use to regulate 
protein abundance, such as the relationship between MAPK/ERK signaling and 
the subsequent stabilization by phosphorylation of c-fos protein as described 
earlier (Murphy et al.). In another example, Nagashima, T et al. stimulated 
human MCF-7 cells with epidermal growth factor, and found an increase in 
mRNA stability for late response genes as a result of MAPK/ERK signaling 
(Nagashima et al.). In that study the authors found that the half-life of mRNA for 
immediate early genes did not increase due to sustained MAPK/ERK activity, 
which means that the ART-induced 2-fold longer c-fos mRNA lifetime (Figure 
2.7A, inset) that we observed may not be attributable to MAPK/ERK signaling, 
though we cannot rule out the possibility since we did not directly test it. No 
decay was found for ART-induced IL-6 mRNA for up to 6 h in the presence of 
transcription inhibitor, and this stability appears to require sustained MAPK/ERK 
signaling, as inhibition of MAPK/ERK signaling led to a reduction in IL-6 mRNA 
levels at 2 h after initial ART stimulation (Figure 2.9A, inset, Appendix VIII). This 
result supports the findings of Nagashima, et al. that sustained MAPK/ERK 
signaling post-transcriptionally prolongs the mRNA lifetime for late response 
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genes, though they do not provide a molecular mechanism for this effect. The 
interplay between MAPK/ERK signaling, c-fos protein, and IL-6 gene expression 
is even more evident as the c-fos protein acts as one part of the heterodimer that 
forms the AP-1 transcription factor, which is known to regulate the expression of 
IL-6 (Angel and Karin). This interplay is an example of how receptor-activated 
intracellular signaling molecules regulate transcription and translation. The 
exogenous luciferase gene provides another perspective on the dynamic 
relationship between receptor activation, intracellular signaling molecules, mRNA 
synthesis and protein expression, where the firefly luciferase gene products 
themselves are not known to regulate mammalian gene expression or stability of 
other gene products.  
In general, there is little correlation between mRNA levels and protein 
abundance, translation efficiency may be a better driving factor for the amount of 
protein expressed so that determining how TE evolves over time may reveal 
critical times when cells commit to full protein expression (Csárdi et al.; Rodnina; 
Schwanhäusser et al.). Our approach to measuring transcription and translation 
rates enable us to establish RET activated responses on TE. For our study, we 
assume that kdeg for Luc protein is invariant over the course of the experiment, 
which allowed us to calculate translation rates using Equation 2. The 
transcription and translation rates from our time-course and decay 
measurements were further used to interpolate TEs for luciferase and IL-6 at 
various times during the response. Due to the intrinsic nature of complex 
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feedback and signaling of the c-fos protein, we decided to focus on the 
translation efficiencies of RET-activated induction of luciferase and IL-6 genes. 
For luciferase, our results suggest that TE is not constant, but instead peaks at a 
level of ~30 molec./min per mRNA at 30 min of ART stimulation, followed by a 
decline to ~10 protein molec./min per mRNA by 60 min, and to ~3 molec/min per 
mRNA by 120 min (Figure 2.5B). These TE values agree with the elegant work 
by Schwanhausser et al. who calculated global protein and mRNA synthesis 
rates in non-stimulated, dividing mouse fibroblast cells, and found median and 
maximum TE rates of 2 protein molec./min per mRNA and 17 protein molec./min 
per mRNA, respectively. Cells that express proteins with dynamically fluctuating 
TE may have an advantage for regulating protein expression. Fluctuations in TE 
over the course of gene activation may provide an opportunity for tuning of gene 
expression, such as through altering the response of signaling molecules (i.e., 
pERK and c-fos). For example, since luciferase TE maximizes at 30 min and 
slowly decreases until it stabilizes at ≥ 120 min after ART stimulation, inhibition of 
signaling in the MAPK/ERK pathway between RET activation and luciferase 
protein expression before or during the time when TE maximizes, would in turn, 
have the greatest impact on protein output, whereas inhibition after maximum TE 
would have a lower effect on protein expression (Figure 2.5B). This scenario is 
demonstrated by our MEK inhibitor experiments that show inhibition of 
MAPK/ERK signaling at times before 30 min after initial ART stimulation had the 
largest impact on luciferase protein output, while inhibition between 60-90 min 
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had moderate influence on protein levels, with little or no impact on luciferase 
production seen when MEK was inhibited ≥ 120 min (Figure 2.12A). Thus, we 
show that by determining the time at which TE is greatest, we can tune protein 
expression by pinpointing the time at which modifications to the signaling 
pathways relevant to gene expression will have the highest impact on protein 
output. Our measurements of the variation TE over time underscores how 
dynamic measurements of signaling events may be a better indicator of the 
biological state of the cell (i.e., whether a cell has reached the time at which it 
has committed to protein expression), rather than simply focusing on the total 
mRNA or protein abundance at some fixed time. However, simply showing that 
inhibiting of MAPK/ERK signaling at the same times at which luciferase TE are 
highest results in lowered luciferase protein production does not address the 
underlying mechanism driving commitment to protein expression. Instead, a 
better question to ask is what causes TE fluctuations? 
Measurements of luciferase protein levels after cells were treated with 
ART for 60 min followed by inhibition of MEK by adding CI1040 demonstrate that 
there is a difference in competency between early and late transcribed mRNA 
(Figure 2.12B). In this case, we define competency as the ability for mRNA to be 
translated into protein. If competency of translation is the same for all mRNA 
transcribed, the TE would be unchanged so that as mRNA increases, so would 
protein expression, but this is not case. Instead, we found that even though 
luciferase mRNA level peaks at 120 min after ART treatment, the TE has fallen 
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by 90% from peak level at 30 min ART stimulation. Furthermore, when we 
inhibited MAPK/ERK signaling 60 min after ART, there was little to no impact on 
protein production. Together, our results led to us hypothesize that there may a 
difference in the competency between ART-induced early transcribed and later 
transcribed mRNA, where the early-transcribed mRNA is more competent at 
being translation. Therefore, early transcribed mRNA results in the high TE 
during early ART treatment, and is able to produce protein at levels even when 
MAPK/ERK signaling has stopped. Future investigation of the competency of the 
luciferase mRNA to be translated, would help us distinguish mechanisms 
responsible for TE fluctuation so that we can understand how cells regulate 
commitment to protein expression. The next three sections address possible 
molecular mechanisms that explain how differences in the competency of mRNA 
translation may occur. 
Our results and the results of others suggest that cells can alter TE as a 
strategy to respond to their environment to adjust protein output as signals 
transduce throughout the cell (Koritzinsky et al.). One possible mechanism for 
altering translation efficiency can occur at the level of translation which is highly 
regulated at multiple steps during the initiation, elongation, and termination steps 
(Chu et al.; Hershey et al.). Translation initiation is the rate-limiting step, and the 
eIF4F and eIF2 initiation factor complexes play crucial roles during translation. 
The eIF4F complex acts as a scaffold between the interaction of 5’ cap mRNA 
and 40S ribosome, while the eIF2 complex bridges active tRNA to ribosomes 
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(Chu et al.; Holcik and Sonenberg; Schröder and Kaufman). Koritzinsky, et al. 
showed that hypoxic treatment of HeLa cells resulted in gene-specific differences 
in translation efficiency, by measuring ribosome density per mRNA over the 
course of hypoxic treatment, where the density of ribosomal activity per mRNA is 
defined as translation efficiency; the higher the density per mRNA, the higher the 
translation efficiency (Koritzinsky et al.) Although their work defined the density of 
ribosomes per mRNA as translation efficiency, which is different from our 
definition of translation efficiency as protein per mRNA, evidence supports that 
the two definitions of TE are correlated with overall protein production for 
heterologous or overexpressed genes (Plotkin and Kudla). Thus, their findings 
may be relevant to our work since luciferase is an exogenous gene and up-
regulated upon ART stimulation. They attributed the variation in hypoxia-induced 
translation efficiency to the disruption of eIF4F by binding factors during 
prolonged hypoxia, and to phosphorylation of eIF2α in the eIF2 complex, which 
inhibits its activity, under acute hypoxic conditions. Both of these effects inhibit 
translation initiation (Koritzinsky et al.). Thus, the initiation factors may be 
possible candidates that attribute to the differences in TE, and that the difference 
in early and late mRNA competency for translation is governed by translation 
initiation.  We could test this hypothesis by measuring the association of eIF4F to 
luciferase mRNA and detect the level of phosphorylation of eIF2α at different 
times at which mRNA is synthesized. In such an experiment, the observation of 
increased phosphorylated eIF2α and decreased association of eIF4F to 
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luciferase mRNA during late ART treatments  would tell us that later transcribed 
mRNA is less efficient at being translated because of impaired translation 
initiation complexes, while the observation that there is no change in eIF2α or 
eIF4F between early and late ART-induced luciferase mRNA would instead 
mean that translation initiation is not responsible for fluctuating TE. 
A second possible mechanism for how mRNA can have differing 
competency for translation can be attributed by the compartmentalization of 
inactive mRNA. Cells can also regulate TE at the mRNA level by deadenylation 
of the poly (A) tail during the initiation of mRNA decay, which is the rate-
determining step of mRNA decay before exonucleases cleaves nucleotides 
(Radhakrishnan and Green; Weill et al.). Co-transcriptional modification of mRNA 
by deadenylases can lead to inactive, untranslatable mRNA that can further be 
compartmentalized and protected from exonucleases in stress granules, and 
sometimes in processing bodies (p-bodies). The compartmentalized mRNA can 
either be degraded in p-bodies since p-bodies possess factors for mRNA 
degradation, or be reactivated for translation in stress granules since stress 
granules contain translation initiation factors (Buchan and Parker; Decker and 
Parker). Because our mRNA measurements using RT-qPCR detected mRNA 
based on the presence of just the short nucleotide sequence between the 
forward and reverse primers, this approach cannot distinguish between 
incompetent and competent forms of the mRNA. Thus, our observation that TE 
drops during late ART treatments times may be due to the compartmentalization 
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of deadenylated late-transcribed mRNA, which would explain the observed 
differences in TE over time. We hypothesize that if compartmentalization of 
mRNA changes over the course of ART treatment, this would mean that early 
transcribed mRNA is not or less likely to be compartmentalized so that they are 
more competent to be translated, and as more mRNA are synthesized over time, 
they are compartmentalized and not translated, resulting in lower competency for 
translation and lower TE over time. We can test this hypothesis by measuring the 
co-localization of luciferase mRNA in p-bodies and stress granules over time in 
the presence of ART treatment, for example through experiments involving RNA-
co-immunoprecipitation of stress granule or p-bodies markers. 
A third possible mechanism to explain a change in mRNA competency for 
translation is through altering mRNA structure so that access by ribosomes and 
translation initiation factors to mRNA affects translation efficiency. Translation 
efficiency can also be regulated co-transcriptionally at the mRNA level. Variation 
in mRNA structure modifies TE by adjusting the looseness or tightness of the 
mRNA coils, so that access to the mRNA by translational ribosomal proteins is 
either enhanced or blocked (Gingold and Pilpel; Gu et al.; Wen et al.). Kudla, et 
al. explored factors contributing to variation in gene expression by introducing a 
synthetic library expressing 240 silent mutations of the same GFP protein into 
bacteria (Kudla et al.). They found that mRNA folding is a more important factor 
in determining gene expression than mRNA level, mRNA decay rate, or coding 
bias, the latter of which showed no correlation (Kudla et al.). Their explanation 
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was that mRNA folding variability could enhance or decrease translation initiation 
by influencing ribosome access, thereby modifying the rate of gene expression.  
We observed a difference in TE dynamic profiles between the IL-6 and 
luciferase genes, where the IL-6 TE remains mostly constant at ~1-2 IL-6 protein 
molec./min per mRNA for up to 240 min after the initiation of ART stimulation, 
and eventually decreases to <1 protein molec./min per mRNA by 360 min (Figure 
2.10 B). Our measurements for IL-6 TE are similar to the median TE for all genes 
measured by the Schwannhauser paper. The initial stability in TE over time may 
be a consequence of strict regulation of feedback between MAPK/ERK signaling 
and c-fos protein stability, since c-fos protein is post-translationally regulated and 
makes up one of the heterodimer to form the AP-1 promoter that regulates the IL-
6 gene as mentioned previously (Tanabe et al.). Variations in TE between 
different genes exist so that genes can ‘compete’ for translation resources (i.e., 
tRNAs, ribosome-associating proteins) (Gustafsson et al.; Pop et al.). Moreover, 
studies on codon bias show that genes that require higher TE code for codons 
that are more abundant (i.e., more readily available for protein synthesis), and 
codon bias is what drives the differences in translation efficiency, termed “codon 
usage bias” (Sharp and Li; Tuller et al.). By measuring the codon usage bias, 
comparisons of relative TEs can be predicted using either the codon adaptation 
index (CAI) or tRNA adaptation index (TAI). These indices assess the frequency 
of codon usage in highly expressed genes, and use them as a reference to 
predict translation levels for other genes. The CAI value for luciferase is higher 
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than that for IL-6, which suggests that the luciferase gene is coded for higher TE 
compared to IL-6. 
Overall, we have quantified the transcriptional and translational effects of 
RET signal transduction of three different genes. Our work highlights the 
importance of measuring events at various stages during signaling so that the 
evolution of signal transduction can be monitored. Furthermore, by generating 
transcription and translation rates, we were able to calculate TE for specific 
genes, which enabled us to test critical times at which cells commit to protein 
expression. Elucidating cellular signaling at the global scale is challenging given 
the complexities that govern cell fate. Detailed quantification of signaling 
dynamics across multiple events in the signaling pathways that induce 
expression of specific target genes restructures the complexities into measurable 
variables that facilitate an understanding of these complex processes. 
2.4 Materials and Methods 
2.4.1 Materials. 
The Actinomycin D (cat. no. A9415) was purchased from Sigma-Aldrich 
(Allentown, PA). The cycloheximide (cat. no. 239763) was purchased from MD 
Millipore (Billerica, MA). The c-fos detection antibody (cat. no. 2250s) and anti-
rabbit-HRP secondary antibody (cat. no. 7074s) were purchased from Cell 
Signaling Technologiy (Danvers, MA). The Mouse IL-6 ELISA Max Deluxe kit 
(cat. no. 431304) was purchased from Biolegend (San Diego, CA). The purified 
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human c-fos recombinant protein (cat. no. ab84143) was purchased from Abcam 
(Cambridge, MA). The purified recombinant firefly luciferase (cat. no. E1701) was 
purchased from Promega (Madison, WI). The rest of materials are the same as 
described in Chapter 1.  
2.4.2 Cell culture 
NB41A3-mGFRα3-SRELuci cells were cultured exactly the same as 
described in Chapter 1.4.2 with the addition of 5 µg/ml of puromycin. 
2.4.3 Luciferase assay 
NB41A3-mGFRα3-SRELuci cells were plated at 1x105 cells/well on an 
opaque 96-well tissue culture plate (Falcon, Miami, FL) and incubated overnight. 
The cells were starved with serum-free DMEM for 12-18 h prior to addition of 1.6 
nM human artemin (ART) for respective times indicated for time course 
experiments. For luciferase decay protein experiments, cells were treated with 
1.6 nM ART for 4 h, and then 100 µM of cycloheximide was added and incubated 
for different times to measure protein decay. For the ART dose-response 
measurements, cells were treated with various ART doses and incubated for 4 h. 
Treatments for CI1040 inhibition experiments were done two ways: 1) 1.6 nM 
ART was added to cells at t=0, then 1 µM CI1040 was added at different times 
until 240 min, or 2) 1.6 nM ART was added to cells for 60 min, then 1 µM CI1040 
was added and incubated for different times. After incubation, cells were washed 
with PBS and lysed with 20 µl of cell culture lysis reagent (cat. no. E1531; 
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Promega, Madison, WI) for 20 min with vigorous shaking. Luminescence was 
measured upon addition of 75 µl 5’-fluoroluciferin (Promega, Madison, WI) using 
a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA).  
2.4.4 pRET and pERK ELISAs 
The NB41A3-mGFRα3-SRELuci cells seeded onto 24-well polystyrene 
plates at 3x105 cell per well and were starved with serum-free DMEM for 12-18 h 
prior to addition of 1.6 nM human artemin (ART) for respective times indicated for 
time course experiments. For the ART dose-response measurements, cells were 
treated with various ART doses and incubated for 10 min. Detection of pRET and 
pERK are the same as described in Chapter 1.4.7 and 8, respectively.  
2.4.5 IL-6 ELISA 
The NB41A3-mGFRα3-SRELuci cells seeded onto 24-well polystyrene 
plates at 3x105 cell per well and were starved with serum-free DMEM for 12-18 h 
prior to addition of 1.6 nM human artemin (ART) for respective times indicated for 
time course experiments. For IL-6 decay protein experiments, cells were treated 
with 1.6 nM ART for 6 h, and then 100 µM of cycloheximide was added and 
incubated for different times to measure protein decay. For the ART dose-
response measurements, cells were treated with various ART doses and 
incubated for 8 h. After appropriate incubation times, supernatant was collected 
and cells were lysed with Radioimmunoprecipitation assay lysis buffer (25 mM 
Tris, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 
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1% triton x-100, 1 mM PMSF, 2 mM Na3VO4). Detection of IL-6 using the Mouse 
IL-6 ELISA Max Deluxe kit (Biolegend; San Diego, CA) was done according to 
manufacturer’s protocol. Briefly, 96-well ELISA plate (Falcon, Miami, FL) was 
incubated overnight at 4°C with 100 µl of diluted supplied IL-6 capture antibody in 
coating buffer, wash plates with PBST 3 times, then block with diluted supplied 
“assay diluent” buffer for 1 h, then wash 3 times with PBST. Coat plates with 100 
µl 1:8 diluted supernatant in serum free DMEM and centrifuged 100 µl 1:5 diluted 
cell lysates in lysis buffer for 1 h, wash 4 times, and follow with 100 µl of diluted 
supplied detection antibody in assay diluent. Wash 3 times, and follow with 100 
µl diluted supplied avidin-HRP antibody in assay diluent, wash 3 times, and 
develop with 3,3’-5,5’-tetramethylbenzidine dihydrochloride (TMB) (Pierce, 
Rockford, IL). The reaction was quenched with 1 M H2SO4 and the absorbance 
was obtained at 450 nm using a SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA). The plastic plate background was measured at 540 nm 
and subtracted from the sample absorbance.  
2.4.6 Real-time reverse transcription polymerase chain reaction (RTqPCR) 
The NB41A3-mGFRα3-SRELuci cells seeded onto 24-well polystyrene 
plates at 3x105 cell per well and were starved with serum-free DMEM for 12-18 h 
prior to addition of 1.6 nM human artemin (ART) for respective times indicated for 
time course experiments. For mRNA decay experiments, cells were treated with 
1.6 nM ART for 1 h or 2 h, and then 4 µM of actinomycin D was added and 
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incubated for different times to measure mRNA decay. For the ART dose-
response measurements, cells were treated with various ART doses and 
incubated for 1, 2, and 8 h. After appropriate incubation times, cells were lysed 
with cell lysis buffer from NucleoSpin RNA Plus kits (cat. no. 740984, Clontech, 
Mountain View, CA), and RNA was extracted per manufacture’s protocol. The 
cDNA synthesis and qPCR were same as described in Chapter 1.4.9. 
Primers sets (Integrated DNA technologies, Coralville, IA)  
GAPDH: forward -5’-GTGGAGTCATACTGGAACATGTAG-3’,  
reverse-5’- AATGGTGAAGGTCGGTGTG-3’,  
c-fos: forward-5’-CGGGTTTCAACGCCGACTA-3’,  
reverse-5’- TTGGCACTAGAGACGGACAGA-3’,  
IL-6: forward-5’-TAGTCCTTCCTACCCCAATTTCC-3’,  
reverse- 5’-TTGGTCCTTAGCCACTCCTTC-3’ 
2.4.7 Detection of c-fos by Western Blot 
The NB41A3-mGFRα3-SRELuci cells seeded onto 12-well polystyrene 
plates at 6x105 cell per well and were starved with serum-free DMEM for 12-18 h 
prior to addition of 1.6 nM human artemin (ART) for respective times indicated for 
time course experiments. Decay of c-fos protein was attempted by treatment with 
1.6 nM ART for 2 h, and then 100 µM of cycloheximide was added and incubated 
for different times to measure protein decay. For the ART dose-response 
measurements, cells were treated with various ART doses and incubated for 2 h. 
After appropriate incubation times, cells were lysed with 
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Radioimmunoprecipitation assay lysis buffer. Concentration of cell lysates were 
measured using BCA Protein Assay Kit (Pierce; Waltham, MA) per 
manufacturer’s protocol. Cell lysates (20 µg of total protein) were separated on 
10% TruPage polyacrylamide gel (cat. no. PCG2009, Sigma-Aldrich, Allentown, 
PA), with molecular weight Precision Plus ladder (cat. no. 1610373, BioRad, 
Hercules, CA). A polyvinylidene fluoride (PVDF) membrane (cat. no. 1708891, 
Biorad, Hercules, CA) was activated in methanol and the gel was placed on top 
of the membrane for transfer at 40V for 90 min. The PVDF membrane was 
blocked in 5% milk in tris-buffered- saline-tween 20 (TBST) for 1 h. The c-fos 
antibody was diluted 1:1000 in 5% milk and the membrane was incubated 
antibody for 1 h at 4° C. The membrane was washed with TBST, and then 
treated with a secondary anti-rabbit HRP antibody diluted 1:1000 in 5% TBST for 
45 min. The blot was developed using ECL Western Blotting substrate (cat. no. 
32106 ThermoFisher, Waltham, MA)  and imaged with ChemiDoc XRS+ (Biorad, 
Hercules, CA). 
2.4.8 Data analysis 
Dose-response data for ART-induced pRET, pERK, luciferase, c-fos, and 
IL-6 proteins and mRNA were analyzed using a logistic four-parameter fit 
equation 1:  
 𝑋 = !!"#!! !"!"!"# !"#$%        (Eq. 1) 
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where X = pRET, pERK, or luciferase, c-fos, and IL-6 proteins and mRNA, Xmax is 
the maximum response upon stimulation by ART; the EC50 represents the ART 
concentration required to achieve half-maximal response; and slope corresponds 
to steepness of the curve. All curve fits were performed using Prism 7 software 
(GraphPad Software Inc., La Jolla, CA). 
Decay curves were fitted to equation 2, 𝑦 = 𝑦! − 𝑦!""#$%  × 𝑒!!" + 𝑦!!!"#$      (Eq. 2) 
where y0 is the initial value at t = 0, yoffset is the final y value at highest time 
measured, k is the rate constant in min-1.
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QUANTITATIVE STUDY OF CROSSTALK BETWEEN ART AND OTHER 
GROWTH FACTORS 
3.1 Introduction 
3.1.1 Receptors detect external stimuli 
External stimuli in the form of ligands, such as growth factors (GFs), 
cytokines, chemokines, and other chemical agents, act as inputs that initiate 
cellular signaling. The expression of different types of receptors on cells is highly 
diverse, yet specific to the cell type, which provides cells the ability to detect 
multiple stimulation events and enables transduction of signals from multiple 
inputs simultaneously. Thus, in the natural cellular state, receptors on cells do 
not function in isolation. Instead, stimulation of receptors develops into a set of 
intracellular processes, each with inputs and outputs that eventually are 
integrated to drive a coherent cellular functional response. Signaling networks 
are the connections between the input and output signals, and decoding their 
complexities is incredibly difficult to do, since many signaling pathways share 
components in common, or interact with each other in other ways, making it 
difficult to predict overall outcomes (Fraser and Germain; Janes et al.). Due to 
this complexity, while the activation mechanisms, signaling dynamics, and 
biological consequences resulting from stimulation of single receptor systems 
have been characterized extensively, our understanding of the interconnectivity 
between different receptors remain limited (Hyduke and Palsson).  
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3.1.2 Crosstalk: When signals converge 
Crosstalk is defined as the interaction of one signaling pathway on 
another. We further define crosstalk as a synergistic effect, or more than the 
additive effects, of multiple stimuli. Since many receptors share common 
downstream signaling pathways and biological outputs, elucidating the 
complexities and interplay of signal transduction, as it occurs in a native context, 
can benefit from taking a quantitative perspective on the coupling between 
multiple stimuli and downstream events, as a means to uncover the mechanisms 
responsible for crosstalk. 
There are many different strategies for studying signaling networks and 
crosstalk. Recent studies have embraced systems biology approaches to 
defining the interrelatedness of signaling networks through computational 
methods, single-cell analyses, proteomics, and microarray technologies 
(Cappuccio et al.; Chitforoushzadeh et al.; Kuchenov et al.; Natarajan et al.; van 
Wijk et al.). For example, Natarajan, et al. applied a systematic, large-scale 
analysis of macrophages stimulated with 22 receptor-specific ligands in 231 
different pairwise combinations, to characterize the effects of crosstalk on Ca2+ 
mobilization, cAMP synthesis, phosphorylation of signaling molecules, and 
cytokine production (Natarajan et al.). They found that each ligand exhibited 
crosstalk with at least one other ligand, and that the effects were non-additive, 
being either synergistically activating or antagonistic. Another group combined 
mathematical modeling and transcriptional profiling of dendritic cells, and focused 
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on quantifying the numerical possibilities of the combinations of signal outputs 
from 4 different input possibilities (control, X, Y, and X+Y) (Cappuccio et al.). 
They narrowed down to 82 output possibilities, and related the outputs to 
biological functional outcomes. The 82 output signals were further grouped into 5 
negative (e.g., negative synergy, X inhibits Y, etc.) and 5 positive interaction 
types (e.g., positive synergy, X restores Y, etc.). They categorized their 
input/output model based on the transcriptional profile data into one of the 10 
output interaction types, and found that 9 out of 10 interaction types related back 
to the effects on signaling pathways, which they argue can be used to predict 
how co-stimulation outputs will affect biological function (Cappuccio et al.).  
These types of crosstalk studies have also been used to propose 
alternative drug development strategies that target signaling pathways and 
evaluate interacting drug effectiveness (Geva-Zatorsky et al.; van Wijk et al.). For 
example, the underlying mechanism of crosstalk between the ligands TNF, 
insulin, and epidermal growth factor, has recently, been uncovered to occur at 
the GATA6 transcription factor (Chitforoushzadeh et al.). Using proteomics, 
transcriptomics, and statistical modeling, the authors mapped the integration of 
signaling networks in response to multi-ligand stimuli in colon adenocarcinoma 
cells. Their model accurately predicted signaling dynamics of Akt signaling in 
response to insulin/TNF crosstalk, exhibited by insulin-induced repression of 
genes that TNF would normally activate. They further validated that the 
mechanism of this repressed Akt pathway crosstalk is through the 
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phosphorylation of Ser37 on the GATA6 transcription factor by the glycogen 
synthase kinase 3. 
There have been ongoing and vigorous efforts to reveal the complexities 
in signaling networks, including meta-data analyses in addition to studies focused 
on the interconnectedness of specific receptors. These studies suggest that 
crosstalk studies that use more than two stimuli in general do not provide more 
information than ones that only use two stimuli (Chatterjee et al.; Geva-Zatorsky 
et al.; Hsueh et al.). Thus, in our work we chose to interrogate crosstalk by 
focusing on just two specific stimuli.  
3.1.3 Crosstalk between RET and other receptors 
The characterization of crosstalk between RET and other growth factors 
has been explored through studies involving glial-derived neurotrophic factor 
(GDNF), a ligand for RET, and different GFs and cytokines including interleukin-6 
(IL-6), vascular endothelial growth factor-A (VEGF-A), nerve growth factor (NGF), 
and brain-derived neurotrophic factor (BDNF) (Esposito et al.; Gattelli et al.; 
Morandi and Isacke; Peterson and Bogenmann; Simpson et al.; Tufro et al. 2). 
Studies have demonstrated that crosstalk by a positive feed-forward loop 
between RET activation and IL-6 up-regulation plays a role in breast cancer 
metastasis (Gattelli et al.; Morandi and Isacke). Crosstalk at the receptor level, in 
which activation of one receptor induces the activation of another receptor, also 
known as transactivation, has been shown between RET and the receptors for 
VEGF-A (VEGF receptor 2;VEGFR2), NGF (tropomyosin receptor kinase A; 
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TrkA), and BDNF (TrkB). Crosstalk between RET and VEGFR2 signaling has 
also been established based on qualitative studies in ureteric bud development 
(Tufro et al.). Crosstalk presented as positive feedback between GDNF-activated 
RET and NGF-induced TrkA activities has been shown to induce neural 
differentiation in studies involving neuroblastoma (Peterson and Bogenmann). 
Additionally, the BDNF-activated TrkB receptors were found to activate RET in 
the absence of its native ligand, which also induced neuroblastoma differentiation 
(Esposito et al.; Simpson et al.). Although these examples of crosstalk between 
RET and other receptors examined the integrated activities at various levels of 
receptor activated signaling, none of them involved any detailed investigation of 
the roles in crosstalk played by intracellular signaling molecules.   
3.1.4 Goal: Reveal effects of crosstalk on signaling 
We aim to identify and develop crosstalk models to investigate the 
mechanism of crosstalk of intracellular signaling pathways by quantifying the 
impact of co-stimulation between RET and other receptor(s) from the vantage 
point of RET. As mentioned in previous chapters, RET downstream intracellular 
signaling involves many classic, well established pathways including MAPK/ERK, 
PI3K/Akt, JNK, p38/MAPK, and others. We screened for crosstalk using the 
MAPK/ERK related luciferase reporter gene cell line we developed in Chapter 1, 
plus a phospho-Akt (pAkt) ELISA method. Herein, we describe our findings that 
the activation of multiple receptors by co-stimulating cells with ART/ insulin-like 
growth factor 2 (IGF2) resulted in crosstalk involving the PI3K/Akt pathway, 
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characterized by an increase in the sensitivity for ART-induced phospho-Akt 
activity when cells were co-treated with IGF2. Using this ART/IGF2 co-stimulated 
synergistic increase in the sensitivity in pAkt response as method to study 
crosstalk, we quantified the combinatorial dose-dependent relationship of ART 
and IGF2 on the sensitivity of pAkt levels.  
3.1.5 Crosstalk in sensitivity between different receptors  
 Crosstalk between different receptors exhibited as either a change in 
sensitivity or as activations of multiple receptors in the presence of co-stimulation 
has been previously studied in different cell-types (Gneo et al.; D. V. Lee et al.; 
Rolvering et al.). Some studies were able to identify the mechanism of crosstalk, 
while others simply reported a synergistic change in the sensitivity of a 
phenotypic response without successfully pinpointing a specific crosstalk 
mechanism.  
One example of crosstalk is between two cytokines, interleukin-27 (IL27) 
and interleukin-6 (IL6), both of which ligands signal through the same gp130 
receptor (Heinrich et al.; Pflanz et al.). In hepatocytes, IL6 binds to gp130 
homodimer receptors, which then activates the Suppressor of cytokine signaling 
3 (SOCS3) intracellular protein, which negatively regulates Jak1 (Kao, Lai, et al. 
27; Kao, Feng, et al.; Schmitz et al.). Jak1 is a tyrosine kinase protein that 
mediates gp130-STAT1 activity (Darnell et al.). Conversely, IL27 activates 
gp130/WSX1 heterodimer receptors, which results in upregulation of the JAK1-
STAT1 response (Darnell et al.). Rovering et al. hypothesized that co-stimulation 
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with IL6 and IL27 would lead to crosstalk of IL6-induced gp130/gp130 activation 
and IL27-induced gp130/WSX1 activation, and that the activity of SOCS3 would 
attenuate the JAK1-STAT1 response (Rolvering et al.). They tested their 
hypothesis by pretreating cells with IL6, followed by co-stimulation with IL27 for 
1-48 h. The authors found that in the presence of IL27 and IL6, STAT1 activity 
decreased while SOCS3 levels increased, compared to cells that were treated 
with IL27 alone. They further validated their crosstalk mechanism by confirming 
that IL27-induced STAT1-luciferase activity was diminished when SOCS3 is 
overexpressed (Rolvering et al.). The authors did not show a change in 
sensitivity when cells were co-stimulated compared to cells that were stimulated 
with either cytokine alone. Instead, they showed a synergistic inhibitory crosstalk 
response when cells were co-stimulated with IL6 and IL27, and although the 
cytokines signal through the same gp130 receptor, the downstream intracellular 
response (e.g., STAT1 versus SOCS3 activities) was different depending on the 
cytokine.  
In another example, Gneo et al. studied crosstalk between TNF-related 
apoptosis-inducing ligand (TRAIL) receptors and TrkAIII receptors in 
neuroblastoma cells (Gneo et al.). TRAIL is an apoptotic-inducing ligand that 
binds to DR4 and DR5 (DR4/5) TRAIL receptors to recruit the death-receptor 
complex that initiates apoptosis, and is composed of the Fas-associated protein 
with death domain (FADD) and caspase 8 (Ashkenazi and Dixit). The TrkAIII 
receptor is a splice variant of the TrkA receptor and is highly expressed in 
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neuroblastoma cells (Tacconelli et al.). The TrkAIII receptor is also constitutively 
active and localized in the intracellular membrane, and results in chronic 
PI3K/Akt signaling (Tacconelli et al.). The authors found that cells expressing 
both TrkAIII and DR4/5 TRAIL receptors were “sensitized” to TRAIL-induced 
delayed apoptosis, compared to cells that only express DR4/5 TRAIL receptors 
(Gneo et al.). Further tests reveal that the TRAIL/TrkAIII receptors crosstalk via a 
formation of complex between the intracellular portion of TrkAIII receptors to 
TRAIL-induced activated non-receptor tyrosine kinase SHP/c-src complex, which 
then dephosphorylates TrkAIII and induces, delayed caspase 8 mediated 
apoptosis (Gneo et al.). Similar to the IL6/IL27 study, no ligand dose responses 
for sensitivity measurements for ligand stimulation with and without co-
expression of DR4/5 TRAIL and TrkAIII receptors were shown as the crosstalk 
was evaluated based on phenotypic measurements for apoptosis. Thus, because 
these studies lack quantitative approaches to measuring synergistic effects, it is 
unclear whether the effect is in fact due to a sensitivity difference or an amplitude 
difference in crosstalk signaling. 
 An example of crosstalk between two ligands and their respective 
receptors for which doses giving half-maximal activation were measured is the 
crosstalk between fibroblast growth factor 21 (FGF21) and insulin (D. V. Lee et 
al.). Both growth factors are known to have biological effects on glucose uptake 
in adipose cells (Kharitonenkov et al.; Xu et al.). FGF21 activates its FGF21 
receptor through interaction with a co-receptor, β-klotho, while insulin binds 
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directly to the insulin receptor (IR) (Ding et al.; Siddle). Lee et al. found that co-
stimulation with FGF21 and insulin in human adipose stem cell derived cells 
resulted in a synergistic sensitization of the cells to FGF21/insulin-induced 
glucose uptake compared to cells that were treated with insulin alone (D. V. Lee 
et al.). Further measurements of signaling pathways including MAPK/ERK and 
PI3K/Akt in response to co-stimulation did not show enhanced sensitivity 
compared to when cells were treated with either growth factor alone (D. V. Lee et 
al.). Thus, they have not definitely identified a mechanism for their crosstalk 
measured by glucose uptake. However, they conducted phosphoproteomics 
analysis and found 23 proteins that were synergistically phosphorylated and 28 
proteins that were synergistically de-phosphorylated upon co-stimulation (D. V. 
Lee et al.). The authors stated that these candidate phospho-protein mediators 
would be evaluated in the future for their possible roles in FGF21/insulin-induced, 
enhanced sensitization of glucose uptake (D. V. Lee et al.). 
 Collectively, these examples of crosstalk characterized as a synergistic 
change in sensitivity in receptor activation under co-stimulation conditions, or 
described as crosstalk mechanisms in which one receptor alters the activation or 
signaling of another type of receptor, show how cells utilize crosstalk in cell 
signaling to mediate biological activity. However, these examples lack 
quantitative detail in evaluating crosstalk. Quantitative approaches to measuring 
crosstalk can be important to identify differences in sensitivity and/or the 
amplitude in crosstalk. Our approach to identifying crosstalk, and the eventual 
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exploration into the mechanisms associated with the effect of crosstalk, provides 
a deeper understanding of how crosstalk between different receptors can 
modulate the sensitization of one of the receptors to its ligand upon co-
stimulation with a second growth factor, but not vice versa. Specifically in our 
case, we measured enhanced sensitivity in pAkt response upon co-stimulation 
with various ART doses plus a single concentration of IGF2 compared to when 
cells were treated with various doses of ART alone. Moreover, we found that co-
stimulation with various IGF2 concentrations in the presence of a single ART 
concentration yielded no change in pAkt sensitivity compared to IGF2 alone. 
Thus, in our example crosstalk occurs only in one direction, where IGF2 
sensitizes ART-induced pAkt response, but not vice versa.  
3.1.6 IGF2 signaling 
Both the insulin receptor (IR) and insulin-like growth factor-1/-2 receptor 
(IGF1/2R) bind to IGF2. The ligand can bind to homodimers of IR or IGF1R or   
to IR/IGF1R heterodimers leading in each case to activation of downstream 
pathways similar to those activated by RET (Figure 3.1) (Denley et al.; Nakae et 
al.). On the other hand, IGF2R acts as a non-signaling ‘trap’ for IGF2, 
sequestering IGF2 and preventing it from binding to other partners (Livingstone). 
Cellular functional roles related to IGF2 signaling are similar to other GFs, 
including proliferation, differentiation, and anti-apoptotic effects (Livingstone 2; 
Siddle). Crosstalk between IGF2 and ART has not been previously reported. 
However, diseased states have been associated with the over-expression of 
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IGF2, IGF1R, and RET in childhood kidney tumor formation and in myxoid 
liposarcoma, a type of connective tissue cancer (H. Cheng et al.; Conyers et al.; 
Schwienbacher et al.). Our exploration of crosstalk in signaling between these 
receptors may provide a framework for a physiological role of crosstalk between 
these receptors.  
3.2 Results 
3.2.1 Identify crosstalk between ART and other GFs at MAPK/ERK pathway 
using luciferase reporter cell line 
Our convenient and robust luciferase reporter gene cell line, NB41A3-
GFRα3-SRELuc, measures activation of the canonical MAPK/ERK pathway 
downstream of many growth factor receptors (see Chapter One). As such, we 
utilized the assay to screen for crosstalk between RET and other receptor 
tyrosine kinases. We additionally measured PI3K/Akt activation using a pAkt 
ELISA as an alternative pathway to identify crosstalk since this signaling pathway 
has been previously well characterized by ART-induced RET activation  and is  a 
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Figure 3.1. Scheme of IGF2 signaling. IGF2 activation can occur by binding to 
IGF1R or IR homodimers, or to an IR/IGF1R heterodimer. Scheme shows only 
pathways pertaining to this study; there are more pathways that IGF2 activates. 
 
Figure 3.2. List of GFs tested to screen for crosstalk with RET.  
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downstream effector of other GF receptors (Lemmon and Schlessinger; S. Li et 
al.). We compiled a list of 22 GF known to activate either one or both of the 
MAPK/ERK and PI3K/AKT pathways, to identify growth factor receptors that 
might crosstalk with RET by modulating RET signaling through these same 
pathways. Since RET is associated with haematopoietic stem cell homeostasis 
and survival, in addition to having neural functional roles such as neural crest 
cells migration, sympathetic axon alignment with blood vessels, and survival of 
motor neurons, we additionally considered GFs that are related to neural or 
stem-cells (Figure 3.2) (Enomoto; Fonseca-Pereira et al.; Hansford and 
Mulligan). To determine what concentration of each GF to use in our 
experiments, we referred to the established half-maximal dose (EC50) 
concentrations listed on the GF vendor’s website (www.biolegend.com). Even 
though the EC50 were measured using functional bioassays, we treated cells at 
concentrations at or above the reported EC50 values (Appendix IX). We treated 
cells for 10 min with varying ART concentrations, with and without co-treatment 
with 4 nM of each GF, except for FLT3L and endostatin which were used at 10 
nM, and compared the luciferase signals seen under ART only and ART plus GF 
treatment conditions. Our initial screens were conducted by stimulating the cells 
with ART for 10 min, followed by the addition of one of the 22 GFs, then lysed 
and measured the cells for luciferase signal after 4 h. This initial screen resulted 
in one possible candidate for crosstalk; co-stimulation with ART and endostatin 
produced a decrease in maximal luciferase activity of cells treated with ART only 
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(Figure 3.3). However, most of the ART/GF combinations tested yielded little 
change in amplitude or in sensitivity compared to ART only treatment, as shown 
for example for IGF2 and cardiotrophin in Figure 3.3. We attempted to optimize 
co-stimulation conditions using cardiotrophin and IGF2 to test whether the 
sequence in which the GFs were added affected our luciferase signal. We 
stimulated the cells with either ART or the other GF first for 10 min, then added 
either various ART concentrations or a single concentration of the other GF for a 
further 10 min. The results showed there was no difference in signal between 
initially stimulating the cells with either ART or the other GF first. We decided to 
treat cells by initially adding various concentrations of ART prior to stimulation 
with the GF for all subsequent experiments, to keep treatment conditions 
consistent. We also tested whether changing the time at when the second GF is 
added after ART affects the outcome of co-stimulation. To that end, we added 4 
nM GFs at different times after initial addition of 1.6 nM ART, for up to 60 min, 
then measured the luciferase signal 4 h after initial ART stimulation. We found 
that co-stimulating the cells by adding GFs after 2 min ART stimulation resulted 
in the greatest increase in luciferase signal compared to other times at which GF 
was added (Figure 3.4). Interestingly, co-stimulation after 10 min of initial ART 
resulted in little change or even a decrease in luciferase activity compared to 
ART alone (Figure 3.4). Even though the signals for when GF was added at 2 
min after ART increased a modest ~10% more than when GFs were added 
simultaneously (t = 0), we decided to modify our co-stimulation conditions to add- 
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Figure 3.3. Effect of co-stimulation with ART and GF on luciferase activity. Cells 
were treated with ART for 10 min before addition of 4 nM GF, followed by 
luciferase measurements after 4 h. Most other GFs tested gave results 
resembling those shown here for cardiotrophin and IGF2 (see Appendix IX for full 
GF panel tested). Error bars represent standard deviation of three independent 
experiments. 
 
 
Figure 3.4. Effect of GF added at different times after 1.6 nM ART on luciferase 
activity measured at 4 hrs.  
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ition of the second GF after 2 min ART to identify crosstalk in cells co-stimulated 
with ART and another GF.  
3.2.2 Crosstalk between ART/Endostain and ART/IGF2 at MAPK/ERK pathway 
Since we optimized the co-stimulation conditions for luciferase activity by 
treating the cells initially with ART for 2 min, then adding GF at a single 
concentration, we revisited our initial hits for crosstalk by measuring luciferase 
activity resulting from co-stimulation of the cells with various ART concentrations 
followed by 4 nM endostatin and IGF2 after 2 min initial ART treatment. We 
determined that, while there is modest increase in luciferase amplitude for 
ART/endostatin and ART/IGF2 compared to ART only treatment, neither of them 
showed an effect on sensitivity of the ART-dependent luciferase response 
(Figure 3.5). Co-stimulation with ART + 4 nM endostatin and ART + 4 nM IGF2 
resulted in maximal increases of ~40% and ~30%, respectively, compared to 
treatment with 10 nM ART only. Treatment with endostatin or IGF2 alone did not 
activate luciferase activity even at 10 nM. These results suggest that these GFs 
potentiate luciferase activity, most likely by crosstalk involving the MAPK/ERK 
pathway, but do not themselves robustly stimulate MAPK/ERK signaling. 
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Figure 3.5. Co-stimulation screens for crosstalk on pERK response by addition of 
GFs after 2 min ART treatment. For co-stimulation, cells were treated with 
varying ART doses for 2 min, followed by addition of 4 nM GF. Cells were lysed 
at 4 h after ART treatment, and the lysate analyzed for luciferase activity. 
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3.2.3 Identify crosstalk at PI3K/Akt pathway 
To complement our screen for crosstalk involving the MAPK/ERK 
pathway, we also measured pAkt activity by ELISA by treating cells with ART for 
10 min, followed by addition of 4 nM GF for an additional 10 min. We found that 
co-stimulation with ART + 4 nM IGF2 resulted in a substantial increase (> 400%) 
in pAkt activity compared to ART only, and that the signal resulting from co-
stimulation overshadowed the ART dose-response completely (Figure 3.6). Since 
IGF2 signals through both the insulin receptor (IR) and insulin-like growth factor 1 
receptor (IGF1R) as either homo- or hetero-dimers, we confirmed that the cell 
line express both receptors by Western Blot (Figure 3.7). We then proceeded to 
optimize the ART/IGF2 treatment conditions to further characterize crosstalk.  
3.2.4 ART/IGF2 crosstalk at PI3K/Akt pathway 
Since initial co-stimulation with ART/IGF2 resulted in pAkt response that 
overshadowed maximal ART-induced pAkt activity, we treated cells with various 
concentrations of IGF2 only to generate a dose-response curve for pAkt to 
determine a sub-saturating IGF2 dose, to better measure ART-induced pAkt 
activity when cells were co-stimulated with IGF2. A dose-response curve for 
IGF2 only was measured, to determine the half-maximal dose for pAkt activity, 
giving EC50 = 6.7 ± 1.2 nM, and that IGF2 concentrations < 2 nM result in pAkt 
response less than 10 nM ART (Figure 3.8 B). The difference in pAkt signal 
sensitivity between ART and IGF2 alone is 3.5-fold, and the difference in 
amplitude between the two GFs is also 3.5-fold.   The  maximum  pAkt  amplitude 
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Figure 3.6. Screen for crosstalk involving the pAkt response upon co-stimulation. 
Cells were treated with various ART doses for 10 min, followed by addition of the 
second GF at 4 nM; after 10 min from GF addition, cells were lysed and analyzed 
for pAkt. 
 
 
Figure 3.7 Western Blot detecting IR and IGF1R in NB41A3-GFRα3-SRELuc 
cells. Molecular weights of IR and IGF1R β are both 95 kDa, while that of pro 
IGF1R β is 200 kDa 
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for IGF2 is greater than 10 nM ART as shown by the orange dashed line in 
Figure 3.8B, but the response to IGF2 is less sensitive compared to ART 
(Figures 3.8 A and B). We refined our co-stimulation conditions for ART/IGF2 by 
adjusting the IGF2 concentration to the sub-saturating concentration of 0.64 nM 
(see Figure 3.8B), and then measured the effect on pAkt levels of stimulating 
cells with ART for 2 min, followed by addition of IGF2, and the signal was 
measured 10 min after. Figure 3.7 A shows that the sensitivity of the cells’ 
response to ART increased by a factor of ~6 upon co-stimulation with sub-
saturating IGF2, from EC50 = 2.0 ± 0.5 nM for cells treated with alone to EC50 = 
0.35 ± 0.16 nM for cells treated with ART + IGF2. The ART only EC50 is similar 
to the value we have previously reported for the parental NB41A3-GFRα3 cells 
from which our luciferase reporter cell line was derived (S. Li et al.). The 
maximum amplitude seen for ART/IGF2 co-stimulation is not statistically different 
from the sum of the maximal pAkt levels  with ART alone plus the pAkt response 
for 0.64 nM IGF2 treatment. Thus, there is no evidence of an effect of ART/IGF2 
crosstalk on the amplitude of the pAkt signal (Figure 3.8 A). We also tested 
whether a shift in sensitivity is observed when cells were treated with one single 
concentration of 10 nM ART for 2 min, followed by adding various concentrations 
of IGF2. We observed no difference in sensitivities between IGF2 only versus 10 
nM ART + IGF2 dose-responses, compared to, EC50 values of 6.7 ± 1.2 nM for 
IGF2 alone versus 4.9 ± 0.6 nM for IGF2 plus 10 nM ART (Figure 3.8 B). Our 
observation that the pAkt sensitivity shift is  present  only  when  IGF2  influences  
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Figure 3.8. Phospho-Akt exhibits crosstalk under ART/IGF2 co-stimulation. (A) 
Cells were treated with various ART concentrations for 2 min, followed by 
addition of 0.64 nM IGF2 (blue curve; EC50 = 0.36 ± 0.16) or no IGF2 (red curve; 
EC50 = 2.0 ± 0.5). At 10 min after the time of IGF2 addition, cells were lysed, and 
the pAkt levels were measured by ELISA. (B) Cells were treated with 10 nM ART 
for 2 min, followed by various doses of IGF2 (orange; EC50 = 4.9 ± 0.6), at 10 min 
after the time of IGF2 addition, cells were lysed and measure by ELISA. IGF2 
only dose-response was also measured (purple; EC50 = 6.7 ± 1.2). Solid lines 
depict the results of four parameter fits to the data, which were used to calculate 
the above EC50 values. Error bars represent standard deviation of 3 independent 
experiments for (A), and the range of two independent experiments for (B). 
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ART-induced RET activation, whereas ART has no effect on the sensitivity of 
IGF2-induced IGF1R/IR activation suggests that the sensitivity shift is one 
directional and limited to crosstalk in signaling through the IGF1R/IR pathways 
since RET activation does not influence the sensitivity of IGF2-induced IGF1R/IR 
signaling.  
We further examined the dose range at which IGF2 signaling affects the 
sensitivity of ART-induced pAkt activity. To that end, we treated cells with 0.1 – 
10 nM ART for 2 min, then added IGF2 at doses ranging from 0.2 – 1 nM and 
measured pAkt levels after 10 min from the time at which IGF2 was added. We 
found that the range IGF2 can be seen to measurably affect the sensitivity of 
ART-induced pAkt only at intermediate concentrations of 0.64 and 0.8 nM. Co-
stimulation at very low concentrations of IGF2 has no significant effect on the 
EC50 values for for ART, while at higher IGF2 concentrations the basal level of 
pAkt is so high the dynamic range of the ART-induced signal is too small to 
permit accurate measurements (Figure 3.9, Table 4).  
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Figure 3.9. ART dose-responses for cells co-stimulated with various 
concentrations of IGF2. Cells were treated with various concentrations of ART for 
2 min, followed by addition of IGF2 at the indicated concentrations, and 
incubated for 10 min after IGF2 addition. Solid lines depict four-parameter fits to 
give EC50 values of single experiment that are summarized in Table 4.  
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Table 3.1. EC50 values for ART dose-response in the presence of various IGF2 
concentrations 
[IGF2] (nM) 
 
EC50 ± SD 
(nM)  0 (ART only) 1.25 ± 0.06 
0.2 1.44 ± 0.05 
0.4 0.84 ± 0.17 
0.64 0.49 ± 0.12 
0.8 0.40 ± 0.20 
1 0.74 ± 0.24 
EC50 = half-maximal concentration 
SD = standard deviation 
3.2.5 ART/IGF2 crosstalk does not affect pAkt lifetime, pRET, and pJNK 
Identification of crosstalk between ART-induced RET and IGF2-induced 
IGF1R/IR signaling, exhibited by the increase in sensitivity of the PI3K/Akt 
pathway to ART, led us to test possible crosstalk mechanisms. One possible 
explanation as to why the sensitivity for pAkt in the presence of ART/IGF2 
increases more than compared to ART only may be attributed to a prolonged 
presence of pAkt, which would contribute to higher levels of the activated 
molecule even at low ART concentrations. In order to test the possibility that the 
increase in sensitivity is due to an increased lifetime of pAkt. We measured the 
decay of pAkt by treating the cells with ART only for 2 min, followed by adding 
IGF2, and administering a highly selective pAkt inhibitor, MK2006 (10 µM) after 
10 min when IGF2 was added; the cells were lysed and measured for pAkt every 
2 min thereafter. However, based on the measurable time scale using the ELISA 
method, we could not detect a difference in pAkt half-lives, ART t1/2 = 0.31 min 
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versus ART/IGF2 t1/2 = 0.36 min (Figure 3.10 A). It is important to note that we 
cannot rule out the possibility that a lifetime difference between ART and 
ART/IGF2 co-stimulation conditions exist, and that we cannot detect using our 
ELISA method, that may attribute to the shift in pAkt sensitivity. We also found no 
difference in either the amplitude or the sensitivity of the RET phosphorylation 
response, between ART only and ART/IGF2 co-stimulation conditions (Figure 
3.10 B). This result demonstrates that the shift in sensitivity observed for pAkt 
response in the presence of ART/IGF2 versus ART only is not present at level of 
RET receptor activation. We additionally measured phosphorylated c-Jun N-
terminal kinase (JNK), an orthogonal signaling molecule downstream of many 
growth factor receptors including RET, to determine whether the sensitivity shift 
is present in other signaling responses., for which we found no effect (Figure 
3.10 C). 
3.3 Discussion 
Here, we identified crosstalk at converging downstream signaling 
pathways when cells were incubated in the presence of two GF ligands. We 
detected crosstalk at the MAPK/ERK pathway as described by a small but 
synergistic increase in the amplitude of luciferase activity when NB41A3-GFRα3-
SRELuc cells were co-stimulated with ART plus endostain or with ART plus 
IGF2. We also observed crosstalk at the PI3K/Akt pathway, as exhibited by 
enhanced pAkt sensitivity to ART in the presence of intermediate concentrations 
of IGF2. In the latter case, the sensitivity shift is tightly dependent on IGF2 conc- 
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Figure 3.10. Phospho-Akt lifetime, 
pRET, and pJNK responses by 
ART only and ART/IGF2 co-
stimulation. Cells were either 
treated with 1.6 nM ART only (red) 
or with 1.6 nM ART for 2 min, 
followed by addition of 0.64 nM 
IGF2 (black), after 10 min 
incubation after IGF2 addition, 
cells were: (A) Induced of pAkt 
decay upon treatment with 10 µM 
pAkt inhibitor, MK2206, and lysed 
every 2 min to measure for pAkt. 
Decays were fitted to one-phase 
decay equation (dotted lines), 
ART only t1/2 = 0.31 min ART/IGF2 
t1/2 = 0.36 min; (B) Lysed for 
pRET measurements using 
ELISA. (C) Cells were incubated 
for 30 min after IGF2 addition, 
then lysed and measured for 
pJNK using ELISA. All data 
represent single experiments. 
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entration, and was clearly seen only over a narrow range of IGF2 concentrations 
encompassing 0.64-0.8 nM. The pAkt dose-responses for stimulation of the cells 
with either IGF2 or ART alone are different in both amplitude and sensitivity. The 
maximum amplitude for pAkt response for cells treated with IGF2 alone is ~3.5-
fold higher than the maximum amplitude for ART only treatment, while the EC50 
for the pAkt response in the presence of ART alone is ~3.5 fold more sensitive 
than treatment with IGF2 alone. The differences in amplitude and sensitivity 
between the two GFs demonstrate that the maximal capacity for activation of a 
given signaling molecule is dependent on the stimulus. In other words, the cell 
cannot maximally phosphorylate all available Akt with ART stimulation alone 
since maximal pAkt levels using IGF2 stimulation are 3.5-fold higher. Co-
stimulation with ART/IGF2 showed that there was no crosstalk in amplitude since 
the increase in amplitude is equal to the sum of the pAkt response of ART plus 
the pAkt repsonse of 0.64 nM IGF2. The increase in pAkt sensitivity in response 
to ART/IGF2 co-stimulation occurring only at IGF2 concentrations of 0.64-0.8 nM 
shows that crosstalk in pAkt is dependent on the narrow range of IGF2 
concentration, and that the pAkt sensitivity for co-stimulation with IGF2 
concentrations slightly above at (1 nM) or below (0.4 nM) that range is between 
the low sensitivity of ART only and high sensitivity of 0.64-0.8 nM IGF2. Our 
results also indicate that the crosstalk is unidirectional as exhibited by an 
increase in pAkt sensitivity only when various doses of ART was co-stimulated 
with IGF2 concentrations at 0.64-8 nM, and not when various doses of IGF2 was 
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co-stimulated with 10 nM ART. There was no change in sensitivity for pRET as a 
result of ART/IGF2 co-stimulation compared to ART only, which shows that 
transactivation by activated IR/IGF1R is unlikely. Furthermore, the unchanged 
sensitivity for pJNK as a result of ART/IGF2 co-stimulation compared to ART only 
also suggests that crosstalk in sensitivity is specific for the PI3K/Akt pathway and 
that the c-jun/JNK and PI3K/Akt pathways do not converge, though we did not 
co-stimulate with other concentrations of IGF2 to test if crosstalk in the pJNK 
response is IGF2 dose-dependent.     
Others who have studied crosstalk at the systems level have generated 
clustering networks grouped by their synergistic features (i.e., inhibitory or 
stimulatory), which provide frameworks for further inquiry into how crosstalk 
relates to the effects of signal sensitivity, amplitude and dynamics as they 
integrate, in addition to dissecting their mechanisms. Just recently, Carsten 
Schultz’s lab developed a novel high-content cellular imaging platform that 
incorporates 40 FRET biosensors to quantify crosstalk between intracellular 
signaling networks by co-stimulating Hela cells with epidermal growth factor 
(EGF) and IGF-1 at varying doses (Kuchenov et al.). They used their technology 
to quantitatively profile the effects of altering the concentrations of co-stimulation 
of diverse signaling pathways. Their findings agree with our observation that 
crosstalk that converges to a specific pathway is strongly dependent on GF 
concentrations, that the change in amplitude over the course of GF stimulation 
can be synergistic or antagonistic (more than the sum of independently 
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stimulated effects) depending on the concentration of EGF and IGF-1 induced 
signaling, and that the effects are difficult to predict (Kuchenov et al.). In other 
words, even if two GFs show stimulatory effects on a pathway when treated 
alone, the co-stimulation effects may or may not be synergistically stimulatory, 
and instead, depending on the concentrations of each GF, the effects can be 
antagonistic. For example, they found that although independent EGF and IGF-1 
stimulations activate S6K, co-stimulation with the two GFs could either decrease 
or have no effect on S6K depending on the growth factor concentrations. Our 
IGF2 and ART co-stimulation results support their finding that crosstalk is 
strongly dependent on GF concentrations, we demonstrated that the ART-
induced pAkt sensitivity was enhanced in the presence of IGF2 concentrations at 
0.4-1 nM, compared to ART treatment alone, and that the sensitivity was 
unchanged at 0.2 nM IGF2, while IGF2 concentrations higher than 1 nM will most 
likely saturate maximal ART-induced pAkt activity (Figures 3.8 and 3.9). 
Moreover, the sensitivity of pAkt signaling to IGF2 alone is lower than the 
sensitivity to ART alone. We unexpectedly observed enhancement in sensitivity 
when ART is co-stimulated with a less sensitive GF, which also shows that co-
stimulatory effects are strongly dose-dependent and synergistic. 
The underlying mechanisms responsible for the sensitivity shift observed 
during ART/IGF2 co-stimulation, and the synergistic increase in amplitude in 
luciferase activity during ART/endostatin and ART/IGF2 co-stimulation remain 
unsolved. The PI3K/Akt pathway involves multiple steps that precede the 
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phosphorylation of Akt (Figure 3.11). We hypothesize that mediators in the 
PI3K/Akt pathway may be responsible for integrating crosstalk, and that 
ART/IGF2 co-stimulation increases the localized concentration of the mediators 
so that they are sensitized to ART-induced activation (Figure 3.11). To test this 
hypothesis, we would measure the localized concentration of mediators that bind 
to the receptors upon co-stimulation, and compare the concentration to 
stimulation with ART alone (i.e., IRS-1, or PIP3 formation). On the other hand, 
since the ART/IGF2 sensitivity shift occurs one-way so that IGF2 increases the 
sensitivity of the AKT response to ART, but not vice versa, this finding raises the 
another possibility that IGF2 affects RET signaling through the action of some 
process that is downstream of IGF1R/IR, but that is not associated with RET 
signaling per se.  
Our luciferase reporter assay demonstrated a synergistic increase in 
amplitude by 30-40% compared to ART only, even though neither endostatin 
alone or IGF2 alone produced a luciferase signal above background (Figure 3.4). 
Since the luciferase activity is a downstream response related to the activation of 
the MAPK/ERK signaling pathway, and activation of the MAPK/ERK pathway 
involves adaptor proteins (e.g., SHC, Grb2, SOS) that associate with the 
activated receptor to activate further downstream molecules (e.g., Ras, Raf, 
MEK, ERK), identification of the most upstream step that also becomes 
synergistically activated in amplitude upon co-stimulation with ART/IGF2 and 
ART/endostatin may reveal which signaling step converge into crosstalk.  
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Figure 3.11. ART/IGF2 co-stimulation results in crosstalk in the PI3K/Akt 
pathway. ART binds to GFRα3 co-receptor and activates RET homodimer 
receptors (left side). IGF2 activates IGF1R homodimers (not shown), insulin 
receptor homodimers (not shown), or IGF1R-insulin receptor heterodimers (right 
side). Black brackets indicate mediators of PI3K/Akt signaling that may be points 
at which crosstalk occurs, where ART/IGF2 co-stimulation increases the 
localized concentration of the mediators so that they are sensitized to ART-
induced activation. 
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Endostain was found to phosphorylate tyrosine residues on SHB (Src 
homology 2 domain-containing adaptor protein B) adaptor proteins, which then 
form multi-protein signaling complexes in endothelial cells treated with fibroblast 
growth factor-2 (FGF-2) and endostatin (Dixelius et al.). The authors further 
mutated the Src homology-2 (SH2) domain on the SHB, and found that in the 
presence of endostatin, SHB can no longer be phosphorylated or form 
complexes with other phosphotyrosyl proteins, which suggests that the SH2 
domain is important for SHB interaction with other phosphotyrosyl proteins. The 
SHB protein is a type of adaptor protein that has been shown to interact with 
tyrosine residues of activated GF receptors such as platelet-driven growth factor 
receptor, fibroblast growth factor receptor (FGFR), and VEGFR2 at the SH2 
domain of the SHB protein (Welsh et al.). This type of receptor-SHB interaction 
was shown to modulate MAPK/ERK signaling, where activation of the FGFR by 
FGF-2 stimulation resulted in association of the SHB protein to phosphorylated 
Tyr 766 on the receptor, which then phosphorylates an intracellular FGFR 
substrate-2, and associates with Grb2 and SOS to initiate MAPK/ERK signaling 
(Cross et al.; Ornitz and Itoh). The RET receptor is not known to associate with 
SHB, but instead interacts with another type of adaptor protein, SHC, which also 
consists of the SH2 domain for interaction with activated GF receptors, and is a 
mediator for MAPK/ERK signaling. Collectively, these studies have led us to 
hypothesize that the synergistic increase in amplitude upon co-stimulation with 
ART/endostatin may be attributed to an enhanced phosphorylation of SHC by 
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endostatin so that more SHC protein can interact with activated RET receptor at 
the SH2 domain, thereby increasing ART-induced MAPK/ERK signaling 
compared to ART and endostatin alone. We can test this hypothesis by 
measuring the phosphorylation of SHC and immunoprecipitation of RET and 
SHC association in the presence of endostatin and ART lone and 
ART/endostatin co-stimulation conditions. 
In their natural state, cells transduce signals as a dynamic complex 
network of inputs and outputs that can be difficult to characterize. Identifying and 
quantifying crosstalk is necessary to de-convolute the complexities that arise 
during signal integration, and as signals progress into cellular function. Our 
results, along with others, reinforce previous assumptions that signaling networks 
are “dynamically encoded” in order to integrate and modulate complex signals 
into cellular processes (Behar, Dohlman, et al.; Behar, Hao, et al.; Geva-Zatorsky 
et al.; Purvis and Lahav; Rohrs et al.). Deciphering complex signaling networks is 
context dependent. Therein alludes to the importance of quantifying crosstalk, 
which could reveal the points of crosstalk that can act as opportunities for 
multiple inputs to regulate biological outputs, versus simply as linear relationship 
of inputs governing overall outputs.  
In contrast to the FGF21/insulin crosstalk study that showed enhanced 
sensitivity to glucose uptake compared to insulin alone, but the converging 
pathways remained a mystery, our results show that for RET and IGF2 on murine 
neuroblastoma cells, crosstalk converges at the PI3K/Akt pathway, and that the 
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responsiveness of the cells to ART can be modulated by IGF2 co-stimulation (D. 
V. Lee et al.). Thus, our analysis provides an alternate perspective on how 
crosstalk affects signaling pathways as a shift in the sensitivity of pAkt response. 
Furthermore, we can apply our method to studying crosstalk in the PI3k/Akt 
pathways to future studies aimed at distinguishing steps in crosstalk where inputs 
can act as modulators and influence cell fate. Since we have identified crosstalk 
in a specific signaling pathways, we can further identify which step(s) in the 
signaling pathway crosstalk occurs and relate those crosstalk effects to biological 
function, such as neurite outgrowth.  
3.4 Materials and methods 
3.4.1 Materials. 
All materials are the same as Chapter 1 except for the following reagents. 
The PathScan phospho-Akt1 Ser473 Sandwich ELISA antibody pair (cat. no. 
7143S), insulin receptor β (cat. no. 3025S), insulin-like growth factor receptor-1 β 
(cat. no. 9750S), and PathScan phospho-SAPK/JNK thr183/Tyr185 Sandwich 
ELISA antibody pair (cat. no. 7217) were obtained from Cell Signaling 
Technology (Danvers, MA).  
3.4.2 Cell culture 
NB41A3-mGFRα3-SRELuci cells were cultured exactly the same as 
described in Chapter 2.4.2. 
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3.4.3 Luciferase assay 
NB41A3-mGFRα3-SRE Luci cells were plated at 1x105 cells/well on an 
opaque 96-well tissue culture plate (Falcon, Miami, FL) and incubated overnight. 
The cells were starved with serum-free DMEM for 12-18 h prior to treatment. 
Initial screens for crosstalk in luciferase response were done by simultaneous 
addition of ART plus the other growth factor (GF) at a single concentration (4 or 
10 nM), and incubated for 4 h. Co-stimulation conditions were also done by 
treating with ART at indicated concentrations for 10 min, followed by addition of 
GF at 4 nM concentration in the presence of appropriate ART concentration, and 
incubated for an addition 10 min after GF was added. Experiments testing for the 
effect on luciferase by adding other GFs at different times after ART were done 
by adding 1.6 nM ART, followed by addition of other GF after 2, 5, 10, 30, and 60 
min initial ART, and incubated until 4 h from initial ART treatment. After 
incubation, cells were washed with PBS and lysed with 20 µl of cell culture lysis 
reagent (Promega, Madison, WI) for 20 min with vigorous shaking. 
Luminescence was measured upon addition of 75 µl 5’-fluoroluciferin (Promega, 
Madison, WI) using a SpectraMax M5 microplate reader (Molecular Devices, 
Sunnyvale, CA).  
3.4.4 pAkt and pJNK ELISAs  
SRE-NB41A3-mGFRα3 cells were seeded overnight in a 24-well plate at 
3x105 cells/well in 0.5 mL growth media. The cells were starved with serum-free 
DMEM for 12-18 h prior to treatment. Initial screens for crosstalk in pAkt 
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response were done by treating cells with ART at indicated concentrations for 10 
min, followed by addition of GF at single concentration in the presence of 
appropriate ART concentrations, and incubated for an addition 10 min after GF 
was added. Crosstalk in pAkt and pJNK responses by co-stimulation with ART 
and IGF2 were done by stimulating cells with various concentrations of ART for 2 
min, followed by addition of IGF2 at single concentration in the presence of 
appropriate ART concentrations, and incubated for an additional 10 min after GF 
was added. For measurements of pAkt decay in the presence of ART and IGF2, 
after cells were incubated for 10 min with ART and IGF2, 10 µM MK2206 inhibitor 
was added, and incubated for 2, 4, 6, 8, 10 min. After incubation, cell were lysed 
and detected for pAkt and pJNK exactly as described in Chapter 1.4.8, except 
appropriate antibodies from PathScan phospho-SAPK/JNK thr183/Tyr185 
Sandwich ELISA antibody Pair kit was used to detect pJNK.  
3.4.5 pRET ELISA 
SRE-NB41A3-mGFRα3 cells were seeded overnight in a 24-well plate at 
3x105 cells/well in 0.5 mL growth media. The cells were starved with serum-free 
DMEM for 12-18 h prior to treatment. Crosstalk in pRET response by co-
stimulation with ART and IGF2 were done by stimulating cells with various 
concentrations of ART for 2 min, followed by addition of IGF2 at single 
concentration in the presence of appropriate ART concentrations, and incubated 
for an additional 10 min after GF was added. After incubation, cell were lysed 
and detected for pRET exactly as described in Chapter 1.4.7. 
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3.4.6 Detection of IR-β and IGF1R-β by Western Blot 
The NB41A3-mGFRα3-SRELuci cells were lifted and 106 cells were lysed 
with Radioimmunoprecipitation assay lysis buffer, and analyzed for IR-β and 
IGF1R-β exactly the same as described in Chapter 2.4.7, except that IR-β and 
IGF1R-β primary antibodies were used and diluted 1:1000 in 5% milk.  
3.4.7 Data analysis 
Dose-response data for pAkt response were analyzed using a logistic 
four-parameter fit equation 1:  𝑋 = !!"#!! !"!"!"# !"#$!        (Eq. 1) 
where X = pAkt, Xmax is the percent maximum upon stimulation with GFs; the 
EC50 represents the concentration required to achieve half-maximal response; 
and slope corresponds to steepness of the curve. All curve fits were performed 
using Prism 7 software (GraphPad Software Inc., La Jolla, CA). 
Decay curves were fitted to equation 2, 𝑦 = 𝑦! − 𝑦!""#$%  × 𝑒!!" + 𝑦!""#$%      (Eq. 2) 
where y0 is the initial value at t = 0, yoffset is the final y value at highest time 
measured, k is the rate constant in min-1. 
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DEVELOPMENT OF FRET REPORTER SYSTEM TO MONITOR RET 
ASSOCIATION EVENTS ON INDIVIDUAL CELLS 
4.1 Introduction 
4.1.1 Growth factor receptor activation mechanisms 
Growth factor (GF) receptors share common features, but also display 
considerable diversity in their structures and modes of action. The large family of 
human GF receptors includes 58 RTKS that can be further divided into 20 
subfamilies based on their structure and function (Lemmon and Schlessinger). 
Given their diverse array of structural compositions, the mechanistic details of 
how GF receptors assemble into an activated complex have been difficult to 
establish. It is clear, however, that for all GF receptors the initial activation step 
requires binding to its specific ligand to form an oligomeric complex. There have 
been observations that inactivated (without ligand) GF receptors exist as 
monomers and multimers on the cell surface, but the relationship between those 
states and ligand activation has been a matter of longstanding debate 
(Atanasova and Whitty; Ballinger and Wells; Chan et al.; Cunningham et al.; 
Moriki et al.; Qazi et al.). There are two non-mutually exclusive mechanistic 
proposals for how binding of the GF ligand brings about receptor activation: (1) 
ligand-induced dimerization, in which monomeric receptors dimerize upon 
binding of ligand; and (2)  
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Figure 4.1. Fluorescently labeled RET receptors to study activation mechanism. 
Growth factor receptors are known to activate by pre-associated oligomerization 
(top) or by ligand-induced mechanism (bottom). RET Dimers depicted here for 
representation of activated complex with two GFRα3 co-receptors, though they 
are not known to exist as dimers in the inactivated forms.   	
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reorganization of pre-associated but inactive receptor dimers into an activated 
form upon ligand binding (Figure 4.1). 
4.1.2 Using FRET to understand activation mechanism of GF receptors 
Monitoring protein-protein interactions (PPI) at the cell surface is 
indispensable in developing a system to fully characterize the initiation of growth 
factor signaling. To this end, we exploited the synergistic capabilities of Förster 
resonance energy transfer (FRET) and flow cytometry (Chan and Holmes; Sklar 
et al.). FRET is based on the principle that donor fluorophores can excite 
acceptor fluorophores when the acceptor’s excitation wavelength overlaps with 
the donor’s emission wavelength. The efficiency of this nonradiative energy 
transfer is dependent on the proximity of donor and acceptor, and has a 
maximum limit of ~10 nm or ~100 Å (He et al.; Sklar et al.).  Combining flow 
cytometry and FRET has the promise to enable quantitative measurements of 
PPI at the single cell level (Banning et al.). Additionally, merging the two 
techniques allow us the ability to monitor receptor activation via the FRET signal 
while simultaneously measuring and/or gating on distinct system parameters 
such as receptor expression levels, to achieve multi-dimensional experiments in 
which the functional effects of key system parameters can be probed in 
quantitative detail within a single experiment. 
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4.1.3 FRET flow cytometry to address receptor activation mechanisms  
Using microscopy and flow cytometry methods to detect FRET has been 
well established in studying protein-protein interactions including receptor 
activation mechanisms. Flow cytometry has the advantage of quantifying 
fluorescence events in many individual cells quickly, and enables multi- 
dimensional analysis of cell populations. Though spectrofluorimetry and confocal 
microscopy techniques for FRET detection enable spatial analysis, they also 
require fixation of the cells, the detection is limited to the field of view of the lens, 
and image acquisition can be slow and subjective. Thus, we are engineering 
FRET reporters to detect RET receptor association events to use with flow 
cytometry and address activation mechanisms of the receptor. 
Application of FRET/flow cytometry methods to study the physical 
activation mechanisms for tumor necrosis factor receptors (TNFRs), c-erbB2 
receptor tyrosine kinase (HER2), and integrins has been successful (Chan et al.; 
Chigaev et al.; Diermeier-Daucher et al.). For example, p60 and p80 TNFRs 
were used as model systems to uncover pre-association complexes in the 
absence of ligand, which they termed the pre-ligand assembly domain (PLAD) 
(Chan et al.). The authors labeled their TNFRs with cyan and yellow FPs, and 
found an increase in FRET signal upon stimulation with the TNFα ligand, but 
decreased in FRET when the PLAD domain was mutated. In another example, 
the homodimerization of the HER2 receptor was quantified using an antibody 
labeling method (Diermeier-Daucher et al.). Two antibodies that target HER2 
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receptors and were found to inhibit HER2 receptor activity through different 
mechanisms were labeled with cyanine-3 or cyanine-5 dyes that act as FRET 
donor and acceptor fluorophores, respectively. The findings, expressed as a 
change in FRET efficiency upon antibody treatment, distinguished two different 
effects on HER2 homodimerization in which one antibody stabilizes homodimers, 
and the other reduces homodimerization. Detection of conformational changes 
by FRET enables quantification of the lateral organization of integrins on the cell 
surface. Chigaev, et al. labeled α4–integrins with a fluorescent peptide as FRET 
donor, and octadecyl rhodamine B as acceptor to study changes in integrin 
distribution on cells laterally and vertically upon stimulation with Mn2+ in real-time 
and at steady state (Chigaev et al., 2003).  
These examples show diverse ways in which FRET reporters can be 
designed to measure receptor activation, and how FRET can be used to address 
different types of questions related to receptor physical activation mechanisms. 
4.1.4 Goal: Develop FRET reporters to monitor RET association events on 
individual cells 
The activated RET receptor is believed to comprise a pentameric complex 
with the composition [RET]2/[GFRα]2/[ligand] (Parkash et al.; Schlee et al.; 
Treanor et al.; X. Wang et al.). The unusual multicomponent composition of the 
activated RET receptor complex provides multiple ways in which the activation 
process can be experimentally manipulated. This composition also makes RET 
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an excellent system to study to broaden our mechanistic understanding of GF 
receptor activation, and to generate knowledge to aid in the development of 
novel strategies to modulate receptor activity since. We describe here the 
development of a FRET reporter system by generating genetically encoded 
fluorescently-labeled RET, to quantify receptor activation mechanisms on 
individual cells using flow cytometry (Figure 4.1). We describe the ability of our 
assay to monitor the FRET response to ligand binding while simultaneously 
measuring RET expression levels on a cell-by-cell basis that enables us to 
analyze RET association events based on low- medium and high-expressing 
receptors on cells within a single experiment, and eventually plot FRET dose-
response curves separately. More specifically, we can treat cells expressing 
fluorescently-labeled RET with various doses of ART, then gate cells based on 
RET expression, and analyze for FRET signal, we can then generate the dose-
response curves corresponding to cells that express difference levels of RET. 
We eventually plan to apply these FRET reporters to test whether or not RET 
expression level affects the FRET dose-response to ART-induced activation, 
which will discriminate between two mechanistic possibilities of ligand-induced, 
pre-associated receptor activation, or a combination of both mechanisms. Our 
future aim is to distinguish these mechanisms by testing the different predictions 
they make concerning how ligand dose-response will change with varying levels 
of RET expression (Whitty et al.).  
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4.2 Results 
4.2.1 Proof of concept for FRET flow cytometry 
We chose two known variants of green fluorescent protein as FRET donor 
and acceptor, that have been engineered to possess enhanced brightness, 
photostability and sensitivity, and have minimal tendency to self-associate 
(Shaner et al.). These are, as FRET donor, monomeric Cerulean (mCer) (Piston 
and Kremers; Rizzo et al.), derived from cyan fluorescent protein, and as 
acceptor, monomeric YPet (mYPet), a yellow fluorescent protein variant (Nguyen 
and Daugherty; Piston and Kremers). Generating proper controls is imperative to 
ensure that our FRET signals accurately monitor the change in the mutual 
orientation of the RET extracellular domains that is believed to occur upon 
activation. We therefore devised proof-of-concept controls to confirm that the 
fluorescent proteins we chose are appropriate for quantifying FRET signal using 
Flow cytometry. Human embryonic kidney (HEK) cells were stably transfected 
with negative and positive control plasmids and were analyzed for FRET signal 
using the LSRII flow cytometer (BD Biosciences). As positive control we made a 
“unimolecular” FRET construct that contains both mCer and mYPet genes 
connected by a 10-amino acid linker. Since both donor and acceptor are situated 
proximal to one another, we expected this construct would give a strong FRET 
signal, which would be evident as a distinct fluorescence shift compared to 
negative controls. As a negative control, separate single donor and acceptor 
constructs were transfected into cells; and their signals were intended to 
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represent the background fluorescence intensities expected when the separate 
FRET donor and acceptor proteins are excited by their corresponding 
wavelengths. FRET intensity were determined by careful selection of the FACS 
settings to allow gating on the relevant region of the FACS dot plot, defined by 
comparison of the positive and negative control constructs. Table 4.1 
summarizes the excitation/emission wavelengths for the donor and acceptor 
fluorescent proteins. 
Table 4.1. Properties of donor and acceptor fluorescent proteins. 
 
 
mCerulean mYpet 
Ex. (nm)/laser  433/violet 517/blue 
Em. (nm) 475 530 
Filter (nm) 450/50 530/30 and 525/50* 
*525/50 filter detects FRET; mCer must be in proximity to mYPet 
Ex.= excitation wavelength 
Em. = emission wavelength 
Filter number indicates bandpass  
 
We detected robust FRET signal for cells expressing the positive control 
construct, while cells that expressed either the donor or acceptor construct alone 
did not display a FRET signal. Our flow cytometry acquisition used the violet (405 
nm) and blue (488 nm) lasers for excitation. Since the violet laser excites the 
donor Cerulean protein, simultaneous detection using the 450/50 bandpass filter 
for the donor only signal, and the 525/50 filter for the FRET signal allows us to 
quantify donor and FRET fluorescence intensities. The annotation for the 
bandpass is as follows: the first number describes the center wavelength, and 
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the number that follows describes the range of the entire band’s width (i.e, the 
detector with a 525/50 bandpass filter means the wavelengths between 500-550 
nm; or 525 ± 25 nm are detected). A separate blue laser (488 nm) directly excites 
the acceptor protein, and the detector with a 530/30 bandpass filter detects the 
mYPet signal. Figure 4.2 shows plots of the HEK cells transfected with our 
control constructs using different detectors. A cells emitting positive FRET 
signals would emit fluorescence intensities, detectable using the 525/50 filter, 
that are higher than cells expressing empty, Cer only, or YPet only since the 
negative controls should not exhibit FRET. The panel showing the FRET signal 
plotted as a function of the Cerulean signal shows that the negative controls, 
comprising cells that express either donor mCer or acceptor mYPet only, did not 
exhibit a FRET signal, while the unimolecular mCer-mYPet expressing cells 
showed a high FRET signal (Figure 4.2 top panels). The plots showing signal 
excited by the blue laser and detected by the YPet (530/30) filter, as a function of 
Cerulean detection, confirm robust acceptor signals for the mYPet only 
expressing cells, and for the cells expressing the positive control construct, while 
the cells expressing mCer only displayed a high Cerulean signal, but an absence 
of fluorescence emission signal for YPet (Figure 4.2, middle panels). We also 
plotted FRET signal as a function of YPet signal to confirm that excitation of cells 
expressing mYpet only by the violet laser does not give a FRET signal, while the 
positive control shows a linear relationship between FRET and Ypet, this result 
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Figure 4.2. Proof-of-concept that donor and acceptor fluorescent proteins chosen 
can generate a FRET signal that is measurable by flow cytometry. Flow 
cytometry analysis of HEK cells transfected with empty vector (black), YPet only 
(red), Cer only (blue), or the positive control construct comprising linked mYpet-
mCer (green). The x- and y- axes correspond to the filters used to detect Cer and 
FRET fluorescence, respectively for the top panels, Cer and YPet fluorescence, 
respectively for the middle panels, and FRET and YPet fluorescence, 
respectively for the bottom panels. The mYpet protein can be excited directly by 
the blue laser or, in the positive control construct that allows FRET, indirectly by 
the violet laser. The violet laser excites the mCer donor, and mYPet emits light at 
530 nm as a result of FRET. The mCer protein is excited by the violet laser and, 
in the absence of FRET, emits at 475 nm. 
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indicates that as cells express more acceptor protein, the increase in FRET 
signal is proportional since donor and acceptor are in the proximity of each other 
(Figure 4.2, bottom panels). This preliminary experiment validates the suitability 
of the donor and acceptor pair as well as the acquisition and analysis of mCer-
YPet FRET using flow cytometry for our FRET reporter system.  
4.2.2 Generation of a cell line that expresses GFRα3 but not RET 
We infected a MSTO-211 (MSTO) mesothelioma cell-line with multi-
cistronic lentivirus encoding human GFRα3, in addition to a monomeric red 
fluorescent protein, mCherry, and the puromycin gene for selection. The MSTO 
cell line does not endogenously express RET, as shown next to cells that were 
transduced with mCer-RET (Figure 4.3A). The selected MSTO-GFRα3-puro-
mCherry cells express all proteins separately, as the multi-cistronic lentiviral 
vector enables expression of up to 3 different proteins using “self-cleaving” 2A 
peptide sequences (Kim et al.). Thus, the proteins expressed are not fused 
together, and function independently once the virus is transduced into cells. We 
confirmed expression of GFRα3 by staining the cells with anti-GFRα3 antibody, 
and detection of the secondary Alexa-647 antibody (Figure 4.3B). We proceeded 
to transduce wild-type human RET (WT RET) into MSTO-GFRα3-puro-mCherry 
and non- GFRα3 expressing MSTO-puro-mCherry cells, in additional to infecting 
non-functional N-terminus fluorescently labeled RET (NF RET) into MSTO-
GFRα3-puro-mCherry cells, to test if the WT RET-GFRα3 proteins expressed on 
cells are functional. We treated the cells with 1 nM or 4 nM of either a  
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Figure 4.3. MSTO cells stably expressing GFRα3 and transiently infected with 
WT RET are functionally active. (A) Western Blot of lysates from MSTO cells 
show they do not endogenously express RET. The positive control is mCer fused 
to the N-terminus of RET, with an expected MW of 202 kDa. (B) Flow cytometry 
analysis of MSTO cells stably expressing GFRα3, stained with anti-GFRα3 
primary and Alexa Fluor 647 secondary antibodies. MSTO-GFRα3-puro-mCherry 
cells were infected with either WT RET or non-functional mCer-RET (NF RET), 
and were treated with either GDNF/GFRα1 or ART for 10 min and analyzed for 
pAkt (C) and pERK (D). 
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combination of soluble ligand/co-receptor pair GDNF/ GFRα1 (1:1 molar ratio), or 
with ART for 10 min, and measuring pAkt and pERK activities. We found that the 
cells treated with GDNF/GFRα1 gave positive pAkt and pERK signals in WT RET 
cells regardless of the presence of GFRα3 (Figure 4.3C,D). The ART treated 
cells gave positive pAkt and pERK signals only in the  WT  RET-GFRα3-
expressing cells, whereas the NF RET did produce any signal regardless of 
GFRα3 expression (Figure 4.3C,D).  
Together, the results show that the MSTO cells do not express 
endogenous RET. Furthermore, we confirmed that the transduced WT RET and 
GFRα3 are fully functional, and we can effectively screen different donor and 
acceptor fluorescently-labeled RET construct designs in parallel, to identify 
functional constructs suitable for competent RET-activated signaling. 
4.2.3 Generation of functional fluorescently labeled RET 
There is no published crystal structure of the RET extracellular domain, and so a 
certain amount of trial and error was required to achieve a connectivity between 
RET and the FRET fusions that retains RET function while giving a robust FRET 
signal upon ligand binding and activation. Initial constructs containing the GFP 
derivatives mCer or YPet fused to the N-terminus of RET were shown not to be 
functional upon expression in MSTO cells, as measured by their inability to 
stimulate ERK and AKT activation, unlike wild-type RET infected into similar cells 
(Figure 4.3C,D). Therefore, we created new constructs in which the 
fluorescent proteins were fused at the C-terminus of RET (Figure 4.4A), 
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using lentiviral vectors (pUltra_RET-mCer and pUltra_RET-mYPet). We 
confirmed expression of the RET-mCer and RET-YPet infected cells by staining 
for RET, then detecting a Alexa-647-labeled secondary antibody using flow 
cytometry (Figure 4.4B). The expression levels of the different types of RET 
show that transduction efficiencies were slightly differences for  each  type.  Cells 
infected with virus encoding RET-mCer showed slightly more RET than RET-
mYPet infected cells, as shown by the higher staining intensity seen with the anti-
RET antibody. Once expression was validated, the resulting MSTO-GFRα3-RET-
mCer/YPet and MSTO-GFRα3-WT RET cells were treated with various doses of 
ART for 10 min to confirm that the engineered RET-mCer/YPet receptors were 
functional. Dose-dependent phosphorylation of both Akt and ERK was observed, 
showing that we have successfully engineered functional RET-mCer/YPet 
fusions (Figure 4.4C-D). The three forms of RET showed corresponding 
differences in the amplitudes for pAKT and pERK responses. The slight 
differences in pAkt and pERK amplitudes can be explained by the differences in 
RET expression, as shown in Figure 4.4B. The highest pAkt and pERK activities 
can be attributed to RET-mCer expressing the highest level of RET relative to 
WT RET and RET-mYPet. The sensitivities (EC50 pAkt: WT = 1.86 ± 0.4 nM, 
mCer = 2.57 ± 0.2 nM, mYPet = 3.03 ± 0.5; EC50 values pERK: WT and mYPet = 
2.83 ± 1.1 nM, mCer = 1.90 ± 0.4 nM) of the responses were similar for the three 
RET constructs, suggesting that the fluorescently tagged RET fusions signal 
similarly to WT RET.  
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Figure 4.4. Infection and 
signaling of WT RET and 
RET-mCer or RET-YPet 
fusions. (A) Construct of 
donor or acceptor fluorescent 
protein (FP) linked with a 6 
amino acid linker at the c-
terminus of RET. (B) MSTO-
GFRα3 cells were infected 
with either WT RET, RET-
mCer, or RET–mYPet and 
stained with anti-RET primary 
and Alexa Fluor 647 
secondary antibodies and 
analyzed for RET expression 
using flow cytometry. Ten 
minute ART dose-responses 
for pAkt (C) and pERK (D) 
were measured for the 
infected cells. Solid lines 
represent four-parameter fits. 
EC50 values pAkt: WT = 1.86 
± 0.4 nM, mCer = 2.57 ± 0.2 
nM, mYPet = 3.03 ± 0.5. EC50 
values pERK: WT and mYPet 
= 2.83 ± 1.1 nM, mCer = 1.90 
± 0.4 nM. Data represent 
single experiment. 
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4.2.4 Use of FRET reporter system to detect RET association by flow cytometry  
Previous reports of cellular FRET assays have shown that FRET acceptor 
molecules should be expressed in excess to donor in cells (Chan and Holmes). 
We therefore quantified the number of viral infecting particles for each donor and 
acceptor virus, in order to calculate the amount of virus needed to infect MSTO-
GFRα3 cells with ratios of donor- and acceptor-tagged RET of 1:2, 1:3, and 1:4, 
to establish the optimal ratio for observing a FRET signal upon ligand stimulation 
(Appendix X). We treated the infected cells with 5 nM ART for 10 min, lifted the 
cells by mechanical pipetting, fixed them with paraformaldehyde to preserve 
molecular associations, and then measured FRET by flow cytometry. Cells that 
expressed only the donor RET-mCer or only the acceptor RET-mYPet fusion 
constructs were infected at the same level as the donor:acceptor ratios were 
included as background controls. The background controls are necessary to 
measure spectral overlap from the donor, also known as when the donor 
emission “bleeds” into the FRET emission detection, so the spectral overlap can 
be subtracted out. Cells that were detected to have higher FRET intensities 
above the donor and acceptor only expressing cells were considered FRET 
positive cells. We gated populations of cells that showed positive FRET and 
Cerulean signals for our analysis, so only a small fraction of the acceptor only 
population were gated out (Appendix XI). By using FRET gating parameters that 
exclude acceptor only, we minimize the possibility of acceptor emission in FRET 
detection, where acceptors emit a FRET signal in the absence of donor. Figure 
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4.5A-B show FRET intensity as a function of donor fluorescence intensity for 1:2 
donor:acceptor ratios. Shifts in overall FRET signal, as shown as the RET-mCer 
and RET-mYPet (blue or red) population of cells have higher FRET signal 
compared to the RET-mCer only expressing (black or gray) populations shown in 
in Figures 4.6 A-B are manifested as a change in linear slopes of the plots of 
individual cells that express RET-mCer/RET-mYPet compared to the linear slope 
of the plots of individual cells that express RET-mCer only (Figure 4.5A,B). This 
indicates that the population of cells expressing donor and acceptor have higher 
FRET signal compared to donor only expressing cells, and that the donor only 
expressing cells represent the background. The background is the spectral 
overlap of the donor emission fluorescence into the FRET emission detectors.  
Since the flow cytometry analysis returned Cerulean, YPet, and FRET 
fluorescence intensity readings for each individual cell, we can calculate the 
FRET efficiency as a ratio of FRET fluorescence intensity to donor fluorescence 
intensity for each individual cell. FRET is the energy transfer from donor to 
acceptor, so a high FRET fluorescence intensity would result in low donor 
fluorescence intensity since the energy is transferred to acceptor as a FRET 
signal. Likewise, the opposite would be true of low FRET signal, where the donor 
intensity would be high. This approach to quantifying FRET efficiency works for 
our analysis since we would be comparing the FRET efficiencies relative to 
different treatment conditions and to proper background controls to compensate  
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Figure 4.5. MSTO-GFRα3 cells expressing RET-mCer and RET-mYPet at a 1:2 
ratio show ART-induced FRET signal. MSTO-GFRα3 cells were infected with 
RET-mCer and RET-YPet virus at a 1:2 ratio (detailed virus titer concentrations 
explained in Appendix X, and were either untreated or treated with 5 nM ART for 
10 min, then fixed with paraformaldehyde and analyzed for FRET, Cerulean, and 
YPet fluorescence intensities. (A) Individual cell signals for FRET versus 
Cerulean and their corresponding linear slopes, for untreated cells expressing 
both RET-donor and RET-acceptor fusions (blue dots), or RET-donor only (black 
dots). (B) Signals for FRET versus Cerulean and their corresponding linear 
slopes for ART treated cells expressing RET-donor and RET-acceptor (red dots), 
or RET-donor only (gray dots). (C) Mean YPet intensity plotted as a function of 
the mean Cerulean intensity for populations of cells that were grouped in 
increments of 100 Cerulean intensity units (gridlines in A and B). (D) ART-
induced fold-change in FRET efficiency, after subtraction of RET-donor only 
background fluorescence ( Eq. 4.2) for cells that were grouped in increments of 
100 Cerulean intensity units; each black dot represents the averaged ART-
induced FRET fold change of cells grouped into the corresponding 100 Cerulean 
intensity units. The red line is the average fold-change for the entire population.  
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for spectral overlap. Thus, we calculated the FRET efficiency (FRETEff) for each 
individual cell according to the following equation,  
 𝐹𝑅𝐸𝑇!"" = !"#$!"#/!"!"#$%"&'!"#/!"                                eq. 4.1 
where FRET520/50 is the intensity detected by the 520/50 filter, and Cerulean450/50 
is the intensity detected by the 450/50 filter. Furthermore, we used 
multidimensional analysis to gate populations based on the RET-mCer 
expression levels, as a measure for the intensity for Cerulean protein since we 
did not include antibody detection of total RET. We justify that the level of 
intensity of Cerulean protein corresponds to the level of total RET, since RET-
mCer and RET-mYPet were infected in ratios, so for example, 2 RET-mYpet are 
present for every 1 RET-mCer for cells infected at 1:2 donor:acceptor molecules 
(Figure 4.5A,B, blue and red dots). We grouped the Cerulean intensities into 
increments of 100 units, starting at 600 intensity units as represented by the grid 
lines in Figure 4.5A,B. Each grouped population is plotted as a point on Figures 
4.5C and D. Thus, the number expressed on the x-axis in Figure 4.5C,D 
represents a population of cells with fluorescence intensities measured in the 
mCer channel that lie between the number indicated and 100 units higher. For 
example, the points in Figure 4.5C-D corresponding to 600 intensity units on the 
x-axis represents the population of cells that were detected to express 
fluorescence units between 600-700, and for 700 intensity units, the population of 
cells that express between 700-800 units. The population plotted at 1500 on the 
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x-axis are cells that express 1500 or more fluorescence intensity units (Figure 
4.6C-D). To show that increasing RET-mCer expression corresponds to 
increased RET-YPet expression, we plotted YPet fluorescence intensity as a 
function of Cerulean fluorescence intensity. As expected, the linear positive 
correlation suggests that the ratio of donor:acceptor tagged RET was maintained 
through the infection process (Figure 4.5C). 
Since the cells were grouped into 100 Cerulean fluorescence intensity 
units, we calculated the average FRET efficiency of cells grouped into each 100 
units for donor:acceptor cells and donor only cells. We can remove the donor 
only spectral overlap by subtracting the FRET efficiency of donor only cells from 
donor:acceptor expressing cells. We proceeded to calculate the ART-induced 
FRET signal as a fold change to untreated cells using the equation 4.2, 
 𝐹𝑅𝐸𝑇!"# !"#$ !!!"#$ = !"#$!"" !"!# !"#!!"#$!""#$ !"#!!"#!"" !"!# !"#$%&#%'!!"#$!"" !" !"#$%&#%'  (eq. 4.2) 
 
where FRETRCRY is the FRET efficiency for cells expressing both RET-mCER and 
RET-mYPet that were untreated, or were treated with 5 nM ART, and FRETRC is 
the FRET ratio for cells expressing RET-mCer only that were untreated or treated 
with 5 nM ART. The analysis shows that the averaged 5 nM ART-induced FRET 
signal for the entire population of cells expressing RET-donor and RET-acceptor 
in a ratio of 1:2 was 1.23 (Figure 4.5D, red line). Cells infected with RET-donor 
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and RET-acceptor in a 1:4 ratio showed a decrease in FRET signal as RET 
expression increases. In these cells, a level of RET expression corresponding to 
1200 Cerulean fluorescence intensity units resulted in the highest ART-induced 
fold change in FRET signal of 1.39. Most of the other RET expression groups did 
not produce any significant ART-induced increase in FRET signal compared to 
untreated cells (Appendix XII). The 1:3 ratio did not produce ART-induced FRET 
signal compared to untreated cells for cells expressing RET at any level, as 
judged by Cerulean fluorescence intensity Appendix XI). For the cell population 
infected at 1:2 ratio, ART-induced FRET signal showed increased with increasing 
RET expression, and a maximum of an ART-induced fold change of 1.9 for cells 
expressing RET as judged by 1100-1200 Cerulean fluorescence intensity units, 
with.However, the magnitude of the ART-induced FRET signal drops with higher 
Cerulean fluorescence above this level (Figure 4.5 D). Since the 1:2 ratio of RET-
mCer:RET-mYPet showed the highest ART-induced FRET signal in the overall 
averaged population of cells, in addition to showing the widest dynamic range in 
ART-induced FRET ratio, we will continue optimizing this FRET reporter assay to 
study the physical activation mechanism of RET activation. 
 4.3 Discussion 
We have developed a FRET reporter assay capable of detecting 
association events on individual cells. Our results show an ART-induced FRET 
signal when cells express FRET donor- and acceptor-labeled RET receptors at a 
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ratio of 1:2. We further demonstrate a positive correlation between ART-induced 
FRET signal and RET expression, which suggests a RET “dose-dependent” 
ART-induced FRET response. Our calculated distance between FRET pairs for 
each population of cells show a decreased distance when cells are treated with 
ART, and the measurements are below the FRET detection limit of 100 Å 
(Appendix XII). Our approach to analyzing ART-induced FRET efficiency takes 
into account the spectral overlap of non-FRET emissions from donor and 
acceptor fluorescence. To better validate this FRET assay in the future, we would 
enhance the method of detecting total RET expression by including antibody 
staining for RET expression so that the levels of total RET would not be based on 
the expression of donor- or acceptor-only RET. Furthermore, we would to 
quantify the concentration of receptors using bead-based calibration of the 
antibody binding capacity (Brotherick et al.).  
 Our FRET assay can potentially be used to distinguish between ligand-
induced and pre-associated receptor activation mechanisms by exploiting our 
method’s ability for multi-dimensional analysis. Using this capability, we can treat 
cells with different concentrations of ART and then analyze the cells by flow 
cytometry, gating on subsets of cells that express low, medium, or high levels of 
RET, similar to what is shown in Figure 4.5. This will allow us to plot separate 
FRET ART dose-response curves for low, medium, and high RET-expressing 
cells from within the same experiment, as described below. Multicolor flow 
cytometry experiments are very well established for analyzing cellular subsets 
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based on differences in surface marker expression (Bryceson et al.; Wimazal et 
al.), but only a few studies have reported the use of multi-dimensional flow 
cytometry experiments to investigate receptor function (Rawstron et al.; Rufer et 
al. 8; Sumner et al.).  
Reports that pre-associated GF receptor oligomers exist on the cells even 
before the binding of ligand lead to three alternative views about how activation 
of RET and similar GF receptors might occur: (1) Ligand and co-receptor engage 
only with monomeric RET, and activate the receptor by inducing receptor 
dimerization (Atanasova and Whitty; Heldin; Stahl and Yancopoulos; Ullrich and 
Schlessinger). In this mechanism, the pre-associated dimers and oligomers that 
can be detected for many receptors represent an inactive “depot” form of the 
receptor. (2) Ligand engages only with pre-associated RET dimers or oligomers 
(Atanasova and Whitty; Macdonald and Pike). (3) Both monomeric and pre-
associated dimeric RET can engage ligand, possibly with different signaling 
consequences, with the overall activation observed reflecting the sum of these 
two parallel processes. The mere observation of a FRET signal upon ligand 
binding cannot definitively distinguish these mechanistic possibilities, because an 
enhancement of FRET could arise either from ligand-induced dimerization or 
from a ligand-induced reorientation of RET molecules within a pre-associated 
dimer. One long-term aim of our research is to distinguish these mechanisms by 
testing the different predictions they make concerning how ligand dose-response 
will vary with varying levels of RET expression. The ability to monitor the FRET 
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response to ligand binding, while simultaneously measuring RET expression 
levels on a cell-by-cell basis, will enable us to gate on low, medium, and high-
expressing cells within a single experiment, and plot their FRET dose-response 
curves separately. We will test whether or not RET expression level affects the 
FRET dose-response, which will discriminate between the three mechanistic 
possibilities. Specifically, if receptor activation occurs exclusively through pre-
associated RET dimers or oligomers, then the concentration of ART required to 
bring this about should be independent of RET expression level (Figure 4.6, left 
panels). However, if RET is activated by ligand-induced dimerization of 
monomeric receptors, then “diluting” the level of monomeric RET on the cell 
surface should increase the thermodynamic barrier for dimerization, resulting in 
an inverse correlation between RET expression level and EC50 for ART 
stimulation (Schlee et al.; Whitty et al.) (Figure 4.6, right panels). If both of these 
processes are occurring in parallel, then the dose-response curve for ART 
stimulation of FRET fluorescence will show heterogeneous behavior, with one 
limb of the curve varying with RET expression level while the other limb is 
invariant. This experiment represents an entirely new approach to addressing the 
longstanding controversy concerning the activation mechanism of GF receptors 
such as RET (Macdonald and Pike; Whitty and Riera)[Atanasova & Whitty, 2102).  
 The FRET probes we developed will also allow us to address other 
important questions concerning GF activation  mechanisms.  For example,  prev- 
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Figure 4.6. Distinguishing candidate mechanisms for RET activation based on 
RET density effects on ART dose-response. Composition of RET receptor 
components is labeled as in Figure 4.1. For a mechanism involving 
conformational rearrangement of pre-associated RET dimers, the sensitivity to 
ART is expected to be independent of RET expression levels, as illustrated in 
(E). In contrast, for the ligand-induced dimerization mechanism, low RET 
expression levels (B) vs. high (D) are expected to require higher concentrations 
of ART to induce formation of the activated receptor complex, as illustrated in (F).  
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ious work from our group has shown that, when cells expressing RET and 
GFRα3 are stimulated with ART, the level of RET phosphorylation builds up over 
a period of a few minutes (depending on ART dose) and then decays over a 
period of hours (Schlee et al.). However, it is not known whether the rate- 
limiting step in this key initiating event in signaling is the assembly of the 
activated receptor complex, or is a conformational or enzymatic step subsequent 
to complex assembly. The FRET reporters will allow us to resolve this question 
by using real-time FACS (Sklar et al.) to determine whether FRET changes 
associated with formation of the activated receptor complex occur faster than the 
accumulation of pRET (S. Li et al.; Schlee et al.), or whether these events are 
coincident. We can also use this method to measure the lifetime of the activated 
receptor complex, by dilution or by addition of a blocking GFRα3 antibody (see 
Chapter 1), thus adding significantly to our knowledge of the kinetics of early 
events in this GF receptor activation mechanism.  
 We have developed a FRET reporter system capable of detecting RET 
activation on individual cells. By combining FRET and flow cytometry 
technologies, our method of measuring activated receptor complex formation can 
be used to address a myriad of RET receptor activation mechanism questions.  
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4.4 Materials and methods 
4.4.1 Materials. 
All materials are the same as Chapter 1 except for the following reagents. 
The Q5 High-Fidelity DNA polymerase (cat. no. M0491L), DH5α competent cells 
(cat. no. C2987I), T4 Ligase (M0202S), and all restriction enzymes were 
purchased from New England Biolabs (Ipswich, MA). The OneShot STBL3 
competent cells (cat. no. C737303) and Geneticin (cat. no. 10131035) were 
purchased from Life Technologies (Carlsbad, CA). The DNA Mini-prep kit (cat. 
no. 1160250) was purchased from Epoch Life Science (Missouri City, TX). The 
QIAquick PCR Purification (cat. no. 28106) and the QIAquick Gel Extraction (cat. 
no. 28706) kits were purchased from Qiagen (Valencia, CA). The H-300 RET-
rabbit antibody (cat. no. 13104) was purchased from Santa Cruz Biotechnology 
(Dallas, TX). The human GFRα3 biotinylated-goat antibody (BAF670) was 
purchased from R&D Systems (Minnieapolis, MN). The Fugene 6 transfection 
reagent (cat. no. E2691) was purchased from Promega (Madison, WI). The 
human embryonic kidney  (HEK)293 and mesothelioma-211H (MSTO) cells were 
gifts from Mark Grinstaff. The HEK293 containing SV-40 T-antigen (293T) cell 
line (cat. no. CRL-3216) was purchased from the American Type Culture 
Collection (ATCC). The hexadimethrine bromide (polybrene; cat. no. H9268-10G)  
was purchased from Sigma-Aldrich (Allentown, PA). All primers were purchased 
from Integrated DNA Technologies (Coralville, IA).  
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4.4.2 Cell culture 
 HEK 293, 293T cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) modified to contain 4 mM L-glutamine, 4500 mg/L glucose, 1 
mM sodium pyruvate, and 1500 mg/L sodium bicarbonate, and 10% fetal bovine 
serum (FBS), 2 mM L-glutamine in an incubator with 5% CO2 at 37°C. MSTO 
cells were cultured in Roswell Park Memorial Institute (RPMI) medium modified 
to contain 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L 
glucose, 1500 mg/L sodium bicarbonate, and 10% FBS in an incubator with 5% 
CO2 at 37°C. 
4.4.3 Cloning of constructs 
Monomeric Cerulean was a gift from Dave Piston (Addgene plasmid # 
15214). pCEP4YPet-MAMM was a gift from Patrick Daugherty (Addgene plasmid 
# 14032. pUltra-hot (Addgene plasmid # 24130) and pUltra-empty (Addgene 
plasmid # 24129)  were gifts from Malcom Moore. pMD2.G (Addgene #12259), 
pMDLg/pRRE (Addgene # 12251), and pRSV-REV (Addgene plasmid # 12253) 
were gifts from Didier Tronto. Human GFRα3 cDNA (cat. no. MHS6278-
202801815) was purchased from Dharmacon (Huntsville, AL). The pcDNA3-
mCer construct was cloned by restriction digests at the EcoRV and AfeI sites). 
The pcDNA3-hRET was a gift from Steve Sazinsky.  
The YPet was inserted into pcDNA3 by the BamHI site and alkaline 
phosphatase, Calf Intestinal treated. Construct monomeric pcDNA3-mYPet by 
mutating YPet at A206K by megaprimer PCR method: first step, generate 
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megaprimer fragment (~700-800 bp) with mutation primers (50 ng template, 10 
µM each of forward and reverse primers and Q5 buffers and enzyme for 50 µl 
reaction; 1 cycle at 95°C for 2 min, 30 cycles at 95°C for 30 sec, 62°C for 30 sec, 
72 °C for 30 sec, 1 cycle at 72 °C for 10 min), followed by second round of PCR 
with megaprimer fragment (50 ng template, 300 ng megaprimer fragment, and 
Q5 buffers and enzyme for 50 µl reaction; 1 cycle at 95°C for 2 min, 5 cycles at 
95°C for 30 sec, 52°C for 1 min, 68 °C for 6 min, , 13 cycles at 95°C for 30 sec, 
55°C for 1 min, 68 °C for 6 min 1 cycle at 68 °C for 10 min). The pcDNA3-mCer-
10aa-mYPet construct was cloned by inserting BspEI site downstream of mCer 
and upstream of mYPet using megaprimer method as described above, then 
pcDNA3-mCer was ligated to mYPet using BspEI and Xho I sites. The pUltra-hot-
GFRα-puro construct was cloned by inserting EcoRI and BspEI sites to 
puromycin resistance fragment, and also inserting BamHI and XbaI sites to 
human GFRα3 gene, and ligation into pUltra-hot plasmid. The  pUltra-WTRET 
was cloned by inserting AgeI site into pcDNA-hRET by mega primer method as 
described above, and ligation into pUltra backbone by AgeI and XbaI sites. The 
pUltra-RETmCer and –mYPet was generated by inserting MluI site before stop 
codon of pUltra-WTRET, and inserting MluI sites flanking the mCerulean and 
mYPet genes, and ligate MluI-mCer-MluI and MluI-mYPet-MluI into alkaline 
phosphatase, Calf Intestinal treated MluI digested pUltra-WTRET-MluI. Primers 
are listed in Appendix XIV. 
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4.4.4 Generation of stable cell lines expressing FPs 
Human embryonic kidney 293 cells were plated onto 6-well polystyrene 
plates at 3 x 105 cells per well with 1 ml DMEM  the day before. Two micrograms 
of plasmids (pcDNA3-mCer/mYPet/mCer-10aa-mYPet) were mixed into 300 µl 
serum free DMEM plus 6 µl of Fugene 6 and incubated for 20 min at room 
temperature. The medium was changed for HEK 293 cells before the 
plasmid/Fugene6 mixture was drop-wise added to cells and incubated for 18 h 
before the media was changed. After 72 h post transfection, cells were selected 
with Geneticin (500 µg/ml) for 14 days, the medium was changed with antibiotic 
every 3-4 days. 
4.4.5 Lentivirus expression and concentration using pUltra constructs 
The 293T cells were plated onto 15 cm polystyrene dishes at 3 x 106 cells 
in 20 ml DMEM the day before. After 12-18 h, cells were transfected by mixing 
the following reagents and pUltra/viral packaging plasmids in 0.5 ml serum free 
DMEM: 88 µl polyethylenimine (1 µg/ml), 7.5 µg pMDLg/pRRE, 7.5 µg pRSV-
REV, 2 µg pMD2.G, and 2 µg pUltra; incubate for 20 min at room temperature. 
Replenish cell medium before adding the transfection reagent/plasmids mixture 
drop-wise to cells. After 12-18 h, change medium to 25 ml and place back into 
incubator. After 24 h, collect first batch of virus, and replenish with 25 ml medium 
and place into incubator. Collect the second batch after 24 h. The collected virus 
was spun using bench top centrifugation at 500x g for 15 min, then Lenti-X 
concentrator was added at 1:3 (Lenti-X:virus volume) ratio and incubated on ice 
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for 4 h.  Virus was concentrated by centrifugation at 1,500 x g for 45 min, the 
supernatant is removed, and virus was suspended in 1 ml PBS per 20 ml of virus 
collected, aliquoted and frozen immediately on dry ice. 
4.4.6 Generate MSTO expressing GFRα3 
The virus expressing GFRα3 was generated similar to section 4.4.5, 
except amended for 6-well format and no concentrating of virus. All volumes 
were adjusted according to the surface area difference between 15 cm and 6-
well plates. The collected virus that was centrifuged to remove debris was 
immediately mixed with polybrene (8 µg/ml), and added onto MSTO cells that 
were plated onto 6-well polystyrene multi-well plates at 5 x 104 cells per well. 
Infection occurred by spinning cells with virus at 500 x g for 45 min, and the virus 
was removed and changed back to RPMI medium. Cells were analyzed for 
transduction efficiency 48-72 h post infection. 
4.4.7 Infect MSTO-GFRα3 cells with WTRET/RETmCer/RETmYPet 
The MSTO-GFRα3 cells were plated onto 6-well polystyrene plates at 5 x 
104 cells per well in 1 ml RPMI medium. Virus (volume calculated based on 
Appendix X) was diluted in 3 ml RPMI media with 8 µg/ml polybrene. The plate 
with virus was spun at 500 x g for 20 min, and moved to incubator. After 18 h 
incubation, medium was changed. Cells were analyzed for transduction efficiency 
48-72 h post infection.  
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4.4.8 pAkt and pERK ELISAs  
MSTO-GFRα3 expressing RET-mCer/mYPet cells were plated onto 24-
well polystyrene multi-well plates at 7 x 104 cells per well 72-96 h post infection in 
0.3 ml RPMI media with 5% FBS. Cells attached for 8-12 h, then changed to 
serum free RPMI for 12 h. Cells were treated with either various doses of ART, or 
1:1 molar ratio of soluble GDNF:GFRα1 for 10 min, then lysed and measured for 
pAkt and pERK exactly as described in Chapter 1.4.8. 
4.4.9 Flow cytometry 
The HEK 293 cells expressing empty, mCerulean, mYPet, or mCerulean-
10aa-mYPet were lifted by trypsin, and resuspended in PBS at 106 / ml, and 
analyzed for FRET, Cerulean, and YPet fluorescence using the BD LSRII (BD 
Biosciences; Billerica, MA) equipped with 405, 488, 355, 561, and 633 nm lasers. 
To measure Cerulean and FRET fluorescence intensities, cells were excited with 
the 405 nm laser, and fluorescence was measured using the 450/50 filter and 
525/50 filter, respectively. To measure YPet fluorescence intensities, cells were 
exicted by the 488 laser, and intensity was measured using the 530/30 filter. For 
each sample, we collected intensity measurements for 50,000 cells. 
MSTO-GFRα3 expressing RET-mCer/mYPet cells were plated onto 6-well 
polystyrene multi-well plates at 105 cells per well 72-96 h post infection in 0.3 ml 
RPMI media with 5% FBS. Cells attached for 8-12 h, then changed to serum free 
RPMI for 12 h. Cells were treated with either untreated or treated with 5 nM ART 
for 10 min, then media were removed and fixed with cold 1% paraformaldehyde 
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by pipetting, and transferred onto ice for 10 min. Cells were resuspended in 400 
µl PBS for flow cytrometry analysis, which was done exactly the same as 
described above for HEK 293 cells. 
4.4.10 Data Analysis 
Flow cytometry data was analyzed using FlowJo software (Ashland, OR) 
by gating entire population of cells by forward and side scatter. We set FRET and 
Cerulean fluorescence intensity gates that exclude acceptor only population to 
minimize spectral overlap of non-FRET induced YPet emission. There was at 
least 1,000 cells for the final populations used to evaluate FRET efficiency, 
except for the RET-acceptor-only expressing cells, since they were gated out. 
Four-parameter fits for pAkt and pERK data were done exactly as 
described in chapter 1.4.12. 
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APPENDICES 
Appendix I. qPCR data to screen for RET-activated target genes 
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Appendix I. qPCR analysis of ART-induced gene expression. Cells were treated 
with various doses of ART for 10 min, 1 h, or 24 h, then lysed for RNA extraction, 
followed by cDNA synthesis and qPCR. Signals plotted as fold-change induction 
to untreated cells. Error bars represent standard deviation for 3 or range of 2 
independent trials as stated in section 1.2.1. 
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Appendix II. qPCR primers to screen for RET-activated target genes 
The pPCR primers were designed using Gene and Transcript-specific primer 
generator for real-time PCR (‘Get Prime’)  http://bbcftools.epfl.ch/getprime 
No. Name Primer Sequences 
Amplicon 
(bp) 
1 
BCL2 FWD 
 
REV 
TGGATCCAGGATAACGGAG 
 
AAATCAAACAGAGGTCGCA 
73 
2 
CCND1 FWD 
 
REV 
AGACCATTCCCTTGACTGC 
AGAAGCAGTTCCATTTGCAG 
 
87 
3 
CCNE1 FWD 
 
REV 
TACAAAGGATACAGGTTGGGA 
 
GGTACCCAGGTAAGATGGA 
 
60 
4 
CDKN1B FWD 
 
REV 
CAAATGCCTGACTCGTCAG 
 
AAGAAGAATCTTCTGCAGCAG 
 
87 
5 
CTNNB1 FWD 
 
REV 
CCCAAGTCCTTTATGAATGGG 
 
CATACTGCCCGTCAATATCAG 
 
80 
6 
FGF2 FWD 
 
REV 
CTGCTGGCTTCTAAGTGTG 
 
GAGTATTTCCGTGACCGGT 
 
91 
7 
HIF1A FWD 
 
REV 
TTTCCCAGCCTAACAGTCC 
 
CCAAATCTAAATCAGTGTCCTGAG 
 
149 
8 
MAP3K14 FWD 
 
REV 
GTGATCACCAAAGGCACAG 
 
CTATTCTCACATTCAGCCTGG 
 
85 
9 
NFKB1A FWD 
 
REV 
CCAACTACAATGGCCACAC 
 
CCAAAGTCACCAAGTGCTC 
 
80 
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Appendix III. Calculation of pRET and pERK molecules per cell 
The number of maximum pRET molecules were quantified previously as 6,500 
molecules per cell in the same cell type (Schlee et al.). Thus, the percent 
maximums of pRET molecules were interpolated according to dose-response 
curve from Figure 2.6A, where 100% maximum equals 6,500 molecules per cell. 
As such, the averaged 1.6 nM ART 10 min stimulation is equivalent to 73 ± 9% of 
maximum pRET. Thus, using the 6,500 molecules per cell to represent 100% 
pRET activation, 73 ± 9% is equivalent to 4,753 ± 611 pRET molecules per cell. 
Time course number pRET molecules were calculated as a fraction of 1.6 nM 
ART at 10 min, where 1.6 nM ART at 10 min = 1 = 4753 ± 611 molecules per 
cell. Errors were propagated using standard deviations for individual 
measurements using equation X:  
!(!/!) (!/!) = !!! ! + !!! !    (Eq. 1) 
Phospho-ERK molecules per cell were calculated similar to PRET, where 100% 
maximum pERK equals 140,000 molecules per cell as determined previously (S. 
Li et al.). Thus, the averaged 1.6 nM 10 min ART stimulation equivalent to 89 ± 
5% of maximum pERK, which is equivalent to 125,505 ± 6520 pERK molecules 
per cell. 
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Appendix IV. Calculation of mRNA molecules per cell 
Purified cDNA fragments were amplified using the same qPCR forward and 
reverse primers sets, and they were included to generate qPCR standard curves 
to calculate number of mRNA molecules per cell. 
Fragment sizes 
c-fos = 920 bp, IL-6 = 76 bp, and Luciferase = 101 bp. 
Calculation of mRNA molecules by purified cDNA equation 1, 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑝𝑖𝑒𝑠 (𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠) =  !"# × !.!""# × !"!"!"#$%&#$'/!"#$! × !!" !!"#$ × ! × !"! !"/!  (Eq. 1) 
Where X is the amount of cDNA in nanograms, and N is the length of amplicon in 
bp; 660 g/mol is the average mass of 1 bp of dsDNA.  
Standard curves used to calculate number of mRNA molecules shown below: 
 
y = -1.23ln(x) + 13.95 
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Appendix IV. qPCR analysis of purified and quantified cDNA fragments. The 
cDNA fragments of IL-6 (top), Luc (middle), and c-fos (bottom) were serially 
diluted, and included in the qPCR analysis of mRNA extracted from cell lysates, 
and were used as standards to quantify absolute mRNA levels measured by 
qPCR. 
y = -1.02ln(x) + 17.51 
R² = 0.97 
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Appendix V. Calculation of protein molecules per cell 
1. Purified luciferase protein were used to generate standard curve below: 
 
Appendix V.1. Luciferase signal of purified recombinant firefly luciferase protein. 
Purified recombinant firefly luciferase protein were serially diluted, and included 
in parallel to measure luciferase signal from cell lysates. Signals from purified 
protein were used as standards to quantify absolute luciferase protein levels. 
 
Relationship between number of molecules and mass of protein were calculated 
by applying Equation 1, 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑎𝑠𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 =  !"!"#$$ !/!"#  × 6.022 × 10!"𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠/𝑚𝑜𝑙  (Eq.1) 
where X is the mass of luciferase protein in grams, and luciferase has a 
molecular weight of 64,800 daltons (grams per mole). 
2. For experiments in which purified luciferase protein was unavailable, we 
calculated the number of luciferase molecules by generating a secondary 
y = 1.12E+08x2 + 4.90E+06x - 6.60E+02 
R² = 1.00E+00 
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standard curve to represent the number of luciferase molecules expressed as a 
percent of maximum, as depicted below:  
 
Appendix IV.2. Absolute luciferase signal as a function of percent maximum 
signal of ART-induced luciferase signal. The absolute molecules of luciferase 
protein were quantified for cells that were treated with various ART doses. This 
curve was used to quantify absolute luciferase protein in cells that were treated 
with ART, and normalized to a percent maximum luciferase signal, but the 
purified recombinant firefly luciferase protein was unavailable at that time. 
 
The number of luciferase molecules was calculated using the purified luciferase 
standard curve (previous figure) for cells that were treated with 1.6 nM ART for 
up to 8 h. The same experimental treatments were calculated as a percent of 
maximum for the 8 h time course. Thus, for time course experiments in which 
purified luciferase protein was unavailable, the number of luciferase molecules 
was calculated using this secondary standard curve. 
3. For calcuating the number of c-fos protein molecules, we detected purified 
human c-fos using Western Blot, and generated a standard curve from. The c-fos 
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detection antibody (Cell Signaling, Danvers, MA) is specific for residues 
surrounding L27 of human c-fos. Alignment of murine and human c-fos residues 
confirms that both species are identicle surrounding L27. Standard curves 
depicted below as original Western Blot (top), densitometry of Blot (middle) and 
signal expressed as a fraction of the signal for 41.75 ng c-fos protein (bottom): 
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Appendix V.3. Densitometry analysis of purified recombinant human c-fos 
protein. Western blot analysis for purified recombinant human c-fos protein that 
was serially diluted (top). Densitometry analysis using ImageJ (protocol detailed 
below). A standard curve was generated of the Western blot signal as a function 
of recombinant human c-fos protein concentration (middle). A secondary 
standard curve for the Western blot signal as a fraction of 41.75 ng of 
recombinant human c-fos protein was plotted as a function of recombinant 
human c-fos protein concentration was also generated (bottom). The secondary 
standard curve was used to quantify the absolute levels of c-fos protein when 
41.75 ng of recombinant human c-fos protein was included in Western blots of 
ART-treated cell lysates. 
 
Quantification of experimental c-fos protein was done by including 41.75 ng of 
purified human c-fos protein to one well on the Western Blot. After densitometry 
of the Western Blot using Image J softeware (Bethesda, MD) for c-fos and for β-
actin loading control, we calculated the number of c-fos molecules using the 
standard curve expressed as a fraction of 41.75 ng protein. The c-fos signal is 
normalized to β-actin control. 
Step-by-step detailed Western Blot analysis using Image J software as described 
on http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-
image-j/ : 
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Image Analysis 
a. Open tiff files in Image J as 8-bit image 
b. Choose rectangular selector to select band in single lane 
c. Press Command + 1 on mac keys or Analyze>Gels>Select 1st Lane 
d. Use mouse to click in middle of rectangle and drag along blot to select 
other wells 
e. Press Command + 2 on Mac or Analyze>Gels>Select Next Lane! repeat 
for other lanes 
f. After last lane, press Command + 3 on Mac or Analyze>Gels>Plot; signal 
plots of bands will appear; press and hold space bar to see other lanes 
g. Exclude background noise by drawing straight line across base of signal, 
do for all peaks 
h. Select Wand tool and click inside peak for all lanes 
i. After all selected, go to Analyze>Gels>Label Peaks 
j. Copy and paste numbers to excel  
Excel Analysis 
a. For each sample, divide the area by sum of peaks for all samples to get 
“relative %” 
b. Use the same sample control across experiments (i.e., untreated sample). 
Calculate “relative density” by dividing relative % of sample by control. 
c. Repeat a. and b. for loading control blot. 
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d. Calculate “normalized density” by dividing relative density of protein of 
interest by relative density of loading control protein 
4. The number of IL-6 protein molecules was calculated by including a standard 
curve using purified IL-6 protein to every IL-6 ELISA experiment. A sample 
standard curve is depicted here: 
 
 
Appendix V.4. A sample of a standard curve for purified mouse IL-6 protein. 
Purified mouse IL-6 protein was serially diluted and included in parallel to ART-
treated cell lysates for ELISA analysis of IL-6 protein. A standard curve was 
generated each time for every ELISA analysis.
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Appendix VI. Sample calculations for transcriptional and translational rates 
1. Midway slopes for luciferase mRNA 
time (min) Luci mRNA stand dev slope 
slope+ 
kdeg[mRNA] 
Slope 
midpoint 
0 17.61 1.88       
10 16.52 6.64 -0.11 0.28 5 
30 70.08 28.63 2.68 3.68 20 
60 392.01 247.92 10.73 16.07 45 
120 1731.99 707.62 22.33 46.87 90 
240 371.15 312.34 -11.34 12.95 180 
360 164.08 69.99 -1.73 4.46 300 
480 69.86 39.26 -0.79 1.92 420 
 
“Slope” = (Luci mRNA2 – Luci mRNA1) – (Time2 – Time1) 
“Slope + kdeg[mRNA]” = slope2 + (mRNA decay rate constant x ((Luci mRNA2 – 
Luci mRNA1) / 2)) 
“Slope midpoint” = (Time2 – Time1) / 2 + Time1 
2. Cubic spline fit using GraphPad Prism Software () enables curves to fit through 
every data point by using a different fit through the space between data points. 
Therefore, no equation is available to describe the fits. Prism uses the equations 
explained in detail in section 4.11 of JC Chambers, et. al, Graphical Methods for 
Data Analysis, Wadsworth & Brooks, 1983. 
We used the following setting, cubic spline method to create curve, 480 
segments (to represent every minute up to 480 min), to generate data points  to 
give number of mRNA or protein molecules at every minute for measured time 
course measurements. We derived synthesis rates by calculating the first 
derivative of the cubic spline curve, with smoothing between 4 neighboring data 
		
200 
points and 2nd order smoothing polynomial. Per the GraphPad Prism description 
of how they calculate derivatives (https://graphpad.com/support/faq/how-prism-
computes-the-derivatives-of-curves/), 
“As part of the Smooth analysis, Prism can convert a curve to its first- or second-
derivative. Curves are defined as a series of line segments, and Prism computes 
the derivative numerically. No calculus involved. It uses this algorithm: 
First Prism sorts the input (X,Y) pairs in increasing order by X values. If two or 
more points have the same X value, Prism averages the Y values to create a 
single (X,Y) pair. So the resulting sorted list of XY pairs will be shorter than the 
original data table if any X values are repeated. We'll call this array of sorted 
(X,Y) pairs the Src array. 
Prism computes the resulting derivative table, with one fewer XY pair than the 
Src array, using a simple idea. Each row in the results table is computed from 
two adjacent rows in the sorted input table. The X value for each row in the 
results table is the mean of two adjacent X values in the input table. The Y value 
in each row in the results table equals the difference between the two Y values, 
divided by the difference between the two X values: 
Resulting X[i] = (SrcX[i+1] + SrcX[i]) / 2 
Resulting Y[i] = (SrcY[i+1] - SrcY[i]) / (SrcX[i+1] - SrcX[i])” 
 
We calculated the area under the curve by GraphPad Prism using the synthesis 
rate generated from the first derivative curves. Prism uses the trapezoid rule to 
calculate the area under the curve. Briefly, the curve is divided into a series of 
trapezoids, and the triangle portion of the trapezoid is further divided into a set of 
2 triangles to form a rectangle, for which the area can be calculated. 
http://www.graphpad.com/guides/prism/7/statistics/index.htm?stat_area_under_t
he_curve.htm 
3. Curve fits for luciferase mRNA synthesis rate 
The spike and sustained curve fit depicted in Figure 2.3B is calculated by dividing 
the curve into three slopes. First slope as a positive slope representing the 
increase in mRNA synthesis rate, using the linear equation 1, 
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𝑦 = 0.69𝑥 − 14.65      (Eq. 1) 
 
Followed by a second negative slope representing the decrease in mRNA 
synthesis rate, using the linear equation 2,  
 𝑦 = −0.59𝑥 + 118.19      (Eq. 2) 
 
The final slope is zero as mRNA synthesis sustains at near constant levels 
during t ≥ 194 min. 
4. Gaussian curve fit using following parameters shows that there are more than 
one type of curve fitting to describe the mRNA synthesis rate data points. 
Gaussian 
Parameters   
σ2 1700 
µ 110 
    
a 0.0092 
b 110 
c 41.23105626 
scale factor 5300 
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Appendix VI. Curve fit of luciferase mRNA synthesis rate using Gaussian 
parameters listed in table above.  
 
5. Synthesis rate for IL-6 mRNA 
The synthesis rate for IL-6 mRNA was calculated as a linear slope from mRNA 
levels measured between 60-360 min, the synthesis rate is constant at 3.8996 
protein molec./cell/min. 
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Appendix VII. Attempt at measuring c-fos protein decay 
 
 
Appendix VII. The effect of adding cycloheximide to ART-stimulated cells on c-
fos protein. Cells were treated with 1.6 nM ART for 120 min, followed by addition 
of Cycloheximide (100 µM). (Top) Cells were lysed at indicated time points and 
measured for c-fos protein by Western Blot. Expected band sizes for c-fos and β-
actin are 41 and 42 kDa, respectively. (Bottom) Densitometry analysis of Blot. 
Signals plotted as percent of c-fos protein after 120 min 1.6 nM ART treatment. 
 
		
204 
Appendix VIII. The effect of inhibiting MAPK/ERK signaling on IL-6 mRNA 
 
Appendix VIII. The effect of inhibiting MAPK/ERK signaling on IL-6 mRNA. Cells 
were treated with 1.6 nM ART for 180 min, followed by addition of MEK inhibitor, 
CI1040 (1 µM). Cells were lysed at indicated time points and measured for IL-6 
mRNA. Signals plotted as percent of mRNA after 8 h 1.6 nM ART treatment. 
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Appendix IX. List of growth factors tested for crosstalk using SRE luciferase 
reporter gene 
Growth factor ED50 (nM) Cat. No. 
Cardiotrophin-1 n/a 
 Epiregulin 0.5 550302
Betacellulin 0.025 551302 
EGF 0.333 598102 
G-CSF 0.013 752102 
M-CSF 0.212 576402 
GM-CSF 0.003 576302 
IGF-2 4 588204 
IL-2 0.023 575402 
LIF 0.002 554002 
FLT3L 1.37 550702 
PDGF-BB 0.205 558802 
SCF 0.824 579702 
thrombopoietin 0.022 593302 
TRANCE n/a 577102 
endostatin 94 557404 
IL-1beta 0.003 575102 
CXCL1 n/a 573702 
CXCL12 alpha 6.3 578702 
human IGF-1 0.263 711308 
FGF-basic 0.061 579602 
beta-NGF 0.075 598102 	
Initial screens for crosstalk for SRE luciferase response using growth factors 
listed above by co-stimulation with various doses of ART plus 4 nM for all GFs 
except for endostatin and FLT3L (10 nM) for 4 h. The result for screens of each 
GF are shown below. 
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Appendix IX. Initial screens for crosstalk in luciferase signal by co-stimulation 
with ART and another GF. Cells were treated with various doses of ART in 
addition to 4 nM GF, except endostatin and FLT3L was added at 10 µM, and 
incubated for 4 h, then lysed and measured for luciferase activity. Luciferase 
signal plotted as a percent of 4 nM ART.
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Appendix X. Calculation of RET-mCEr and RET-mYPet virus titer 
MSTO-GFRα3 cells were infected with 50 µl of concentrated virus at 5 x 104 cells 
per well onto 12-well tissue culture plates. Stains were stained with RET and 
Alexa Fluor 647 antibodies, and detected using Facscalibur (BD Bioscience, San 
Jose, CA) in the FL-4 channel. Percent positive cells were gated out, and virus 
titers were calculated using following equation 1  
(from https://www.addgene.org/protocols/fluorescence-titering-assay/),  
 !"#$% !"#$%!" =  !"#$"%& × !!      (Eq. 1) 
 
where Percent is the percent positively stained cells from flow cytometry 
analysis, N is the number of cells transduced, and V is the volume of virus added 
for infection in µl. 
We tested the different number of viral particles for infection using RET-
mYPet virus, and measured YPet fluorescence intensity (shown below), we 
determined that ~9 x 106 total titer units is most optimal to attain highest 
fluorescence. Thus, we infected virus at different ratios for total titer units 
equaling ~9 x 106. 
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Appendix X. Histogram of the YPet fluorescence intensity of cells infected with 
various titer units of RET-mYPet virus. MSTO cells analyzed for YPet 
fluorescence intensity 72 h post infection, 10,000 events collected, and cells 
were gated for forward and side scatter populations before YPet fluorescence 
analysis. 
 
Total titer units equaling ~9 x 106 used to calculate virus titer for donor and 
acceptor to infect cells at donor:acceptor ratios of 1:2, 1:3 and 1:4. 
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Appendix XI. Background FRET signal by acceptor RET-mYPet only cells  
 
Appendix XI. Dot plot of individual cells used to measure ART-induced FRET 
signal. Minimal number of acceptor-only RET-mYPet cells (black and orange 
dots) were included in our FRET analysis, which shows that gating of the 
populations excluded most of the acceptor only cells detected in the FRET 
fluorescence. Many cells expressing donor and acceptor RET were included in 
our analysis (blue and red dots). 
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Appendix XII. ART-induced FRET using 1:3 and 1:4 donor:acceptor ratios 
Cells expressing donor: acceptor ratios of 1:3 and 1:4 did not show ART-induced 
FRET fold change to untreated. The analysis is the same as described for Figure 
4.6D 
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Appendix XII. ART-induced FRET signal compared to untreated cells for cells 
infected at different donor:acceptor ratio. (Top) 1:3 donor:acceptor expressing; 
(Bottom) 1:4 donor:acceptor expressing MSTO-GFRα3 cells were infected with 
1:4 donor:acceptor virus titer units. Cells were either untreated or treated with 5 
nM ART for 10 min, then fixed using 1% paraformaldehyde, and analyzed for 
FRET, Cerulean, and YPet fluorescence. Cells were grouped in 100 Cerulean 
fluorescence intensity units, and calculated for the averaged FRET efficiency for 
each group. ART-induced fold change to untreated was calculated according to 
Chapter 4, Eq. 2. Each black dot represents the ART-induced FRET signal of 
each group of cells within 100 Cerulean fluorescence intensity units. The red 
dotted line represents the average ART-induced signal for the entire population. 
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Appendix XIII. FRET distance calculations for cells infected at 1:2 donor:acceptor 
ratio 
The relationship between FRET efficiency and the distance between donor and 
acceptor dipoles can be described by the following equation 1,  
 𝐸!"#$ =  !!! !!! !     Eq 1. 
where r is the distance between acceptor and donor dipoles and R0 is the Förster 
distance of given donor-acceptor pair, also known as the distance when FRET 
efficiency is 1, which is 50 Å for mCer and mYPet, and the length between donor 
and acceptor dipoles is 0 (He et al.). The plot below represents the relationship 
between FRET efficiency and the distance between donor and acceptor dipoles. 
 
Appendix XIII. Plot of FRET efficiency as a function of distance between donor 
and acceptor. The plot represents eq. 1. 
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As such, we can use our 10 amino acid linked mCer-mYPet construct 
positive control, which is equivalent to a 57.5 Å linker and extrapolate from the 
graph above that the FRET efficiency for the 10 amino acid linker is equal to 
0.30. Thus, to generate a donor-acceptor distance plot that can calculate the 
donor-acceptor distance directly by the FRET fluorescence intensity measured; 
we “corrected” the FRET efficiency by the following equation 2,  
 𝐹𝑅𝐸𝑇!"##$!%$& = (𝐼!" − 𝐼!) ×  ( !.!"!!"#$%!!!"#$)  Eq. 2 
where IDA is the mean FRET intensity detected for cells expressing donor and 
acceptor, ID is the mean FRET intensity detected for cells expressing donor only, 
IposDA is the FRET intensity for the 10 amino acid linked mCer-mYPet, and InegD is 
the donor only expressing cells gated the same as IposDA population. Thus, for 
every population gated in 100 intensity units for Cerulean fluorescence a FRET 
corrected value was calculated and using equation 1, the distance between 
donor and acceptor dipoles for each 100 unit Cerulean fluorescence intensity 
population was calculated, and summarized in table below. 
 
 
 
  
Cerulean 
population 
(per 100) 
Mean I 
DA 
Mean I 
D 
Mean I 
DA - 
Mean I D 
FRET 
corrected 
Distance 
(Å) 
  
Positive/ 
Neg D 10400 2422 7978 0.302 57.500 
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1:2 
RC:RY 
untreated 600 2370 1963 407 0.015 99.986 
  700 2832 2344 488 0.018 96.955 
  800 3312 2677 634 0.024 92.720 
  900 3744 2973 771 0.029 89.675 
  1000 4121 3403 718 0.027 90.780 
  1100 4582 3783 798 0.030 89.139 
  1200 5435 4174 1261 0.048 82.354 
  1300 5953 4534 1419 0.054 80.666 
  1400 6175 4789 1386 0.052 81.000 
  1500 8237 7376 862 0.033 87.978 
1:2 
RC:RY 5 
nM ART 600 2325 1954 370 0.014 101.599 
  700 2787 2289 499 0.019 96.595 
  800 3219 2502 717 0.027 90.802 
  900 3796 2800 997 0.038 85.795 
  1000 4226 3234 993 0.038 85.854 
  1100 4887 3285 1603 0.061 78.944 
  1200 5211 3813 1398 0.053 80.871 
  1300 5690 4199 1492 0.056 79.954 
  1400 6663 4420 2243 0.085 74.318 
  1500 8375 6435 1941 0.073 76.292 
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Appendix XIV. Primers for the generation of FRET constructs 
Construct Primer Sequences 
pcDNA3-
mYpet 
(A206K) 
For-CTGAGCTACCAGAGCAAGCTGTTCAAGGACCCC 
Rev-TAGAAGGCACAGTCGAGG 
pcDNA3-
mCer-BspeI 
For-TAATACGACTCACTATAGGG 
Rev- CTGAGTCCGGATCCTCTTGG 
GCTTCCTCCCTTGTACAGCTC 
pcDNA3-
BspeI-
mYpet 
For-GATCCACCGGTCTCCGGAGCCACCATGGTG 
 
Rev-TAGAAGGCACAGTCGAGG  
EcoRI-puro-
BspEI 
For-GAGACGACCTTCCGAATTCATGACCGAGTAC  
Rev-GAGACGACCTTCCGAATTCATGACCGAGTAC 
BamHI-
GFRα3-XbaI 
For- GAGACGACCTTCCGAATTCATGACCGAGTAC 
Rev- GAAGTCCAGCTAGGATCCCCATAGGCTCAG 
AgeI-WT 
RET 
For-CAAGCTTCCCGCCACCGGTATGGCGAAGGCGAC  
Rev-AGAAGTAGAGGCCCAATGCCACTT  
pUltra-
WTRET-
MluI 
For-TGCAGCGAGGAGATGTACTG 
Rev-GCCGGATCCTCTAACGCGTGAATCTAGTAAATG 
MluI-mYPet 
For-GTCGCCACCATGACGCGTGTGAGCAAAGG 
Rev-TAGAAGGCACAGTCGAGG 
 
MluI-mYPet-
MluI 
For-TAATACGACTCACTATAGGG  
Rev- GATCCGTTGGCCGCTACGCGTTTACTTATAGAG 
 
MluI-mCer For-GTCGCCACCATGACGCGTGTGAGCAAGGG Rev-TAGAAGGCACAGTCGAGG 
 
MluI-mCer-
MluI 
For- TAATACGACTCACTATAGGG 
Rev- 
GATCTGAGTCCGGAACGCGTTTACTTGTACAGCTC 	
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